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cannot possibly go wrong goes wrong it usually turns out to be 










This thesis is submitted in partial fulfilment of the requirements for the degree of 
Doctor of Philosophy at the University of Edinburgh. Unless otherwise stated this 
work is my own and has not been submitted for any other degree or professional 
qualification. 
 
Chapter 3: All simulations were performed by Jason Kalapothakis. 
 




…………………………...                         





I would firstly like to acknowledge and thank my supervisors Dr Perdita Barran and 
Professor Cait MacPhee for all the help, guidance and support they have given me 
since I was a senior honours student. Without their assistance none of this would 
have been possible.  
 
A special thank you to all my fellow group members over the last four years for 
everything, especially helpful discussions, cakes, cups of tea, office singing, bodging 
of lab equipment, group meetings and advice concerning where the bit of hardware 
left over when the instrument was reassembled should have gone. So, in vaguely 
chronological order, thank you: Jason, Peter, Stefan, Roland, Martin, Jude, Yana, 
Ewa, Sophie, Kamila, Bex and Jakub. Thank you also Max for your invaluable help 
in the face of my luddite approach to molecular modelling. Finally I am grateful to 
my project students Tom and Callum for all their hard work.  
 
I would like to acknowledge SIRCAMS members Stefan and Logan for their 
assistance with FT-ICR MS measurements. I am also grateful for all the technical 
help provided by Stuart and Davey from the mechanical workshop and Donald from 
the electronics workshop. A big thank you also to Jane Patterson and the fantastic 
teams in Chemistry Stores and in the Chemistry Administrative Office.  
 
Finally I am indebted to my family, Chris and my friends for their love and support, 
cheering me up and providing a different perspective. A special mention to Ludo and 








Proteins and peptides can convert from their native form into insoluble highly 
ordered fibrillar aggregates, known as amyloid fibrils. The process of fibrillogenesis 
is implicated in the pathogenic mechanisms of many diseases and, although mature 
fibrils are well characterised by a plethora of biophysical techniques, the initiation 
and early steps remain, to date, ambiguous. Mass spectrometry can provide 
invaluable insights into these early events as it can identify the low populated and 
transient oligomeric species present in the lag phase by their mass to charge ratio. 
Recent evidence has shown that oligomers formed early in the aggregation process 
are cytotoxic and may additionally be central to the progression of diseases 
associated with amyloid fibril presence. The hybrid technique of ion mobility mass 
spectrometry can be employed to provide conformational details of monomeric and 
multimeric species present and elucidate the presence of oligomers which possess 
coincident mass to charge ratios. Molecular modelling, in conjunction with 
experimental results, can suggest probable monomeric and oligomeric structural 
arrangements.  
In this thesis three aggregating systems are investigated: amyloidogenic 
transthyretin fragment (105-115), insulin and two A peptides. Initially 
amyloidogenic endecapeptide transthyretin (105-115) is studied as it has been widely 
utilised as a model system for investigating amyloid formation due to its small size. 
Secondly insulin, a key hormone in metabolic processes, is investigated as extensive 
research has been carried out into its aggregation into amyloid fibrils. The formation 
of insulin amyloid fibrils rarely occurs in vivo; however localised amyloidosis at the 
site of injection and the aggregation of pharmaceutical insulin stocks present 
problems. Thirdly the aggregation of A peptides A(1-40) and A(1-42) and their 
interactions with an aggregation inhibitor, RI-OR2, are characterised. A(1-42), 
although less commonly produced in vivo, is more cytotoxic and has a faster 
aggregation mechanism than A(1-40). Both A peptides are implicated in the 
aetiology of Alzheimer’s disease whilst RI-OR2 has been reported to prevent the 
production of high molecular weight oligomers, with particular suppression of 




A  amyloid beta peptide 
AFM  atomic force microscopy 
APP  amyloid precursor protein 
ATD  arrival time distribution 
AUC  analytical ultracentrifugation 
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Physical Constants and Quantities 
 
d  distance 
e  elementary charge, 1 e = 1.6021765 x 10
-19 
C 
E  electric field strength 
Ek  kinetic energy 
K  mobility 





Kd  dissociation constant 
m  mass 
m/z  mass to charge ratio 
n  oligomeric order 
N  number density  
P  pressure 
q  net charge  
t  time 
T  temperature  




v  velocity 
V  potential difference 
z  nominal charge   
µ  reduced mass 
  density  
  angular frequency 
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Introduction and Motivation 
 
 
The ability of proteins and peptides to convert from their soluble native form to 
insoluble highly ordered fibrillar aggregates is the subject of intense scientific 
interest and relevance. The formation and presence of these structures, known as 
amyloid fibrils, is implicated in the development of degenerative diseases. The 
precise processes by which this conversion occurs are still elusive, particularly in 
their initial stages, but mass spectrometry, ion mobility mass spectrometry and 
molecular modelling can provide invaluable insights into the early events which 
occur in the fibrillogenesis pathway. 
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1.1. Introduction 
 
The first observations of amyloid plaques in the organs of the deceased date as far 
back as 1639 
1
. Amyloid plaques were so named by Rudolph Virchow, who in 1854 
discovered the positive iodine staining of cerebral plaques, and thus identified them 
as starch, from which the term amyloid originates (derived from the Latin ‘amylum’ 
and Greek ‘amylon’). Five years later Friedreich and Kekule refuted the supposition 
that amyloid plaques were composed of carbohydrates, correctly identifying their 
proteinaceous nature based on their high nitrogen composition. Latterly researchers 
have discovered over twenty proteins (Table 1.1) which can convert from their 
soluble native state into insoluble fibrillar aggregates in vivo 
2
. These proteins vary 
hugely in their primary sequence, tertiary structure and evolutionary function, 
however, post fibrillogenesis, the aggregates can be of a startlingly homogeneous 
fibrillar structure composed predominantly of a single protein or peptide 
3,4
. The 
histological diagnostic test for amyloid fibril presence is the chemical binding of 
Thioflavin T 
5
 and green birefringence observable on binding Congo Red dye 
6
. The 
biophysical definition of an amyloid fibril, whether in vivo or in vitro, is one that 





The disparity of amyloid-forming proteins and peptides, coupled with the 
homogeneous and highly stable fibrils produced, suggests that cross--sheet structure 
may be a global potential energy minimum for many proteins, energetically 
preferential to their native state 
8
. This assertion is supported by the findings that, 
under denaturing conditions, proteins unconnected with amyloid disease can form 
amyloid fibrils in vitro 
9
. It is postulated that amyloid fibril formation is a generic 
property of all polypeptide chains as the hydrogen bonds which stabilise the fibril 
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1.2. Aggregation in vivo 
 
Fibrils are stable under physiological conditions because of their numerous strong 
hydrogen bonds. A protein’s external environment is already carefully 
homeostatically regulated, particularly in terms of pH and temperature, but in 
addition, to prevent fibril formation, proteins are chaperoned during folding 
transitions 
9
. Misfolded or unfolded proteins are targeted and destroyed by 
chaperones and housekeeping mechanisms before they can form fibrils 
11
. However 
when the homeostatic control or the degradation mechanisms which deal with 




A diverse range of diseases, known as amyloidoses, are characterised by amyloid 
fibril presence. A decreased efficacy of the cellular response pathways which deal 
with unfolded or misfolded proteins, combined with increased propensity for protein 
damage to occur with age, could explain why the majority of amyloidoses develop 
late in life 
9
. In the developed world, with its aging population, these are predicted to 
become increasingly prevalent. Some amyloidoses and their associated proteins are 
shown in Table 1.1.  
 
Disease Associated Protein(s) 
Alzheimer’s A peptides and Tau protein 
Atherosclerosis Apolipoprotein A1 
Dialysis-related amyloidosis 2-microglobulin 
Familial amyloidotic polyneuropathy Transthyretin 
Familial non-neuropathic amyloidosis Lysozyme 
Huntington’s disease Huntingtin 
Injection-localized amyloidosis Insulin 
Parkinson’s syndrome -synuclein and Tau protein 
Primary systemic amyloidosis Immunoglobulin light chain 
Senile systemic amyloidosis Transthyretin 
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Transmissible spongiform encephalopathies Prions 
Type-II diabetes Islet amyloid polypeptide 
 
Table 1.1 | Examples of amyloidoses and their associated proteins or 
peptides 10,13. 
 
Amyloid diseases are classified into neurodegenerative conditions, non-neuropathic 
localised amyloidoses and systemic amyloidoses depending on the location of the 
amyloid deposits, known as ‘amyloid plaques’ 
14
. In systemic and localised 
amyloidoses large quantities of fibrils build up, disrupting organ function 
15
. 
However, for neurodegenerative conditions, studies have shown that pathogenesis 
can occur before the presence of mature fibrils 
16
 and there is no direct correlation 
between the quantity of fibrillar deposits and pathogenic effects 
17
. It is suggested 
that aggregate plaques may be the end product of a process in which the principle 
disease-causing species are small, soluble oligomers that form early in the 
aggregation process 
18
. Increasing numbers of studies have shown that 
preamyloidogenic forms of proteins exhibit cytotoxicity 
17
; cytotoxic oligomers have 







. Whilst studies of the peptides implicated in the development of 
Alzheimer’s disease have indicated that intermediate metastable states, not mature 




Evidence has been collected which implies that the cytotoxicity of prefibrillar 
aggregates and soluble oligomers is not just confined to the proteins associated with 
known amyloid diseases 
26
. Specific antibodies have been developed which are 
claimed to cross-react with early aggregates of different proteins, but not with their 
monomeric or fibrillar states, to inhibit their toxicity 
27
. These studies suggest that the 
cytotoxicity of soluble oligomers which precede mature fibrils may have a common 
structure and pathogenic mechanism, and the formation of these may also be a 
common property of all proteins 
27
. Most recently the discovery of a highly cytotoxic 
prion monomer with -helical structure has broadened the scope of understanding 
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beyond oligomers and mature -sheet aggregates 
28
. If certain monomers and soluble 
oligomers are cytotoxic it is possible that amyloid fibril formation is an evolutionary 
protective mechanism to sequester these dangerous oligomeric species into a stable 
and harmless form.  
 
Thus the characterisation of all of species, and conformers of species, present in the 
aggregation process is vital due to the role they may play in pathogenesis. The 
aggregation pathway is complex and can contain species which do not culminate in 
mature amyloid fibrils; these are known as ‘off-pathway’ products, whereas those 
which form amyloid fibrils are ‘on-pathway’. Many of these species are non-
covalently bound, transient and present in small quantities, making them difficult to 
observe experimentally, unlike amyloid fibrils which have a stable and ordered 
structure.  

Perhaps unsurprisingly evolution has utilised the ability of proteins to form amyloid 
fibrils. These are known as ‘functional amyloid proteins’ due to the beneficial effect 
they confer upon their host. Functional amyloid proteins are utilised by bacteria, 
fungi, insects and mammals in diverse roles 
3
. Some examples are the Escherichia 
coli curlin protein which assembles into fibrils to aid bacterial colonisation and 
binding with host cells 
29
 and, in humans, the formation of fibrillar striations along 




1.3. Aggregation in vitro 
 
Globular proteins can be converted into amyloid fibrils via exposure to mild 
denaturing conditions which cause partial protein unfolding 
31
. This allows the 
aggregation process to be studied in vitro and denaturing conditions include elevated 
temperatures 
32,33
, low pH 
34
, and the presence of organic solvents 
35,36
. The ability of 
amyloid fibrils to self assemble, in response to changes in external environment, into 
a predictable ordered structure, in addition to intrinsic properties such as their high 
tensile strength, opens up a wealth of opportunities for biomaterial design 
37
. One 
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example of this is the use of self assembling peptides to support tissue repair. 
Amyloid filaments are of similar dimensions to the biological scaffolds found in 
nature, but with the additional benefits of controlled assembly and disassembly and 
the potential to incorporate growth factors or drugs, allowing either slow drug release 
or drug delivery to specific sites 
38
. A recent study showed that a self-assembled 




1.3.1. Structure of Amyloid Fibrils 
 
A plethora of techniques have been used to study the structure of amyloid fibrils and 
their protofilament subunits. Until recently it was not possible to characterise fibrils 
at the molecular level due to their large size and non-crystalline structure, as these 
attributes create difficulties in probing their structure by either Nuclear Magnetic 
Resonance Spectroscopy (NMR) or X-ray crystallography. Therefore structural and 
morphological information was obtained from low resolution techniques such 
Transmission Electron Microscopy (TEM), Atomic Force Microscopy (AFM) and 
X-ray fibre diffraction 
7,40,41,42,43
. Recently, the development of solid state NMR 
(SSNMR) 
44,45,46
 and achievements in growing small peptide crystals, which can be 
analysed by X-ray crystallography 
47,48
, have allowed amyloid fibrils to be 
characterised at much higher resolution. SSNMR can measure inter-nuclear distances 
and torsion angles of peptide systems 
44,49
, leading to the significant finding that 
fibrils possess a degree of almost crystalline uniformity, explaining, in part, their 
great stability. Other techniques which can be used to elucidate amyloid fibril 
structure are Circular and Linear Dichroism and Synchrotron Radiation Circular 
Dichroism (SRCD) which can provide detailed information on the secondary 
structure present in fibrils, including quantity of -sheet, orientation of strands and 
inter- and intra-strand interactions. There have been recent exciting developments in 
fluorophore photophysics which have applications for self-assembling 
nanomaterials 
50
 and Förster resonance energy transfer (FRET) which allows the 
classification of different fibril structures 
51,52
. Hydrogen Deuterium Exchange 
(HDX) can be used in conjunction with nano-electrospray ionisation mass 
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spectrometry to determine the tertiary and quaternary structure of fibrils by studying 
their solvent accessibility 
53
.  HDX, NMR and mass spectrometry have observed 
dynamic equilibria between fibrils and oligomers, owing to monomer/oligomer 




Typically amyloid fibrils consist of between two and six protofilaments which have a 
diameter of 2 to 5 nm 
40
. Studies using X-ray fibre diffraction report that 
protofilaments possess cross- structure with -strands perpendicular to, and 
hydrogen bonds parallel to, the fibril axis 
7,55
. There appear to be two categories of 
protofilament association; either a lateral arrangement which results in a long ribbon 
fibril of a width of up to 30 nm and thickness between 2 to 5 nm 
56
, or a twisted rope 
of protofibrils between 7 and 13 nm wide 
40
. Most fibrils share a core region of 
between two or four -sheets, however the length of these and whether they are 
parallel or antiparallel is variable 
3
. SSNMR and X-ray crystallography techniques 





Figure 1.1 | Molecular model of a SH3 domain 
amyloid fibril derived from cryo-EM data. Four 
protofilaments twist together to form the 
mature fibril. The cross- sheets are shown 
inside the EM density data, which is 
represented by the transparent blue 
surface. Figure and caption adapted from 
Dobson 10.   
 
In addition to the heterogeneity which exists 
between amyloid fibrils composed of different 
subunits, fibrils formed by a single protein or 
peptide can exhibit varying architectures 
56,57,58
. These are believed to originate from 
differences in the position of the polypeptide chains within mature fibrils 
59
. 
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Preformed seeds can propagate their molecular architecture, even in non favourable 
conditions, templating the resulting fibrils in their image 
59
. This can play a key role 
in cross species prion transmission 
60
. Fibrils can be formed with distinct 
morphologies, and the most kinetically favoured conformation, in a particular set of 
conditions, will be the most dominant. This is in contrast with that of a natively 
folded protein where one conformation is significantly more stable and exists at a 
well defined energy minimum 
3
.   
 
Therefore, although properties of the polypeptide chain determine the framework of 
fibrillar architecture and the core region, variations in the sequences of different 
proteins and peptides lead to both differences in the diameter and the number of 
protofilaments which constitute a fibril and heterogeneous fibril morphologies. This 
is due to the unique side chain interactions of each protein or peptide sequence with 






Fluorescence measurements have played a major role in monitoring fibril growth 
kinetics as fibrils bind Thioflavin T and Congo Red dyes, whereas prefibrillar forms 
and oligomeric species with no -sheet structure do not 
61
. The time course of 
fibrillogenesis generally displays sigmoidal kinetics, consisting of an initial lag phase 
followed by a period of accelerated growth 
62,63
. These kinetics are believed to be the 
result of a complex combination of primary and secondary nucleation processes. 
Primary nucleation is the creation of a species which can elongate by monomer or 
oligomer addition, whereas secondary processes involve nucleation at interfaces and 
fibril fragmentation and branching. The length of the lag phase is very sensitive to 
environmental conditions such as pH, agitation, protein concentration 
64
 and the 
presence of salt 
65
. Fibril formation can be accelerated by ‘seeding’ the solution i.e. 
the addition of preformed aggregate nuclei or oligomers. In the case of disease, 
seeding can accelerate the illness progression and even act as an “infectious 
catalyst.” Such seeding could come about from the ingestion of an intermediate, as 
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1.3.2.1. Transition from Native Structure 
 
The conformational change required for the transformation of a protein’s native 
structure to the cross--sheet form of amyloid fibrils, is often dramatic, and requires 
a partial or complete unfolding of the structure to occur 
10,31,67
. This can be induced 
by a destabilisation of the protein’s native fold by environmental conditions in vitro 
such as low pH, high temperatures or the presence of organic solvents 
34,68,69,70
. 
Inherited protein mutations in vivo can destabilise a protein’s native structure, 
leading to amyloid formation. There is a strong correlation between decreased 
conformational stability and aggregation propensity in disease related proteins 
68,71
. 
Thus small molecules or ligands which bind to a protein and stabilise its native fold, 




Despite the common propensity of proteins to aggregate into amyloid fibrils, the 
individual amino acid sequence of each peptide or protein has a profound effect on 
how probable this event is. Charge on the molecule is crucial, as highly charged 
species are prevented from self association by their mutual repulsion 
36,74
. This is 
verified by the observation that if macromolecules are present in the solution, 
negating the high charge on the aggregating protein, aggregation will occur at a 
swifter pace 
75,76
. Another key factor in the predisposition of a polypeptide chain to 
aggregate is the hydrophobicity of its residues. Once a protein’s native fold has been 
disrupted, the exposure of previously protected hydrophobic regions can lead to 
aggregation. Evolution has selected against sequences of amino acids which promote 
the formation of -sheets, such as those with many adjacent hydrophobic residues 
77
 
or an alternating pattern of hydrophilic and hydrophobic residues 
78
, which would 
encourage aggregation into fibrils. Computer algorithms can predict the sequence 
sections of an unfolded polypeptide chain which are vulnerable to aggregation 
79
; 
more recently this method has been extended to include folded proteins and those 
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with some degree of structure 
80
. These calculations are particularly important as they 
enable the prediction of how mutational changes would effect the aggregation of 
proteins and may eventually aid in combating amyloid disease.  
 
1.3.2.2. Prefibrillar Intermediates 
 
In vitro a range of structures can be observed prior to the presence of mature fibrils: 
soluble oligomers, amorphous larger aggregates and diverse protofibrils. There is 
some confusion in the literature regarding the distinction between oligomers, 
protofibrils and protofilaments. For the purposes of this thesis oligomers are defined 
as clusters of non-covalently bound protein or peptide monomers, whilst protofibrils 
are aggregates of about 2 to 5 nm in diameter with some -sheet structure and 




Oligomers are observed very early in the lag phase (Figure 1.2a), where they exist in 
rapid equilibrium with the monomeric population. Protofibrils are structurally 
diverse and can be spherical or chain-like (Figure 1.2b). They are observed for a 
variety of amyloidogenic proteins such as transthyretin 
81





. Their growth and structure is dependent on solution conditions and 





Figure 1.2 | Prefibrillar A(1-42) intermediates (a) TEM of A(1-42) oligomers 
incubated at 4 °C for six hours. (b) TEM of A(1-42) protofibrils incubated at 
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37 °C for six hours. (c) TEM of A(1-42) fibrils incubated at 37 °C for 12 
days. Figure and caption from Ahmed et al. 83.   
 
Protofibrils form from the assembly and -sheet structural reorganisation of these 
small structurally disorganised oligomers 
84,85,86,87,88,89
. The precise mechanism of 
protofibril growth is unknown as it is challenging to monitor this dynamic situation; 
it may be that a specific oligomeric species is responsible for nucleating protofibril 
formation, following which protofibrils grow by monomer or oligomer addition 
and/or the coalescing of protofibrils 
88,90,91
. Protofibrils contain sufficient -sheet 
structure to allow binding with Thioflavin T and Congo Red dyes, hence their 
detection. Protofibrils lengthen during the lag phase and can persist even when 
mature fibrils have developed, although their population is reduced 
41,82,90
. 
Experimental data have shown that in some cases protofibrils are involved in the 
formation of fibrils 
41,63




Kayed et al. discovered the specific binding of certain antibodies to oligomers 
(and/or  protofibrils, these are not distinguished by this study) of different proteins, 
but not with their monomeric or fibrillar states 
27
. This suggests that there are 
structural elements common to these early order species, regardless of sequence 
variation. In large quantities these antibodies also mitigated the cytotoxic effects of 
oligomers (and/or protofibrils). Caughey and Lansbury have suggested that the 
cytotoxicity of oligomers/protofibrils (undistinguished in this study) comes from 




1.3.2.3. Fibril Assemblies 
 
Mature amyloid fibrils can self associate to form assemblies, the most common of 
which are the visible amyloid plaques found in organs: the hallmark of amyloid 
disease. Other assembly structures which have been observed are spherulites 
92,93,94
, 
monodisperse particulate structures 
95
 and the lateral association of mature fibrils to 
form broad ribbons 
57
. Spherulites, observed in vivo and in vitro, are tens of microns 
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in diameter and composed of radially orientated amyloid fibrils 
92
, in some cases 
with an amorphous core. They can be identified under cross-polarised optical 
microscopy by their Maltese cross extinction pattern 
92
 and are slow forming under 
conditions of high molecular charge. Particulate structures conversely are observed 
only in vitro when there is little or no net charge on the molecule 
94
 and have been 
predominantly studied in relation to whey products and food production. These 
structures tend to be spherical and hundreds of nanometres in diameter 
95
 and are 
composed of short, randomly arranged, amyloid fibrils.   
 
1.3.3. Why Mass Spectrometry? 
 
Mass spectrometry (MS) has a unique role to play in the study of the early events of 
fibrillogenesis, about which little is known. This is because the small, transiently 
populated heterogeneous oligomeric states which precede fibril growth, and could be 
the pathogenic agents in many diseases, are difficult to investigate using traditional 
biophysical techniques. To date oligomers have been characterised mostly using low 





 and light scattering techniques 
98
. SEC and AUC are 
dependent on the assumption that oligomeric species do not interconvert on their 
experimental timescales. Another technique, fluorescence correlation spectroscopy, 
can detect oligomers but not differentiate between them 
99
. MS enables the real time 
observation of which oligomers are present in the lag phase, and how these oligomer 
populations change over time. Thus MS can elucidate both the self assembly 
processes and off pathway events from their earliest steps, although it is not possible 
to distinguish between these. Individual species can be observed, however transiently 
and low populated, in contrast to other techniques which average data over the whole 
population present. A recent study 
100
 suggests that MS can be used to quantify the 
heterogeneous oligomer populations present in an aggregating system, and agrees 
very favourably with SEC quantification data. Practical considerations such as small 
sample volumes, speed of data acquisition and ability to sample directly from an 
aggregating solution also favour MS use. Thus MS is an exciting high resolution 
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technique to observe and quantify oligomers. Ion mobility MS can add to the 
information by identifying conformational families within oligomeric orders and 
different oligomeric orders which appear at a coincident mass to charge ratio. The 
collision cross sections of oligomers can also be measured, which, combined with 
molecular dynamics simulations, is a powerful method for analysing conformational 
dynamics and structural characterisation.  
 




The basic principle underlying all mass spectrometers is the production and injection 
of ions from a source which pass through a mass analyser to a detector where they 
are recorded according to their intensity and distinguished by their differing mass to 
charge ratios (m/z). 
 
1.4.2.  Ionisation methods  
 
1.4.2.1. Electrospray Ionisation 
 
The first studies of electrospray were undertaken by Zeleny in 1917 
101
, and, over 
fifty years later, Dole used electrospray ionisation (ESI) to determine molecular 
weight 
102
.  Fenn developed this method, showing that biological molecules could be 
transferred into the gas-phase as multiply charged ions and their molecular weight 
determined 
103,104
, work for which he shared the Nobel Prize in 2002 
105
. ESI is now 
an invaluable tool for protein analysis as biological molecules can be conveyed intact 
from solution to vacuum 
106
 and non-covalent interactions preserved, allowing for the 
transfer of entire protein complexes into the gas-phase 
107,108,109
.  
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For the process of ESI to occur the compound being analysed must be in solution. 
The analyte is infused from a syringe at atmospheric pressure, nebulised, and enters 
the mass spectrometer as charged droplets through the entrance aperture – the 
‘sample cone’ (Figure 1.3). Desolvation occurs from the exit of the capillary to the 
first vacuum pumping stage of the mass spectrometer. As with all mass 
spectrometers, the analyser region is kept at very low pressure. Ion transition 
between these two pressures is achieved using numerous differential stages of high-
capacity vacuum pumps and focusing multipole lenses. A key advantage of ESI is 
that from droplet formation to analyte entry into the analyser, very little 
fragmentation of molecules occurs, a property particularly crucial in protein studies.   
 






atmospheric pressure vacuum stages
 
Figure 1.3 | Schematic of a n-ESI source, showing Taylor cone formation, 
production of multiply charged droplets, droplet fission, desolvation and entry 
of analyte ions into the source of a mass spectrometer through the sample 
cone.  
 
An electric field is produced by applying a potential difference between the capillary 





, resulting in accumulation of charges (the polarity of the charges depends 
whether positive or negative ionisation mode is in use) at the liquid surface of the 
capillary. At low voltages the surface of the drop at the capillary tip appears spherical 
and elongates as accumulated charges in the tip exert pressure in the stronger electric 
field 
110
. This culminates in the surface tension of the drop breaking, leading to the 
formation of a ‘Taylor Cone’, from which a plume of nebulised ions is produced 
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(Figure 1.3). Gomez and Tang 
111
 found that as droplets are deformed mechanically, 
the dispersion of droplets can occur before the limit imposed by the Rayleigh 
equation is enforced – thus reducing the necessary repulsive forces. The solvent 
containing the droplets now begins to evaporate, causing an increase in charge 
density, causing the droplets to divide further due to the interplay between cohesive 
and repulsive Coulombic forces. Eventually only very small droplets are left which 
are dispersed by a low flow rate of nitrogen gas, injected coaxially. Remaining 
solvent molecules are removed by passing the droplets through a curtain of heated 
inert gas and the heated sample cone. The desolvated analyte ion passes into the mass 




























Figure 1.4 | Schematic of the charged residue model where a multiply 
charged and solvated cluster of ions produces single, desolvated analyte 
ions. a fission of ions. b further fission. c complete desolvation.  
 
The process by which a charged droplet becomes a desolvated ion is believed to 
occur by one of two processes. The more commonly occurring process 
112
 is the 
charged residue model 
102
 whereby droplets undergo sequential droplet fission until 
single solvated analyte ions remain which are then desolvated (Figure 1.4). This 
model is more relevant for large biomolecules such as those which are the topic of 
this thesis 
113
. However a competing mechanism, favoured by small ions, is the ion 
evaporation model 
114
 where analyte ions are expelled from droplets due to the 
presence of Coulombic repulsive forces which increase as the droplet decreases in 
size.  
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In large molecules, such as proteins, the charge observed is related to the availability 
of ionisable sites. This links with an important property of ESI; it produces multiply 
charged ions from large molecules due to charge accumulation in the droplets. 
Advantages of this are that it allows the analysis of molecules with a high molecular 
weight 
106
 and improves detector sensitivity. ESI spectra of proteins display 
consecutive peaks corresponding to multiply charged molecular ions which have 
been protonated or deprotonated. It is necessary to determine the molecule’s original 
mass before assigning the peaks to particular oligomeric and charge states.  
 
1.4.2.2. Nano-electrospray Ionisation 
 
A technological advancement in ESI which uses much lower flow rates, sample 
volumes and concentrations is nano-electrospray ionisation (n-ESI) 
115,116
. n-ESI 
utilises a glass capillary with a micron diameter tip, rather than the metal needles 
employed in ESI which have tip opening of circa 0.1 mm (Figure 1.3). Electric 
charge is supplied to n-ESI needles via a wire inserted into the analyte, or the 
capillary itself is covered with a conductive coating. Droplets produced by n-ESI are 
significantly smaller than those produced by ESI 
116,117
 which results in a less non 
specific aggregation and a gentler desolvation process as the number and energy of 
collisions necessary to desolvate the analyte molecules are fewer 
118
. As droplets are 
originally smaller, the final droplets will contain lower concentrations of unwanted 




1.4.3. Mass Analysers  
 
Once produced, ions are separated according to their m/z ratio by mass analysers. 
There are a number of mass analysers available, which use different principles to 
obtain m/z separation. Utilised in the experiments which follow and discussed in 
detail below are the quadrupole, time of flight and Fourier transform ion cyclotron 
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resonance (FT-ICR) analysers. Quadrupole analysers separate ions based on the 
differing trajectory stabilities of ions of different m/z values, time of flight analysers, 
as their name suggests, separate according to flight time and FT-ICR analysers 
exploit differing m/z resonance frequencies.  
 
1.4.3.1. Quadrupole Analyser 
 
A quadrupole mass analyser consists of four parallel rods to which a direct current 
(DC) and an alternating radio frequency (RF) potential are applied. Opposing rods 
have an in-phase RF potential (e.g. positive polarity) whilst adjacent rods are out of 
phase with respect to RF potential (e.g. negative polarity). This creates an oscillating 
electric field, described by Equation 1.1: 0 is the potential applied to the quadrupole 
rods, U is the DC potential, V the zero-peak amplitude of the RF potential,  the 
angular frequency of the RF potential and t is time. 
 
)cos(0 tVU ω−±=Φ±  Equation 1.1 
 
Ions entering the quadrupole will be attracted to a rod of opposite polarity. However 
as the polarity of the rods is continually changing due to the alternating RF potential 
ions prescribe an oscillating path. Ion trajectory through the quadrupole is therefore 
dependent on the values of U, V and . Ions of a specific m/z have specific values of 
U, V and  which will enable a stable path through the quadrupole (resonant ion), 
and if these variables are fixed at these values all other ions will possess unstable 
trajectories in the oscillating field causing them to collide with the quadrupole rods 
and not reach the detector (non resonant ion) 
119
. In this way the quadrupole can be 
used to select ions of a specific m/z to transmit, a function utilised when performing 
collision induced dissociation (CID). Therefore V is scanned through a range of 
amplitudes to allow ions with multiple m/z values to pass through the quadrupole. 
Figure 1.5 displays a typical quadrupole analyser.  
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Figure 1.5 | Schematic of a quadrupole analyser, consisting of four perfectly 
parallel (shown) or hyperbolic rods with a circular cross section. Adjacent 
rods have the opposite sign. Resonant ions (red) have a stable trajectory 
through the analyser; non-resonant ions (blue) collide with the quadrupole 
rods and discharge.  
 
Quadrupoles operating in only RF mode can focus an ion beam by creating a 
potential well along their central axis. This has led to the development of hexapoles 
and octapoles, which are utilised as ion guides in many modern mass spectrometers 
to transfer ions between different sections and vacuum gradients. Identical principles 
apply to those described above, although the shape of the potential well differs 
according to the number of rods present. Quadrupoles have the greatest focussing 
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1.4.3.2. Time of Flight Analyser 
 
Conceptually described in 1946 
120
 and commercially developed in 1955 
121
, time of 
flight (TOF) mass analysers accelerate ion packets into a drift tube via a potential 
difference, or pusher pulse. Following this they enter a field-free region in which 
their velocity is dependent on their m/z ratio. Therefore their m/z can be inferred from 





Leaving the source, the kinetic energy (Ek ) of an ion with mass (m) and total charge 






 Equation 1.1 
 
From basic equations of motion the time taken (tf) for the ion to travel the distance d 
at velocity v is 
v
d

















 Equation 1.3 
 
Equation 1.3 demonstrates how the m/z ratio of the ion can be calculated from its 
time of flight. There is no theoretical upper limit to the mass range which can be 
analysed by a time of flight mass analyser.  
 
However the closer the ion’s proximity to the accelerating voltage the greater the 
potential difference it experiences. Therefore ions of the same m/z ratio could enter 
the drift tube with differing kinetic energies, contrary to the equations above. The 
resolution of original linear drift tubes suffered as a result of this as these ions would 
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arrive at the detector at slightly different times. This problem was solved by the use 
of a reflectron (Figure 1.6). 
 
Ion beam
Ion with high 
kinetic energy







Figure 1.6 | Schematic of a TOF mass analyser. Ions with identical mass but 
differing kinetic energy entering the TOF arrive at the detector at the same 
time. This improves mass resolution by eliminating differences in the energy 




 is a series of ring electrodes which create a retarding field, acting as 
an ‘ion mirror’ to reflect ions back towards the detector. Ions which leave the pusher 
with a higher kinetic energy travel further into the reflectron than those with a lower 
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kinetic energy but identical mass. Thus the distance ions with a high kinetic energy 
travel inside the reflectron is further; adjusting the ion mirror enables ions of the 
same m/z ratio to arrive at the detector at the same time, regardless of their kinetic 
energy. This, coupled with the effective doubling of the length of the TOF tube, 
increases instrument resolution dramatically, although with the penalty of 
introducing a mass limitation.  
 
1.4.3.3. FT-ICR Analyser 
 
Fourier Transform Ion Cyclotron Resonance (FT-ICR) MS was developed in 
1974 
123
 and a comprehensive review has been published subsequently 
124
. FT-ICR 
MS can obtain very accurate mass measurements, and due to its high resolution, 
isotopic baseline resolution of high charge states. It is based on the principle that ions 
in a uniform magnetic field will experience a force perpendicular to the direction of 
the applied magnetic field. This is known as the Lorentz force and is described by 









×===   Equation 1.4   
 
Ions travelling at a constant speed will be diverted by the Lorentz force into an arc - 
cyclotron motion.  As the Lorentz force acts as a centripetal force and can be 
described by Equation 1.5 where m is mass, r is radius of ion path curvature, z is 






  Equation 1.5 
r
v
=ω   Equation 1.6 
 
Further manipulation of Equation 1.5 and Equation 1.6, where  is angular velocity, 
results in:  
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rzBrm ωω =2  Equation 1.7  
 
This can be transformed into: 
m
zB
=ω  Equation 1.8 
 
Thus ions of the same m/z ratio, regardless of their kinetic energy, have the same ICR 
frequency. In practice, ions are pulsed into the ICR cell where they are trapped by 
confining potentials applied to the trapping plates. Ions can be stored in the ICR cell 
for hours, where they undergo motion due to the magnetic and electrical forces they 
experience. This motion is best described as cyclotron motion around the centre of 























































Figure 1.7 | Schematic of an FT-ICR cell. The ion undergoes cyclotron 
motion orthogonal to the magnetic field.  
 
Ions undergoing cyclotron motion do not produce any detectable signal. The ions 
must be excited using a resonant frequency, applied to parallel plates of the ICR cell 
(which are perpendicular to the magnetic field direction), to obtain larger cyclotron 
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radius 
125
. Ions of same m/z move in coherent packets; these packets, passing near the 
electrodes, induce a charge in that electrode. This creates an alternating current in the 
detector circuit and this signal is amplified and digitised. An excitation frequency 
sweep (broadband excitation) allows ions of multiple m/z values to increase their 
orbit and be detected 
123
. This is in contrast to other mass spectrometry 
instrumentation where ions are destroyed in the process signal detection. Resolution 
is limited by length of acquisition time (as all ions are detected simultaneously) and 




1.4.4.  Detectors 
 
Mass spectrometry detectors are devices which detect ions and create an electric 
current of corresponding amplitude. There are several types of commonly used 
detectors, a comprehensive review of which can be found in ‘Metastable Ions’ by 
Cooks 
126
 but is beyond the scope of this thesis. The detectors utilised in the 
experiments in the following chapters are described below.   
 
1.4.4.1. Photomultiplier Detector 
 
If only the quadrupole mass analyser is used, ions are detected on their entry to the 
TOF tube by a photomultiplier (Figure 1.8). The incident ion beam strikes a 
conversion dynode which emits electrons. These electrons then collide with a 
phosphor screen which emits photons. These photons pass into a photomultiplier 
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Figure 1.8 | Schematic of the photomultiplier detector. Red dotted line 
indicates the path of the ion when the detector is not used. 
  
1.4.4.2. Microchannel Plate Detector 
 
Microchannel plate detectors (MCPs) consist of many miniature electron multiplier 
channels (Figure 1.9). When an ion collides with the semiconductor surface on a 
microchannel, electrons are ejected. These electrons also strike the microchannel 
walls, displacing more electrons. This process is repeated causing a cascade of 
electrons travelling towards the ground potential which are accelerated into a series 
of continuous dynode electron multipliers, as each microchannel can be thought of as 
a continuous dynode structure 
127
. This progression results in a measurable current 
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corresponding to the detection of one ion. An amplifying effect of up to 10
8 
can be 








Figure 1.9 | Schematic of a MCP detector, with an enlargement of one 
microchannel. 
 
Short secondary electron path lengths in the channels enable a quick response, 
allowing the determination of precise arrival times and correspondingly high signal 
resolution.  
 
1.4.4.3. FT-ICR MS Detector 
 
A broadband frequency sweep produces a signal in the detector plates which is a 
superposition of sine waves of different frequencies and amplitudes induced by the 
proximity of different m/z ion packets. Applying a Fourier transform to this results in 
a spectrum of the component cyclotron frequencies and their respective amplitudes. 
Cyclotron frequency can then be converted into a conventional m/z versus ion 
intensity spectrum using Equation 1.8.  
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1.5. Ion Mobility Mass Spectrometry 
 
1.5.1.  Introduction 
 
Ion Mobility Mass Spectrometry (IM-MS) is a gas-phase electrophoretic separation 
technique which differentiates between ions based on their mass, charge and 
mobility. Historical investigations into the movement of ions in different gases 
128,129
 
led to the development of the first drift tube where ions travel through a buffer gas 
filled tube under the influence of a weak electric field 
130
.  Combining ion mobility 
spectrometry (IMS) with MS instrumentation created a powerful new analytical 
technique 
131
. Since its conception in 1963 the field of IM-MS has blossomed, with a 
significant growth in publications utilising this technique 
132,133
. There are three types 
of IM-MS instrumentation most commonly used in industry and research groups; 
Field Asymmetric Ion Mobility Spectrometry (FAIMS), Travelling Wave Ion Guides 
(TWIGS) and Drift Tube Ion Mobility Mass Spectrometry (DT-IM-MS). Of these 
DT-IM-MS most closely resembles historical IMS apparatus. All IM-MS 
experiments performed in this thesis utilised DT-IM-MS, which is described in detail 
below. FAIMS and TWIGS are briefly described, comprehensive reviews of all 
IM-MS instrumentation can be found in both Hill et al. 
134






By measuring the time taken for ions to move through a drift cell, filled with a buffer 
gas, under the influence of a weak electric field, it is possible to determine the 
rotationally averaged collision cross sections of the ions present. The larger the cross 
section of the ion available for collisions with the gas atoms (known as the collision 
cross section or CCS), the slower that ion will drift through the cell. Small, compact 
ions will travel more quickly than larger ions with an extended conformation (Figure 
1.10). Ion intensity is recorded as a function of time, in a plot called an arrival time 
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distribution (ATD). This measures the mobility of the ion which provides details 

































































Figure 1.10 | IM-MS separation: a diagram showing how the charge and 
conformation of ions influences their arrival time distribution. 
  
The electric field can be described in terms of the length of the drift cell and the 
voltage applied across the cell by Equation 1.9: E is the electric field across the cell, 
L is the length of the drift cell and V is the potential applied across the cell. 
L
V
E =   Equation 1.9 
 
The ratio of the electric field applied across the cell to the buffer gas number density 
(E/N) determines the motion of an ion through the cell. The physical unit of the ratio 




. At high values of 
E/N ions align in the electric field and their mobility is dependent on E. Values of 
E/N which are  10 Td are known as the low field limit; in the low field limit ion 
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velocity is constant and linearly proportional to the electric field 
136
, as described by 
Equation 1.10 where vd is drift velocity and E is electric field. The constant of 
proportionality, K, is the low field ion mobility.  
EKvd ⋅=   Equation 1.10  
 
Low field ion mobility is proportional to buffer gas pressure, inversely proportional 
to ion CCS and can be converted to the ‘reduced’ mobility K0 by Equation 1.11 









0 =      Equation 1.11 
 


















==   Equation 1.12 
 
Arrival time, ta, measured by the ATD, is the time from ion injection into the cell 
until detection. It is equal to the time taken for the ions to drift through the cell, td, 
plus the time the ions spent outside the drift cell (known as the dead time t0). 
doa ttt +=   Equation 1.13 
 
If the temperature of the drift cell is kept constant, a graph of arrival time against P/V 
will give a linear relationship with an intercept equal to the dead time. The gradient 
of the line of best fit is equal to the inverse of the reduced ion mobility, as the values 
of L and T in the equation are known.   
 
The relationship between reduced ion mobility and the ion’s CCS is described by 
Equation 1.14: z is ion charge, e is electron charge, N0 is the buffer gas number 
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density,  is the reduced mass of the buffer gas and ion, kb is the Boltzmann constant, 




















  Equation 1.14 
 
By measuring the ATD and obtaining the reduced ion mobility, the momentum 
transfer collision integral, , can be calculated. , by kinetic theory, can be 
approximated to the CCS of the ion . For most geometric shapes of ion, the 
differences between  and  can be corrected for empirically. CCSs are dependent 
on the buffer gas present in the drift cell 
137,138
. The resolution of DT-IM-MS 
depends on gas pressure and the length of the drift cell, as increasing the time ions 
spend in the drift cell allows the greatest mobility separation. With DT-IM-MS it is 






Introduction of commercially available TWIGS instruments; the Synapt G1 
140
, G2, 
and as of 2012, the G2-S, has expanded the number of research groups with the 
capability to use IM-MS. In brief TWIGS instruments use a series of stacked ring RF 
ion guides 
141
, combined with a travelling wave of voltage, to separate ions. Ions are 
stored in the first ion guide before injection into a mobility separator where a 
travelling wave of transient DC voltages are applied in conjunction with an RF 
voltage. Ions with highest mobility ‘ride’ the crest of the travelling wave, whilst 
lower mobility ions fall behind successive wave fronts before reaching the end of the 
separator. Upon exiting the separator the third ion guide conveys the ions to the TOF 
compartment. There is no theoretical equation relating the mobility of ions in 
TWIGS devices and their CCSs 
142
, therefore a calibration must be applied using 
standards whose CCSs, determined by DT-IM-MS, are known 
143,144
. However 
parameters on commercial TWIGS instruments must be carefully controlled to 
prevent excessive heating of ions, which can induce conformational changes 
145
. 
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Thus issues of calibration and ion heating remain a caveat in comparing TWIGS gas-




FAIMS, in opposition to traditional DT-IM-MS, utilises high field mobility of ions at 
atmospheric pressure 
146,147
. Ions travel between two electrodes against a flow of gas; 
one electrode is grounded whilst an asymmetric waveform constituting long low 
voltages and short, opposite polarity, high voltages is applied to the second. The 
electric field the ions experience is orthogonal to the gas flow and causes them to 
follow oscillating paths. To prevent collision with the electrodes a compensating DC 
voltage is applied. The ratio of an ion’s high field to low field mobility determines 
which value of the compensation voltage will allow the ion to pass through the 
device 
148
, hence allowing the separation of different ions. An ion’s low field 
mobility, and hence its CCS, cannot be determined from the FAIMS technique; 
however FAIMS is a powerful separation technique alone, and when combined with 
DT-IM-MS can provide an additional separation dimension. Commercial instruments 
are available from Thermo Scientific, Ionalytics and Agilent Technologies in 
collaboration with Owlstone.    
 
1.6. Molecular Modelling 
 
Theoretical CCSs can be calculated using molecular coordinates obtained from an 
array of biophysical techniques such as NMR, X-ray crystallography and molecular 
dynamics simulations. The comparison of experimentally derived CCSs with these 
theoretical CCSs can allow structural assignments, or at least, indications of structure 




 can calculate CCS from molecular coordinates using one of three 
methods; exact hard sphere scattering (EHSS), projection approximation (PA) or the 
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trajectory method (TM). The PA is the least computationally demanding as each 
molecular atom is modelled as a hard sphere with interactions between buffer gas 
and ions also as hard sphere collisions; the resulting CCS is averaged over all 
possible orientations of the ion. An improvement on the PA is the EHSS model 
which includes terms for multiple collisions and scattering. The most representative 
model of the interactions between buffer gas atoms and ions is the TM, which 
considers the analyte ion as a collection of molecules, possible multiple collisions 
and the long range interactions which occur between drift gas atoms and the ion. 
However, as a result of this it is the most computationally expensive. For small 
convex ions the PA provides a sufficiently accurate representation of CCS, however 
for proteins it drastically underestimates the CCS. For these more complex 




1.7. Use of MS and IM-MS to Study Biological 
Molecules 
 
As MS and IM-MS measurements of biological molecules are performed in the gas-
phase the relevance of these gas-phase structures to solution phase structures is an 
important question. Initial evidence comes from the fact that the mass spectrum of a 
protein is influenced by its solution environment prior to ionisation and entry into a 
mass spectrometer 
153,154
. Denaturing conditions produce a larger and more highly 
charged envelope of species than those produced from a ‘native’ solution, suggesting 
that the protein has unfolded under these solution conditions, and these unfolded 
species are preserved into the gas-phase. It could also be argued that the gas-phase 
environment of a mass spectrometer, where the dielectric constant is 1, is more 
similar to that proteins experience in their cellular environment (from 2 - 6 
155
) than 




. Upon desolvation a loss of 
hydrophobic interactions will occur and electrostatic interactions will be 
strengthened. Despite these changes, soft landing experiments on lysozyme and 
trypsin found that their biological activity was unimpaired by their passage through a 
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Evidence for the retention of non-covalently bound solution structures in the gas-





and haemoglobin complexes 
109
. Robinson et al. 
160
 performed one of the first studies 
to provide direct evidence that protein quaternary complexes could remain in their 
native form in a mass spectrometer. Using a TWIG instrument, CCSs of assemblies 
of the tryptophan RNA binding protein, TRAP, were determined. X-ray 
crystallography has shown that TRAP forms a ring topology of 11 subunits 
161
. MS 
of the unbound apo form of TRAP revealed a charge state envelope of 22+ to 19+ 
ions. IM-MS measurements revealed that the conformation of the assembly is 
dependent on charge state, although the charge is below the limit calculated to cause 
coulombic unfolding. The 19+ ion presents predominantly in one conformation, the 
CCS of which agrees with the calculated CCS of the X-ray ring structure. As these 
experiments were performed in the early days of TWIGS, and corresponding early 
calibration protocols, absolute CCS values should be treated with caution. CCSs of 
the 20+ ion exhibit a bimodal distribution, indicating considerable structural 
heterogeneity; from a ring topology to more collapsed conformations. The two most 
highly charged ions, 21+ and 22+, have compact CCS distributions which, in 
conjunction with modelling results, are postulated to be very compact structures with 
closely packed subunits. Thus the 11-membered ring topology of the complex was 
postulated to have been preserved, in vacuo and without the presence of bulk water.  
 
Stability of the TRAP ring complex is known to increase on binding to tryptophan 
(Trp) 
161
, although the MS spectra of apo TRAP and TRAP in the presence of Trp 
appear very similar. The maximum CCS experimentally observed for both apo and 
Trp bound form are similar, from which it can be inferred that Trp bound TRAP 
retains its ring topology. However, for the 20+ ion the conformational heterogeneity 
of the apo TRAP ion is converted into a single conformation which is of a CCS 
consistent with the ring structure. From this difference it can be inferred that the 
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postulated ring structure of TRAP is indeed more stable in the presence of Trp even 
in the absence of bulk solvent.  
 
Many aspects of protein structure can be preserved in the absence of solvent, 
including secondary, quaternary and/or compact structure and hydrogen bonding 
interactions 
162
. It is not expected that identical interactions will be present in the 
presence and absence of bulk solvent, but that the overall size and majority of the 
binding interactions found in solution can be successfully preserved in vacuo. 
Breuker and McLafferty 
163
 evaluate the temporal evolution of protein structure 
which occurs on transfer into the gas-phase from experimental evidence and 
molecular dynamics (MD) simulations. On the 10
-12
 seconds timescale after 
desolvation, charged side chains collapse which can transiently stabilise the native 
fold of a large, compact proteins, whilst on the 10
-3
 seconds timescale, loss of 
hydrophobic interactions and dissociation of electrostatic bonds can occur. New non-
covalent bonds can be formed within seconds to minutes. However ionic interactions 
and those of residues buried deep in the core of the protein are unlikely to be affected 
by desolvation.  
 
1.7.1. Amyloidogenic Peptides and Proteins 
Studied by MS, IM-MS and Modelling 
 
A growing body of work assessing the configurations of species formed during 
aggregation has utilised MS 
13
 and IM-MS techniques, often combined with 
simulations; a brief review follows of those systems which have been investigated 
most extensively.  
 
1.7.1.1. Islet Amyloid Polypeptide 
 
The aggregation of human islet amyloid polypeptide (hIAPP) into amyloid fibrils is 
implicated in the pathogenesis of type II diabetes 
164
. However, the rat homologue, 
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rIAPP, which differs by six residues in the ‘core mutation region’, does not form 
amyloid fibrils 
165
. The sequences of hIAPP and rIAPP are shown below with the 
differing residues highlighted.  
hIAPP:      KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
rIAPP:      KCNTATCATQRLANFLVRSSNNLGPVLPPTNVGSNTY 
This provides an opportunity to compare the non-amyloidogenic oligomeric species 
formed by rIAPP and the on or off pathway oligomers present in the lag phase of 
hIAPP fibrillation 
27
. At pH 6.4 mass spectra of rIAPP and hIAPP have almost 
identical charge state distributions; a dominant [M+3H]
3+
 peak, a less intense 
[M+4H]
4+
 and a small signal from a [2M+5H]
5+
 species (Figure 1.11A) 
166
. However 
important conformational differences can be divulged from the monomer ATDs. For 
the dominant 4+ charge state hIAPP contained a later arriving ATD peak in addition 
to the two earlier arriving peaks which are shared with rIAPP. Further studies 
implied that this extended conformer originated from a solution structure family 
rather than being an experimental artefact. Replica exchange MD (REMD) 
simulations of rIAPP and hIAPP monomers identify the mutual compact structures as 
helix-coil, whilst the unique hIAPP extended conformation is suggested to 
correspond to a -hairpin structural family. Secondary structure sequence analysis 
confirmed that sequence variations between rIAPP and hIAPP have a drastic effect 
on peptide conformation, with the ‘core mutation region’ adopting coiled and -
strand structures respectively.  
 
The population of this -hairpin family by hIAPP could be responsible for its 
amyloidogenic nature, supported by the absence of any -hairpin conformer in rIAPP 
experiments and simulations 
166
, and similarities with a solid-state NMR structure 
167
. 
Study of the 5+ dimeric species which is present in both rIAPP and hIAPP at lower 
intensities than the monomeric species (Figure 1.11A) 
168
 revealed multiple 
conformational families (Figure 1.11B). The most populated hIAPP dimer 
conformation is 12% larger than the rIAPP dimer, consistent with the hIAPP -
hairpin monomers which were 17% larger than the coil-rich rIAPP monomers 
166
. It 
is therefore suggested that hIAPP dimers could be composed of -hairpin monomers.  
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Figure 1.11 | IAPP A) n-ESI mass spectrum of hIAPP. (B) Rat and Human 
IAPP dimer ATDs contain multiple features. C) hIAPP trajectory shows 
conversion of coil into -strand upon dimerisation. Figure and caption from 
Dupuis et al. 168. 
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MD simulations of dimers suggest that rIAPP forms disordered compact dimers from 
coil-rich monomers, whereas hIAPP dimers are more extended and -strand rich. The 
interaction of hIAPP monomers occurs between -strand conformational areas 
containing the mutation region and side by side assembly of -hairpins was the 
dominant binding mode 
168
. Simulations have also shown some evidence that hIAPP 
-strand rich monomer interfaces can recruit coil and helix regions in during the 
dimerisation process. Thus hIAPP extended -hairpin monomers form extended -
strand rich dimers (Figure 1.11C), in contrast to the rIAPP formation of compact, 
coil rich dimers 
166
. To summarise, IM-MS and MD have elucidated a possible 
mechanism for the ability of hIAPP to aggregate, contrasted with unamyloidogenic 
rIAPP.  
 
1.7.1.2. 2 -microglobulin 
 
2-microglobulin (2m), is part of the major histocompatibility complex class 1 
molecule 
169,170
, which protects native cells from attacks by T lymphocytes 
171
. A 
complication of long term haemodialysis is dialysis-related amyloidosis, where 
fibrils largely composed of 2m form in tissues. This is believed to be due to the high 
concentrations of circulating 2m which build up in the bloodstream as they are not 




The presence of different conformers of a protein can be inferred from the existence 
of different charge state distributions in an ESI-MS spectrum 
173
.  This allowed 
Ashcroft et al. to follow the pH driven unfolding of 2m via a broadening of charge 
state distribution and a shift to more highly charged protein ions and compare the 
behaviour of wild type (WT) 2m with that of mutants 
174
. Three conformational 
families of 2m monomer were identified at pH < 5; a native, partially folded and an 
acid unfolded state 
174,175




IM-MS has significantly advanced research into the early aggregation in vitro of 
2m. It allows the unambiguous separation of conformers prior to mass analysis and 
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thus makes superfluous the deconvolution of charge state distributions. The 
conformational families of oligomers can be quantified in terms of shape, dynamics 
and population 
177,178
 and monitored in different solution conditions.  
 
 
Figure 1.12 | 2m (a) and (b) Time course mass spectra of aggregating 17 
M 2m at 37 °C of in (a) 150 mM ammonium formate at pH 3.6 and (b) in 
100 mM ammonium formate pH 2.5 (shaken at 200 rpm). (c) and (d) Fibril 
growth kinetics at (c) pH 3.6 and (d) pH 2.5 monitored using Thioflavin T 
fluorescence (continuous line in (c) and open squares in (d)). Concentration 
of monomeric 2m measured by nESI-MS is shown in (c) and (d) as filled 
circles (error bars represent one standard deviation from the mean). (e) and 
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(f) EM images of fibrils formed at (e) pH 3.6 and (f) pH 2.5 (scale bar 
200 nm). Figure and caption from Smith et al. 91 
 
Under different conditions in vitro two fibril morphologies have been 
observed 
70,91,179
. Low pH and ionic strength solution conditions result in the 
formation of long, straight (LS) fibrils (Figure 1.12f) via a nucleation mechanism, 
conversely higher pH and ionic buffer strength result in the spontaneous assembly of 
shorter worm like (WL) curved fibrils (Figure 1.12e). During aggregation 2m 
monomer depletion and corresponding evolution of oligomers can be observed by 
ESI-MS 
91
 for both fibril species (Figure 1.12a,b). In the lag phase of LS fibril 
assembly, at pH 2.5, the acid unfolded monomeric conformation is the most highly 
populated, with dimer, trimer and tetramer species also detected by 
ESI-IM-MS 
91,180
. Calculation comparison with experimental CCSs suggest that 




At pH 3.6 2m is chiefly a partially folded monomer (as measured by NMR); 
additionally less abundant oligomers of dimer to hexameric order are 
present 
91,174,179
. When the ionic buffer strength is increased to initiate WL fibril 





experiments show dynamic and rapid oligomeric subunit exchange. When exchange 
rates for trimer, tetramer and pentamer decrease, oligomers of >14-mer are observed. 
It was postulated that the CCS values of these suggested that, instead of a globular 
shape, the oligomers consist of stacked monomers held together by edge on edge 
interactions which retain a -sheet native structure 
180
. Under both LS and WL fibril 
conditions, high charge state trimers display fast subunit exchange whilst more 
compact, lower charge state trimers are more stable 
180,181
. Tetramers present in the 
LS fibril assembly pathway are less compact and more highly charged than the 
compact tetramers which are present only in WL fibril assembly 
180
. It is 
hypothesised that an increase in partially folded monomer populations could lead to 
compact tetramers, which might catalyse the spontaneous WL fibrillation. This 
implication from this hypothesis is that monomer conformation has an effect on 
mature fibril morphology 
180
.  
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1.7.1.3. -synuclein 
 
Aggregated -synuclein is the predominant component in Lewy bodies and neuritis, 
which are characteristic of Parkinson’s disease and related synucleinopathies 
182
, and 
is implicated in the pathogenic process which culminates in Parkinson’s disease. 
Protofibril assemblies of -synuclein cause membrane leakage and destroy vesicular 
membranes 
183
 suggesting that non-fibrillar oligomeric species are cytotoxic species 
for neurons. Frimpong et al. recently performed a MS study of -synuclein under 
conditions which were unlikely to cause amyloid formation in vitro 
184
. They 
observed four distinct conformational monomer states, from random coil to highly 
compact structures; a conformational heterogeneity which has been observed in other 
studies 
185
. Compact structures were consistent across a pH range of 2.5 to 10 and an 
ethanol content of 0 to 60%, but were most populous in acidic conditions, whilst 
partially folded conformations were present in significant percentages of alcohol 
184
. 
CD experiments have been utilised to analyse the different secondary structure 
present in -synuclein under different experimental conditions; at low pH -
synuclein displayed increased -helical content, whilst the presence of ethanol 
increased the quantity of -sheet present 
186
. These experiments led Frimpong et al. 
to postulate that the compact structures contained increased -helical structure whilst 
partially folded conformations contained high -sheet content.  
 
Bernstein et al. observe pH dependent conformations of  -synuclein ranging from 
compact monomers at pH 2.5 to extended monomeric conformations at neutral 
pH 
187
. This is explained by the intrinsically disordered structure of -synuclein at 
neutral pH and its high net negative charge. Protonation of the acidic C-terminus at 
pH 2.5 decreases the net charge and causes partial folding, a supposition which is 
supported by solution phase studies which suggest the formation of a partially folded 
intermediate is the nucleating step to fibrillogenesis 
188
. It is postulated by Frimpong 
et al. that the partial folding at low pH could be -helical in nature 
184
. When 












 compared favourably to compact globular structures, whereas higher 
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charge state CCSs agreed with elongated structures. Injection energy experiments 





A family of compact monomers are observed in the ATDs of Parkinson’s disease 








.  Conversely another mutant A30P, also related with early onset Parkinson’s, 
displays only a compact species in the ATD of [M-6H]
6-
. This suggests that the A30P 
mutation causes a structural enlargement, preventing the formation of a compact 
structure when the net charge greater than -6. Spermine is a polyamine, present in 
neurons, which binds to -synuclein at the C-terminus and is known to increase the 
aggregation rate 
75
. The addition of spermine to the WT and two mutants at pH 7 
resulted in a dominant -6 spermine--synuclein complex peak and a reduction of the 
dominant free -synuclein charge state from -10 to -6 
189
. From ATD space it is 
visible that the compact monomers are more highly populated in the presence of 
spermine. The increased aggregation rate of -synuclein in the presence of spermine 





Prions are glycoproteins which can undergo a conformational transformation from 
the normal -helical cellular form PrP
C






 has a high 
aggregation propensity, enriched
 
-sheet structure, and is resistant to degradation by 
proteases and high temperatures 
191
. Cerebral accumulation of fibrillar PrP
Sc
 is 
diagnostic of transmissible spongiform encephalopathies (TSEs), a class of highly 
infectious neurodegenerative diseases for which there is no effective treatment. The 
extreme stability of PrP
Sc
 causes problems with medical instrument sterilisation, and 
TSEs can cross species barriers by ingestion of PrP
Sc 192
.   
 
Residues 106 to 126 of PrP are highly conserved amongst the PrP homologues, and  
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the synthetic PrP (106-126) peptide is amyloidogenic, neurotoxic in vivo and in vitro 




. A comparative study of PrP (106-126) and 
two non-amyloidogenic (in vitro) variants, a species where the methionine residues 
are oxidised 
194
 and a scrambled PrP (106-126) control sequence, utilised IM-MS and 
REMD. ATDs of PrP (106-126) and its oxidised form contained an extended 
conformation which was assigned by REMD secondary structure predictions, 
supported by CD measurements, as a -hairpin monomer 
193
. At 24 and 72 hours the 
ATD of the PrP (106-126) contained earlier arriving peaks, which correlated with the 
loss of the extended conformation. These peaks were assigned as oligomers, 
oligomerisation was only observed for PrP (106-126); ATDs of scrambled sequence 
peptide and oxidised PrP (106-126) did not change over same time period. 
PrP (106-126) and oxidised PrP (106-126) peptides have comparable secondary and 
tertiary structure, implying that the inability of methionine oxidised peptide to 
aggregate is a result of a reduction in inter-peptide hydrophobic interactions, which 
may inhibit -sheet formation. Results from CD experiments indicate that the 
scrambled sequence peptide displays less -sheet content and a higher proportion of 
-helical and random coil components; structural differences which are  probably 
accountable for its unamyloidogenic characteristics.  
 
The conformational stability of residues 90-231 of recombinant Syrian hamster prion 
protein PrP, -PrP, was studied by Grabenauer et al. 
195
.  -PrP is -helical, does not 
aggregate and is deemed to be comparable with  PrP
C
. MS shows a bimodal charge 
state distribution, representative of distinct conformational families present in 
solution. IM-MS data support this and observe an additional conformational family. 
Compact, intermediate and extended conformational families are observed, present in 
monomer charge states; +7 and +8, +7 to +11 and +12 to +15 respectively. Ions 
which were injected into the drift cell with low injection energy were 
conformationally more compact suggesting that these are the structures present in 
solution. Increasing the injection energy of -PrP caused a transition to more 





were exceptionally stable. Conformational stability studies, investigated using 
temperature, found that compact structures were converted into intermediate 
Chapter 1: Introduction and Motivation 
 







 conversion from compact 
conformation to an extended state was complete by 475 K. [M+10H]
10+
 completely 
converted to an extended structure by 575 K. The most thermally stable was 
[M+9H]
9+
, which retained intermediate structure at 600 K. Based on the amino acid 




 are the most likely charge states to be 
present in solution at physiological pH, suggesting that these solution structures have 
an unusually high stability. The common resistance to thermal denaturation and 
remarkable conformational stability shared by PrP
Sc
 and -PrP suggests features of 
PrP
C




Another conformational isoform of recombinant Syrian hamster prion protein 
PrP (90-231) was studied by IM-MS in direct comparison with -PrP (90-231) 
196
. 
The isoform is identical in amino acid sequence but has been refolded into a -sheet 




-helical -PrP (90-231), the 
conformational isoform has been observed to aggregate in solution. A 
physiologically relevant pH study was undertaken as PrP experiences an acidic 
environment in the cell (pH 5.5) and a subsequent neutral pH environment when 
anchored to the cell membrane. At neutral pH no difference was observed in the 
ATDs of the two isoforms, however at pH 5.5 differences were apparent. The ATD 
of -helical -PrP (90-231) was much broader than that of PrP (90-231), suggesting 
the presence of multiple conformations, and contained a more significantly populated 
later arriving peak. The pH environment had a greater influence on -PrP (90-231), 
which most closely resembles PrP
C
, than on the -sheet rich isoform. This study 
additionally advocates the use of IM-MS as a screening technique for the in vivo 
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1.8. Summary  
 
MS is the only technique that can separate the species present in the lag phase, 
identifying the many transient oligomeric orders according to their m/z ratios 
revealing their relative abundance. The hybrid technique IM-MS combined with 
molecular modelling enhances this picture by probing the conformational landscape 
of the aggregating system. In this thesis three aggregating systems are investigated; 
amyloidogenic transthyretin fragment (105-115), insulin and A peptides.  
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Descriptions of the instruments used in the following chapters are detailed, with 
schematic representations and typical tuning parameters. An example of data 
acquisition and processing is given for an ion mobility mass spectrometry 
experiment. Nano-electrospray conditions and solution preparation details are also 
provided. 
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2.1. Reagents  
 
Organic solvents were analytical HPLC grade and supplied by either Sigma Aldrich 
(Dorset, UK) or Fisher Scientific Ltd (Loughborough, UK). Acids were supplied by 
VWR International Ltd (UK). Very pure water was distilled using an Arium 611 
water purification unit (Sartorius, Göttingen, Germany) or supplied by Fisher 
Scientific Ltd (Loughborough, UK). Solids were weighed with a Mettler AC100 
balance to an accuracy of ±0.0001 g. Solution pH readings were taken using a 
Jenway 3505 pH meter to an accuracy of 0.01 units. Details of peptide and protein 
suppliers and purities can be found in the relevant chapters. Sodium iodide, used as a 
calibrant, was supplied by Sigma Aldrich (Dorset, UK).  
 
2.2. Mass Spectrometry 
 
2.2.1. Sample Introduction - Nano-Electrospray 
Ionisation  
 
All MS and IM-MS instruments utilised were fitted with nano-electrospray (n-ESI) 
sources. n-ESI capillaries were prepared in house from thin walled glass capillaries 
(Precision Instruments, Stevenage, UK) using a micropipette puller (Fleming/Brown 
P-97, Sutter Instruments, Novato, CA, USA). Sample solutions were inserted into 
capillaries using gel micro-loading tips (Eppendorf, Hamburgh, Germany) and 
charged via the insertion of a thin platinum wire, to which a voltage was applied. 
Capillary voltage was adjusted to give optimum spraying conditions and ideally a 
consistent visible plume of ions. The precise voltage used depended on the sample 
solution composition (e.g. high organic content required low capillary voltages due 
to increased solution volatility) but voltages were normally in the region of 1.6 kV. 
For viscous aggregated samples a nitrogen backing gas was applied to encourage a 
good spray.  
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Application of decreasing voltages diverts the plume of nebulised ions, produced by 
the n-ESI source, perpendicularly into the mass spectrometer through the sample 
cone opening, and again perpendicularly through another source component called 
the extractor cone (Figure 2.2). This is known as a Z Spray ion source, and has the 
advantage of eliminating the bulk of the neutral species (excess solvent, uncharged 
proteins etc), thus preventing the need for frequent cleaning of the source 
components. Unless stated otherwise the source block was heated to 80 
°
C to 
promote ion desolvation. Ions then pass through the RF lens and into the quadrupole 
analyser.  
 
2.2.1.1. Elevating the Source Pressure 
 
Gentle desolvation and an elevated source pressure enabled the transmission of larger 
aggregates with minimal fragmentation. To achieve elevated source pressures a 
Speedivalve (SP25, Edwards, West Sussex, UK) was inserted into the vacuum line 
between the source rotary backing pump and the source block. Partially closing the 
Speedivalve, thus throttling the source backing pump, enabled source backing 
pressures of up to one
 
mBar (as measured by a Pirani gauge (Edwards, West Sussex, 
UK) on the source rotary) to be achieved (Figure 2.3). All QTOF MS instruments 
and the IM-MS instrument utilised in the following experimental chapters possessed 
this source modification. Optimisation of the source pressure was undertaken for 
each system studied, the most favourable pressure being approximately 3x10
-1 
mBar 
for all instruments.  
 
2.2.1.2. Source Heating Block 
 
To enable samples to be heated during an MS or IM-MS experiment, a source 
heating block was designed and constructed. This consists of an aluminium block to 
hold the capillary carriage, with an additional space for the insertion of a cartridge 
heater. The cartridge heater used was rated 120 V and 20 W from the CSS series 
(Omega, USA). A power pack applies voltage to the cartridge heater, which is 
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regulated by a K type thermocouple in a thermostatic feedback loop enabling the 
aluminium block to be heated to a set temperature. When the desired temperature is 
reached, the power pack ceases to supply a voltage and subsequently, when the 










Figure 2.1 | Photo of the modified source block (A) with cartridge heater (B) 
inserted. The power supply (C) supplies a voltage via the red wires (D) to the 
cartridge heater. A thermocouple (E) detects the temperature of the source 
block and inputs this information via the green wires to the power pack (C). 
The temperature of the source block is detected by a thermocouple (G) and 
externally verified with a portable thermometer (F).  
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2.2.2. Ion Transfer, Analysis and Detection 
 
The quadrupole analyser can be used either as a mass filter or to select only ions of a 
specific m/z value for collision induced dissociation (CID). CID is performed in the 
hexapole collision cell (Figure 2.2), filled with argon gas at an adjustable pressure of 
~1.5 mBar. When CID is not performed ions traverse the collision cell after being 
accelerated through a potential difference, and the presence of argon gas improves 
the resolution of the resulting spectra. When CID is performed, ions of a specific m/z 
will enter the collision cell at increasing kinetic energies. Fragmentation of the ions 
will eventually occur and these fragments are recorded in the TOF detector. 
 
Upon exiting the collision cell ions pass through a transfer hexapole and into the 
TOF region (Figure 2.2). The pusher accelerates the ions into the TOF tube until they 
reach the reflectron where they are refocused and reflected back to the microchannel 
plate (MCP) detector. Ion detection signals are converted by a 4 GHz time-to-digital 
converter in the embedded computer and relayed to MassLynx software, resulting 
in a total ion count (TIC) chromatogram which can be deconvoluted into a mass 
spectrum.  
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2.2.3. Instruments 
 
Instruments used were a QTOF 2 and a QTOF Ultima, both manufactured by Waters 






























Figure 2.2 | Schematic of a QTOF mass spectrometer. All relevant 
components are labelled.  
 
QTOF mass spectrometers have three sections; the source, quadrupole and TOF, 
which are pumped differentially to create a decreasing pressure gradient along the 
length of the mass spectrometer (Figure 2.2). Each region is kept at vacuum by a 
turbomolecular pump, backed by a rotary pump (Figure 2.3). Representative 
pressures for each region of the instruments used are detailed in Table 2.1, Table 2.2 
and Table 2.3.  
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Figure 2.3 | Schematic of a QTOF mass spectrometer with pumping 
components and vacuum gauges labelled. The schematic is adapted from 
the Waters QTOF 2 users manual.    
 
All instruments were calibrated with a 2 mgml
-1
 aqueous solution of NaI, with 
known m/z values of NaI clusters used to obtain an accurate calibration. Data were 
processed using MassLynx Software 4.1 (Waters, Manchester, UK). 
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2.2.3.1. Instrument Tuning Parameters 
 
Instrument Parameters Setting 
Capillary / kV 1 to 2 
Cone / V 10 to 40 
RF Lens 0.5 
Aperture 1 0 
Source / °C 80 
LM Resolution 5.0 
HM Resolution 5.0 
Collision Energy 8.0 
Ion Energy 2.0 
Steering / V 0.00 
Entrance / V 70.0 
Pre-filter 6.0 
Transport 2.0 
Aperture 3 9.0 
Acceleration / V 200 
Focus / V 0 
Tube Lens / V 100 
Offset 1 / V -0.3 
Offset 2 / V 0.0 
Pusher / V 980 
TOF / kV 9.10 
Reflectron 35.52 
Pusher Cycle Time / µs 150 
Pusher Frequency / Hz 666.6667 
Multiplier 550 
MCP 2000 
TDC Start / mV 750.0 
TDC Stop / mV 150.0 
TDC Threshold 0.0 
Source Pressure / mBar 3.07 x 10-1 
Analyser Pressure / mBar 1.45 x 10-3 
TOF Pressure / mBar 4.27 x 10-7 
 
Table 2.1 | Typical Settings for the QTOF Ultima in positive polarity. 
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Instrument Parameters Settings / +ve mode Settings / -ve mode 
Capillary / kV 1 to 2 1 to 2 
Cone / V 10 to 40 10 to 40 
Extractor 0 0 
RF Lens 0.55 0.55 
Source / °C 80 80 
LM Resolution 5.0 5.0 
HM Resolution 5.0 5.0 
Collision Energy 10.0 10.0 
Ion Energy 2.7 2.8 
Steering / V 0.00 1.00 
Entrance / V 70.0 65.0 
Pre-filter 6.0 5.0 
Transport 3.7 20.0 
Aperture 2 8.0 14.5 
Acceleration / V 200 200 
Focus / V 1 0 
Tube Lens / V 100 120 
Offset 1 / V -0.5 0.0 
Offset 2 / V 0.0 0.0 
Pusher / V 980 980 
TOF / kV 9.1 9.1 
Reflectron 34.66 34.66 
Pusher Cycle Time / µs 124 124 
Pusher Frequency / Hz 8064.5161 8064.5161 
Multiplier 650 550 
MCP 2000 2000 
TDC Start / mV 300.0 300.0 
TDC Stop / mV 50.0 50.0 
TDC Threshold 0.0 0.0 
Source Pressure / mBar 1.75 x 100 1.77 x 100 
Analyser Pressure / mBar 1.5 x 10-3 1.5 x 10-3 
TOF Pressure / mBar 3.39  x 10-7 3.39  x 10-7 
 
Table 2.2 | Typical Settings for the QTOF 2 in positive and negative 
polarities.  
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Ion mobility mass spectrometry measurements were performed on an in-house 
modified QToF 1 (Waters, Manchester, UK), known as the “MoQTOF” 
1
. It has been 
adapted to be capable of making temperature dependent CCS measurements via the 
inclusion of a 5.1 cm long copper drift cell and supplementary ion optics, which are 
situated post source optics and prior to the quadrupole analyser. The drift cell is filled 
with helium gas (BOC Speciality Gases, purity 99.999 %) at a pressure of between 
3.0 and 3.7 Torr and a weak static electric field is applied to compel ions to drift 
through. The pressure in the drift cell is measured with a Baratron (MKS 
Instruments, Andover, Massachusetts, USA). Although the drift cell has heating and 
cooling capacity, all measurements presented in this thesis were taken at ambient 
temperature (~300 K). As a consequence of the inclusion of a drift cell, and to avoid 
overloading the standard turbomolecular pumps, the drift cell chamber is kept at 
vacuum by the inclusion of an extra turbomolecular pump, backed by a dual stage 
rotary pump (Edwards, West Sussex, UK). 
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Figure 2.4 | Schematic of the drift tube IM-MS instrument – the “MoQTOF”. In 
house modifications are labelled; all other components are as labelled in 
Figure 2.2.  
 
The MoQTOF can be used in both MS and IM-MS modes; in the former ions drift 
continuously through the cell, whereas in the latter ions are released into the drift cell 
in discrete pulses. These pulses are achieved by applying a ‘trapping voltage’ to the 
top hat lens which leads to the accumulation of ions at the entrance to the drift cell 
(Figure 2.4). Periodically the voltage on the top hat lens is lowered for a duration of 
40 µs and the accumulated packet of ions enters the drift cell. The pusher period of 
the TOF, itself determined by the m/z range required to observe all experimentally 
interesting species, determines the frequency of ion packets entering the cell. The 
frequency is regulated by a Stanford generator (Stanford Research Systems, 
Sunnyvale, CA, USA). 
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On exiting the drift cell ions are refocused in the post-cell hexapole, pass through a 
quadrupole mass analyser which is run as a wide band pass filter, and finally travel 
into a time of flight analyser where they are detected by the MCP detectors. Arrival 
time distributions are recorded for all of the ions detectable, and may be 
deconvoluted into selected ion arrival time distributions (ATDs) via MassLynx 4.1 
(Waters, Manchester, UK). 
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2.3.1.1. Instrument Tuning Parameters 
 
Instrument Parameters Settings / +ve mode Settings / -ve mode 
Capillary / kV 1 to 2 1 to 2 
Cone / V 10 to 40 10 to 90 
Extractor 110 110 
RF Lens 0.55 0.55 
Source / °C 80 55 – 80 
LM Resolution 5.0 5.0 
HM Resolution 5.0 5.0 
Collision Energy 2.3 2.3 
Ion Energy 2.0 2.0 
Steering / V 0.00 0.00 
Entrance / V 39.9 39.9 
Pre-filter 10.8 10.8 
Transport 5.0 5.0 
Aperture 2 12.6 12.6 
Acceleration / V 200 200 
Focus / V 1 0 
Tube Lens / V 80 80 
Guard 64.0 64.0 
TOF / kV 7.20 7.20 
Reflectron 35.0 35.0 
Pusher Cycle Time / µs 105 105 
Pusher Frequency / Hz 9523.8095 9523.8095 
Multiplier 655 655 
MCP 3000 3000 
TDC Start / mV 300.0 300.0 
TDC Stop / mV 40.0 40.0 
TDC Threshold 0.0 0.0 
Source Pressure / mBar 1.4 x 10-1 1.4 x 10-1 
Analyser Pressure / mBar 1.45 x 10-3 1.36 x 10-3 
TOF Pressure / mBar 2.0 x 10-7 1.2 x 10-7 
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Figure 2.5 | Schematic of the MoQTOF drift cell with surrounding lenses. H1 
is the pre-cell hexapole, H2 the post-cell hexapole, TH1 and TH2 pre and 
post cell top hat lenses. L1, L2 and L3 pre-cell lenses, L4 post-cell lens. C1 cell 
body one and C2, cell body two.  
 
The voltages applied to the additional lenses and drift cell, required for the MoQTOF 
to have ion mobility capability, are generated by an external power supply. Pre drift 
cell lenses (H1, TH1, L1, L2 and L3) are referenced to C1 and the post drift cell lens 
(L4) is referenced to C2. H2 and TH2 both float above the collision cell voltage (CV) 
which is set by the instrument tuning page and C2 and H1 are referenced to this and 
the source voltage respectively, which is set manually by the internal power supply. 
A schematic of the drift cell with surrounding lenses is shown in Figure 2.5 and 
representative drift cell lens voltage settings are tabulated in Table 2.4.   
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Lens Applied Voltage / V Actual Voltage / V 
H1 35 H1 + C1 = 105 
TH1 7 TH1 + C1 = 77 
L1 -27 L1 + C1 = 43 
L2 -100 L2 + C1 = 30 
L3 21 L3 + C1 = 91 
C1 70 Ref CV 
C2 10 Ref CV 
L4 -8 L4+ C2 = 2 
 
Table 2.4 | Typical Drift Cell Lens Stack Settings for the MoQTOF for IM-MS 
in positive mode. 
 
2.3.1.2. Injection Energy Experiments 
 
The kinetic energy with which ions enter the drift cell can be increased by raising the 
potential difference between the pre-cell hexapole and the first drift cell lens. An 
injection voltage range between 25 V to 54 V can be obtained (at present restricted 
by power supply limitations). Individual experimental chapters detail the specific 
injection energies used.  
 
2.3.2. Example IM-MS Experiment 
 
The following experiment illustrates the method of IM-MS data acquisition and 
analysis.  
 
An ion which adopts an extended conformation will take longer to traverse the drift 
cell, as a result of undergoing more collisions with the buffer gas, than a smaller, 
more compact, structure. This allows disparate structures to be distinguished which 
are identical in mass and chemical composition. This has previously been 
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demonstrated for synthetic cyclic and linear peptides 
2
, however it can also be used to 
separate organic compounds.  
 
For example, the ligand C89H84N8O6 can be knotted by the action of metal ions, 






Figure 2.6 | Chemical structures of ligand isomers. (1) precursor ligand (2) 
trefoil knot and (3) unknot macrocycle. Figure adapted from Barran et al. 3 
 
These three isomers all have the same molecular formula, but can be distinguished 
by their size and the relative flexibility of the multiply charged molecular ions 
produced by the n-ESI process. Under acidified conditions the following mass 
spectra are produced:  
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Figure 2.7 | Mass spectra of the three compounds acquired on the MoQTOF, 
unassigned peaks in the open chain isomer mass spectrum correspond to 
fragments.  
 
For all species the [M+2H]
2+ 
ion is the most dominant charge state present. In the 
case of the trefoil knot this is the only significant species present, suggesting a very 
conformationally restricted structure. The absence of the [M+3H]
3+
 species for the 
trefoil knot is indicative of a compact conformation unable to support the mutual 
electrostatic repulsions of three protons. IM-MS can be used to quantify these 
observations. 
 
IM-MS data were taken for each isomer at eight drift voltages; 60 V, 50 V, 40 V, 
35 V, 30 V, 25 V, 20 V and 15 V. For each drift voltage a total ion ATD is generated 
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every 200 scans, until at least 12 were collected (Figure 2.8). From the total ion ATD 
a mass spectrum can be generated (Figure 2.7) and from this a deconvoluted ATD of 
an individual m/z peak created.  
 
Figure 2.8 | Trefoil knot total ion ATD at a drift voltage of 50 V. Each peak is 
a collation of 200 scans.  
 
Deconvoluted ATD peaks are summed and the average scan number of the resulting 
distribution multiplied by the pusher period to give an arrival time for the selected 
species at this drift voltage. Arrival time, ta, measured by the ATD, is the time from 
ion injection into the cell until detection. It equates to the time taken for the ions to 
drift through the cell, td, plus the time the ions spent outside the drift cell (known as 
the dead time t0). The arrival time of ions results from their low field mobility (K), 
which is inversely related to their rotationally averaged CCS () (Chapter 1, Section 
1.5.11, Equation 1.14).  
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Figure 2.9  | Comparison of highest observed charge state ATDs of the trefoil 
knot [M+2H]2+, unknot macrocycle [M+3H]3+ and the open chain isomer 
[M+3H]3+. Data shows the ATDs at a drift voltage of 50 V. Intensities are 
normalised to the peak areas.  
 
A graph of experimentally measured arrival times at different drift voltages against 
P/V will give a linear relationship with an intercept equal to t0 and slope of gradient 
1/K (Figure 2.10). The pressure and temperature of the helium gas are recorded at the 
start and end of each mobility experiment, the average of each taken and these values 
(P and T) used to convert K into reduced mobility K0. The equation for the time spent 
by the ions in the drift cell, td, can therefore be calculated: P and T are averaged 
experimental helium pressure and temperature, V is the voltage applied across the 
drift cell, L is the length of the drift cell, K0 is reduced low field mobility, T0 is 









0 =−=   Equation 2.1 
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Figure 2.10 | Graph of P/V versus arrival time for the trefoil knot [M+2H]2+ 
species.  
 
The gradient of the line of best fit is equal to the inverse of the reduced low field ion 
mobility. The linear fit should have a high R
2
 value (> 0.9995, and ideally = 0.9999), 
deviations from this imply either low quality experimental data, or, if deviation is 
observed at the higher drift voltages, that the experiment was not conducted in the 
low field limit. If the fit is good then the gradient can be used to calculate the 
rotationally averaged CCS of the molecular species using Equation 2.2.  is the 
momentum transfer collision integral (rotationally averaged CCS), z is nominal ion 
charge, e is elementary charge, N0 is the buffer gas number density,  is the reduced 
mass of the buffer gas and ion, kb is the Boltzmann constant, T is the effective 




















  Equation 2.2 
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Figure 2.11  | CCSs for all observed species of the three isomers. Data are 
the average of three repeats; error bars represent the associated standard 
deviation.  
 
As the number of charges on a molecular ion increases, the size of the adopted 
conformations increases as electrostatic repulsions try to force the largest distance 
between the charges that the molecule will allow. In general, observed CCSs increase 
with the amount of charge that a flexible structure carries. In addition to the 
magnitude of the CCS, the broadness of the distribution indicates the flexibility (the 
number of differently sized and shaped conformations adopted) of the molecular 
structure. 
 
The open chain isomer, which is expected to have a large degree of flexibility, 
exhibits the broadest ATD. The unknot macrocycle has a narrower ATD and the 
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trefoil knot displays the narrowest ATD, reflecting its inflexible structure (Figure 
2.9). The largest CCSs of the open-chain isomer [M+3H]
3+
 and unknot macrocycle 
[M+3H]
3+
 were 395 ± 3.5 Å
2
 and 368 ± 5.3 Å
2
, respectively. The largest CCS 
observed for the trefoil knot [M+2H]
2+
 ion was 292 ± 1 Å
2
. Therefore for the highest 
charge state observed for each species, the open-chain isomer has a larger molecular 
cross-section than the unknot macrocycle which, in turn, has a much larger cross-
sectional area than the trefoil knot. Furthermore, the open-chain isomer has the 
broadest CCS distribution, followed by the unknot macrocycle, with the trefoil knot 
having the narrowest range. These results indicate that the trefoil knot has a much 
more compact and inflexible structure than the unknot macrocycle, which is more 
compact and less flexible than the precursor strand. Thus chemically identical 




2.3.3. Multiple ATD Peak Fitting 
 
For ATDs with multiple peaks which are not baseline resolved (Figure 2.12), values 
for average scan numbers (and hence average arrival times) of separate species can 
be obtained by fitting the ATDs with a Gaussian function in Origin 8.0 (OriginLab, 
Northampton, MA, USA). The Gaussian function used is stated in Equation 2.3, 
















π  Equation 2.3 
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Figure 2.12 | Experimental ATD of insulin m/z peak 1912 at a DV of 50 V 
(grey shading). Two species are present; [2M+6H]6+ and [M+3H]3+. Gaussian 
fits (red and blue lines respectively) allow the centre of each species ATD to 
be calculated. The cumulative peak fit is the sum of the Gaussian fits and 
closely approximates the experimental ATD data.  
 
The centre of the fitted peak xc can be converted into the average arrival time for 
each species at this drift voltage. When xc values have been obtained for all drift 
voltages a plot of P/V versus arrival time is made, as in Figure 2.10. Data processed 
in this way tend to have a lower R
2
 value for the best fit line, so the >0.9995 criterion 
is relaxed to >0.995. As previously, the gradient is then used to calculate the 
rotationally averaged CCS of the molecular species. This method is comparable to 
the method used elsewhere in the literature where the ATD is fitted using the 
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High resolution MS was performed on a 9.4 Tesla Apex Qe Fourier Transform Ion 
Cyclotron Resonance mass spectrometer (FT-ICR MS) (Bruker Daltonik GmbH). 
Differential pumping is employed for the transition of ions from atmospheric 
pressure to the ~2 x 10
-11 
mBar vacuum present in the analyser cell. The source 
region comprises a capillary (an in-house developed heated brass capillary to 
improve desolvation), skimmers and a hexapole. Ion optics transfer analyte ions from 
the hexapoles to the ICR cell.  
 
Calibration of between 6 and 10 ppm accuracy was achieved using Bruker tune mix 
and data processed using DataAnalysis 4.0 (Bruker Daltonik GmbH). Simulated 
isotopic distributions were created from theoretical empirical formulas using the 
Simulate Isotopic Pattern function of DataAnalysis 4.0 (Bruker Daltonik GmbH). 
FT-ICR MS provides 
13
C isotopic distributions which confirm the identification of 
the peaks as isobaric aggromers or as conformers of the same species.  
 
2.4.2. Nano-Electrospray Ionisation Source 
Attachment 
 
To ensure that FT-ICR MS source conditions emulated as closely as possible those of 
the QTOF and MoQTOF instruments utilised in other parts of the experiment a 
QTOF n-ESI source attachment was clamped in front of the entrance aperture 
(Figure 2.12). An external voltage was applied using a power pack to produce spray. 
The geometry and distance between the capillary and the entrance aperture was 
similar to that of a traditional Z Spray source. 
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Figure 2.13 | Photo of the n-ESI source clamped in front of the FT-ICR MS 
entrance aperture.   
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Small fragments of amyloidogenic proteins can have fibrillogenic characteristics in 
vitro 
1
. These amyloidogenic peptides are easier to synthesise and less 
computationally demanding to simulate, qualities which make them ideal for use as 
model systems to investigate amyloidogenesis. The evolution of oligomeric species 
formed by an aggregating solution of transthyretin (105-115) is examined using MS 
and IM-MS. Experimental results are compared with MD simulations to further 
elucidate oligomeric structures. 
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Transthyretin (TTR) is a 55 kDa homotetrameric protein 2, present in plasma and 
cerebrospinal fluid, which functions as a carrier for vitamin A (retinol) and thyroid 
hormone (thyroxine) to bodily tissues. Each 127 residue TTR monomer consists of 
eight -strands, connected by loops, which are labelled conventionally from A to H, 
with orthogonal strands CBEF and DAGH separated by 10 Å 3. Dimers are formed 
through -strand interactions, resulting in hydrogen bonding between strands F and 
F’ and H and H’ of each monomer (Figure 3.1). Tetramer assembly is mediated by 
hydrophobic and hydrophilic interactions of the AB loop and H’ strands (Figure 3.2). 
Higher aggregation requires interactions across the A strands, which have evolved to 
















Figure 3.1 | TTR dimer with labelled -strands. Representation rendered 
orthographically using VMD from pdb file 2PAB 3. 
Chapter 3: Transthyretin (105-115) 
 - 84 - 
a b
 
Figure 3.2 | Location of TTR tetramer binding sites: (a) red arrow denotes the 
position of the thyroxine binding channel (b) 90o rotation about the vertical 
axis, red circle shows the location of the retinol binding pocket. 
Representations of pdb file 2PAB 3 rendered orthographically using VMD. 
 
Diseases associated with TTR aggregation are known as “Transthyretin 
amyloidoses”. These include Familial Amyloid Polyneuropathy (FAP), Familial 
Amyloid Cardiopathy (FAC), Senile Systemic Amyloidosis (SSA) and Central 
Nervous SSA. Over 25 % of people over the age of 80 are estimated to be affected 
by SSA 4, which results from the aggregation of wild type (WT) TTR, fibrils of 
which are deposited in cardiac tissue 5. Conversely FAP, one of the most common 
inherited amyloid diseases, is predominantly caused by a single point mutation in 
TTR, resulting in fibril deposition in the peripheral nervous system. There are over 
80 known mutations of TTR which increase propensity to aggregation 6; however 
crystal structures obtained for some of these variant TTR complexes show no 
significant structural differences from native TTR 7.  
 
Fibrils present in FAP patient amyloid plaques have been studied by EM and X-ray 
diffraction. Initial studies found that fibrils consist of four protofilaments of between 
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40 and 50 Å in diameter aligned in parallel around a hollow centre 8. The 
protofilaments themselves contain four -sheets which twist together in a rope-like 
fashion parallel to the axis of the protofilament. Conflicting work observed ex vivo 
fibril diameters of between 80 and 120 Å in diameter, composed of four 
protofilaments of 20 Å diameters, which contained two -sheets 9. NMR coupled 
with HDX allowed Olofsson et al. 10 to investigate the fibril structure of a disease 
related TTR variant. The degree of residue protection from bulk solvent was 
ascertained, leading to the postulation of a fibril core of six -strands A-B-E-F-G-H, 
with strands C and D exposed to solvent and A and B available for external 
associations. This is critical as one of the functions of the CD region is to protect the 
hydrophobic surfaces of the A B strands and prevent aggregation. Thus C and D 
strands, and any mutations therein leading to conformational variability, have a 
dramatic impact on the aggregation propensity 11,12. The postulate that the mobility of 
the C D section is vital for protofibril assembly is gaining substantial experimental 
backing. However protofibril formation may only proceed after a conformational 
change, such as a slipped edge interaction 12.  
 
A universal characteristic of the TTR fibrillation process is the initial destabilisation 
of the native homotetrameric structure 13. TTR tetramer dissociation has been 
observed under non-denaturing conditions 14. Modification of a QTOF mass 
spectrometer to allow the transmission of large macromolecular assemblies enabled 
Sobott et al. 15 to preserve the TTR homotetrameric structure, complexed with 
thyroxine and retinol, into the gas-phase. The role of retinol, in conjunction with the 
retinol binding protein, in stabilising the TTR homotetramer was elucidated by 
Hyung et al. 16 and is of particular import as physiological low levels of retinol 
binding protein have been recorded in FAP patients 17. MS and HDX have been 
utilised to study tetramer and monomer populations in WT and variant TTR by 
Nettleton et al., who discovered a correlation between increasing amyloidogenicity 
and tetrameric instability in the gas-phase 18. The presence of thyroxine in solution 
stabilised the tetramer, as did the presence of water in the central channel. 
Amyloidogenic variant TTR monomers were perceived to partially unfold their 
-sheet structure, suggesting that monomer unfolding is a key step in the fibrillation 
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process. The stability of TTR has been studied also by molecular dynamics 
simulations 19 which supported the conclusions of Nettleton et al. 18 that the tetramer 
was stabilised by binding with thyroxine and additionally showed that solution 
conditions need to be neutral to favour the formation of tetramers. 
 
The link between the instability of TTR tetramer mutants and the aggressiveness of 
their associated diseases was studied by Babbes et al. 20, judging tetramer stability by 
the ease with which urea denatured the structure. Tetramers were observed to first 
dissociate into monomers which then partially unfolded. A correlation was observed 
between the amyloidogenicity of the mutant form and the instability of the tetramer, 
in agreement with Nettleton et al. 18. Relative to the wild type tetramer, the most 
aggressive variants were found to have destabilised quaternary and tertiary 
structures, whilst those of intermediate severity possessed either an unstable 
quaternary and stable tertiary structure, or vice versa. These studies and others have 
sparked interest from the pharmaceutical industry in finding ligands which could 
specifically bind to tetrameric TTR and stabilise the native state. Such compounds 
could be potential therapeutics for transthyretin amyloidoses 21. 
 
The gas-phase dissociation of the tetramer was further probed by MS by Sobott et al. 
who report the tetrameric form dissociating, by means of collisions with buffer gas 
atoms, into highly charged monomeric and less charged trimeric ions 22. Asymmetric 
dissociation was also observed for octameric ions. It was suggested that the tetramer 
fragments to form monomers which then associate into trimers. Collisional activation 
of the TTR tetramer followed by IM-MS analysis showed an expansion of the CCS 
prior to dissociation 23. Simulations suggested the cause of this was the almost 
complete unfolding of one monomer subunit initially, followed by progressive 
unfolding of the remaining components at increasing activation energies. This 
provides evidence that partially unfolded complexes can remain intact on the 
millisecond experimental timescale and give insights into the mechanism of tetramer 
dissociation.  
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Multiple studies have reported that first steps in fibrillogenesis are the break up of 
the TTR homotetramer followed by the formation of a partially folded monomer, 
which acts as an aggregation intermediate 13,24-27. At low pH, conditions which, in 
vitro, promote TTR aggregation 24, monomers represent the most populated 
species 25. TTR reassembles into its native structure by an unusual monomer-dimer-
trimer-tetramer pathway 28. Assuming that TTR aggregation does progress via a 
monomer intermediate, both the reassembly and aggregation processes must be 
reliant on the concentration of monomer. For reassembly, the monomer must be 
folded and for aggregation to proceed it must be partially unfolded; it is postulated 
that monomer conformation depends on the concentrations of aggregates and 
reassembly intermediates present 28. If concentrations of aggregates are high, an 
increased proportion of monomers partially unfold, leading to increased aggregation 
rates. Therefore in individuals where the rate of aggregate clearance is slower (such 
as the elderly) increased rates of aggregation occur, explaining the late onset and 
degenerative nature of amyloid disease. 
 
Although deposition of fibrillar material can inhibit cell function, studies have found 
that TTR amyloid fibrils and large aggregates over 100 kDa in size were non toxic to 
cells. Instead preamyloidogenic cytotoxic forms of TTR were discovered 29, with 
further studies identifying these as monomeric species and rapidly formed transient 
oligomers up to hexameric order. This stresses the importance of further research 
into prefibrillar intermediates 30.  
 
3.1.2. Fibrillogenic Transthyretin Fragments  
 
Investigations into the fibrillogenic characteristics of synthesised TTR fragment 
peptides discovered two sequence regions, TTR (10-20) and TTR (105-115), which 
were capable of forming amyloid fibrils in vitro  31. Below is the primary sequence of 
a TTR monomer. Cyan highlighting represents the presence of -strands, magenta 
the presence of turns and yellow the presence of an  helix.  
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1    3         6               12                18 19     22                29                35  37     39  41                 48      
GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSE 
 
   53 55   57    60 61 63     66                73  75                 81            87                               9899  101 
SGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPR 
 
104               112    115                   123      127 
RYTIAALLSPYSYSTTAVVTNPKE 
 
TTR (10-20) corresponds to -strand A of the TTR monomer (Figure 3.3) which, in 
tetrameric form, lines the thyroxine binding channel. Fibrillogenesis can be induced 
by acidic solution conditions and the resulting fibrils are measured by EM to be 14 
nm in diameter. Addition of urea to disrupt the fibrils enabled the measurement of 
protofilament diameters of 3 to 4 nm 32. Further disruption of protofilaments with 
urea and high temperatures was unsuccessful; however their dissociation into 
monomeric peptide was achieved using high concentrations of TFE. The inference 
drawn from this is that peptides forming protofilaments are strongly bound together 
by hydrophobic and electrostatic forces whereas the interactions between 
protofilaments to form mature fibrils are weaker and hence more vulnerable to 
disruption.  
 
TTR (105-115), corresponding to -strand G of the TTR monomer, is more 
amyloidogenic than TTR (10-20), as it does not require acidified solution conditions 
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3.1.3. Transthyretin (105-115)   
 
The amino acid sequence of residues from position 105 to position 115 of TTR is 
Tyr-Thr-Ile-Ala-Ala-Leu-Leu-Ser-Pro-Tyr-Ser. TTR (105-115) comprises -
strand G (Figure 3.3), which in the native tetramer is situated at the surface of the 
thyroxine channel (Figure 3.2). A high resolution structure of fibrillar TTR (105-115) 
has been discerned to atomic resolution by magic-angle spinning SSNMR 
spectroscopy (Figure 3.4) 33. Residues in the fragment were isotopically labelled, 
enabling the calculation of the backbone torsion angles and distances. From these it 
was observed that the peptide was in extended -strand conformation within the 
fibrils 34. Differences between this and the similarly extended conformation adopted 
by residues (105-115) in the whole protein 3 can be accounted for by the greater 
impact of a proline residue in the shorter peptide sequence, causing a kink in the 
fragment polypeptide chain. More detailed studies determined a large number of 
NMR distances and dihedral angle restraints on the polypeptide chain including the 
conformation of side chains. All torsion angles were almost at their optimum values, 
allowing the peptide to have a molecular conformation of very low energy even in 
fibrillar form, a fact that would contribute greatly to high fibril stability and 
structural organisation. TTR (105-115) also possessed a degree of long range 
uniformity leading to the postulate that fibrils should be modelled as a polypeptide 




Figure 3.4 | Structure of fibrillar TTR (105-115). Orthographic representation 
rendered using VMD from pdb file 1RVS 33. 
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When TTR (105–115) fibrils are partially chemically denatured with urea and 
scanned by TEM, measurements of protofilament dimensions reveal an average 
diameter of 4.3 ± 1.6 nm 32. NMR data calculates the length of the TTR fragment 
peptide between the tyrosine and serine carbon C atoms as 3.4 ± 0.2 nm, increasing 
by 0.4 nm if side chains are included 32. The diameter of the protofilament is not 
much greater than the length of the peptide, suggesting that protofilament -sheets 
are composed of a hydrogen-bonded array of TTR (105-115) monomers in an 
extended conformation. Results from X-ray fibre diffraction show a distance between 
-strands of 0.47 Å and a -sheet spacing of 0.8 to 1 nm 35. Therefore four -sheets 
in a “cross-” configuration are postulated to compose each protofilament. 
Furthermore, as TEM provides an average diameter of 10.8 ± 1.2 nm for mature TTR 
(105–115) fibrils it suggests that a maximum of four protofilaments are wound 
together form the fibril structure 33.  
 
 
Figure 3.5 | TTR (105-115) fibrils imaged by AFM (left) 36 and EM (right) 34.  
 
The morphology and mechanical strength of TTR (105-115) can be tested using 
AFM 36. Although polymorphism is exhibited, the prevalent structure is straight 
fibrils of circa 1 µM in length and between 7 to 12 nm in diameter, with some 
displaying a surface striation every 90 nm perpendicular to the fibril axis 32. The 
surface striation supports the assertion that mature fibrils are composed of at least 
two entwined protofilaments. Fibrils were unaffected by tapping mode AFM in air, 
200 nm 
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however in water fibrils were destroyed by AFM within 90 minutes. Contact mode 
AFM imaging in air allowed the strength of the fibrils to be precisely tested; at 
vertical forces below 40 nN fibrils were unaffected, increasing the force beyond this 
led to deformation, with all permanently distorted at applied forces of 100 nN. 
Finally the effect of solution conditions was investigated, with the fibrils retaining 
their structural stability from pH 3 to pH 8 in aqueous conditions and in sodium 
phosphate buffer concentrations between 50 mM and 1 M. AFM has also been used 
in conjunction with Fourier transform infrared spectroscopy (FTIR) to investigate 
fibril stability at high hydrostatic pressures 37. Mature fibrils withstood hydrostatic 
pressures of up to 1.3 GPa, whilst the oligomers preceding fibril formation could be 
dissociated at 220 MPa. The implication is that early oligomers are only weakly 
bonded by predominantly electrostatic and hydrophobic interactions, whereas fibrils 
are robust as they have a large number of hydrogen bonds stabilising the structure 
from which bulk water is excluded. 
 
Concerns that the observed cross- structure of fibrils was a result of the dehydrated 
conditions used to observe previous samples were allayed by an X-ray scattering 
study into hydrated samples of fibrils 38. Inter-strand and inter-sheet reflection 
properties were shared by both hydrated and dried samples over various 
concentrations. Furthermore the hydrated samples showed that strands were axially 
aligned to the fibril axis whilst the -sheets were equatorially aligned, a configuration 
indicative of a cross- structure. Interestingly this outcome implies that the -sheets, 
when stacked together, must have several interfaces which are protected from bulk 
water, in agreement with Dirix et al. 37.  These results were crucial to allowing the 
presumption of a fibril cross- structure in studies conducted with experimental 
techniques which require a sample solution, as opposed to dehydrated fibrils.  
 
All-atom 5 µs MD simulations have been constructed to analyse the formation and 
structure of TTR (105-115) dimers, trimers and tetramers preceding 
fibrillogenesis 39. Peptides self associated into  rich structures, with two different 
formation pathways for aggregates dominated by  structure and those dominated by 
-helical structure. Anti-parallel conformations of -strands were favoured, 
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supported by the propensity of the central residues (106-111) to form inter-peptide 
hydrogen bonds. The use of experimentally calculated distances and dihedral 
restraint angles 33 increased the peptide’s aggregation propensity. Chemical shift data 
from experiment and simulated data from the generated structures were in 
agreement, illustrating that MD may aid in discriminating between potential 
structures for oligomers and fibrils. The interstrand re-arrangements in 
TTR (105-115) dimers were also studied by MD in implicit solvent 40. The study 
found that it was probable that both parallel and antiparallel strand arrangements 
would be present although parallel aggregates were separated by energy barriers 
depending on their precise alignment. Interstrand rearrangements could take place in 
a variety of ways, including differing reptation movements. 
 
The fibrillogenesis of TTR (105-115) has been observed using FRET probes 41,42. 
These can detect fibril structural arrangements by virtue of changing FRET 
efficiency, complemented by direct EM observations of fibril formation. Parallel 
arrangements of TTR (105-115) within a -sheet were postulated, with adjacent 
sheets arrayed in an antiparallel conformation. An intermediate state was observed 
which underwent a conformational compaction on production of mature fibrils. Cell 
adhesion and control sequences attached to C-terminus of TTR (105-115) peptides 
which undergo fibrillogenesis produce fibrils which are bioactive and interact 
specifically with cells 43. The development of functionalised fibrils which could 
interact specifically with many cell varieties could have important medical and bio-
mimetic uses.  
 
In this chapter we extend current approaches by using MS and IM-MS to examine 
the change in the population of oligomers present in an aggregating solution of 
TTR (105-115). The distribution of oligomeric species at a zero time point is 
identified using n-ESI MS and quantified by IM-MS ATD intensity. Experimental 
CCSs are compared with those obtained by molecular modelling. Finally changes in 
the population of oligomers and their CCSs as a function of time are observed and 
analysed.  
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3.2. Methodology 
 
3.2.1. Sample Preparation 
 
Peptide TTR (105-115) was obtained as a lyophilised powder at >98 % purity from 
CSBio (USA). Unaggregating conditions were dilute (10 to 50 M) solutions in 
49.5:49.5:1 H2O:ACN:HCOOH, and in buffer conditions with a higher percentage of 
ACN. To create an aggregating solution the peptide was dissolved at a concentration 
of 10 mg/ml in 90:10 H2O:ACN adjusted to pH 2 with HCl. These samples were 
immediately flash frozen in liquid nitrogen and stored in a -28 °C freezer. For time-
course experiments a 10 mg/ml sample was defrosted and aliquots were taken at 
appropriate time points and diluted to a concentration of 80 µM in a solution of 
49.5:49.5:1 H2O:MeOH:HCOOH immediately prior to mass spectrometry.  
 
3.2.2. Mass Spectrometry 
 
Mass spectrometry was performed on a QTOF 2 mass spectrometer (Waters, 
Manchester, UK). Mass spectra were recorded for samples in positive mode utilising 
an n-ESI ionisation source. High resolution mass spectra provided 13C isotopic 
distributions which confirmed the identification of peaks where several assignations 
might have been made due to the presence of oligomers with coincident m/z values. 
Source voltages and pressures were tuned to enable optimal aggregate transmission.  
 
3.2.3. Ion Mobility Mass Spectrometry 
 
IM-MS measurements were performed on an in-house modified QTOF 1 (Waters, 
Manchester, UK), the ‘MoQTOF’ 44. More details of this instrument can be found in 
Chapter 2, Section 2.3.1. Samples were ionised using an n-ESI source in positive 
mode with an applied capillary voltage of ~1.8 kV and a cone voltage of 50 V. 
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Source pressure was increased to optimise transmission of oligomers, as other studies 
have reported 15. Ions were accelerated through a potential difference of 35 V and 
injected into the drift cell. The drift cell was filled with helium gas at a pressure of 
between 3.0 and 3.5 Torr. The temperature and pressure of helium was recorded at 
the start and end of each mobility scan and the average taken. The voltage applied 
across the cell was varied from 60 V to 15 V and ATDs recorded at eight voltages. 
The resolution of the MoQTOF is not sufficient to give isotopic 13C spacing. 
Therefore oligomeric species were assigned using potassium adduct spacing from the 
mass spectrum in addition to information gleaned from ATDs.  
 
3.2.4. Simulation Strategies 
 
All simulations were performed by Jason Kalapothakis 45,46.  MD simulations utilised 
the AMBER9 programs 47, employing ff99 force field parameters. Simulation 
temperature was regulated with the Berendsen velocity thermostat 48; a 1 fs time-step 
was used in all simulations and the SHAKE algorithm 49  was used to prevent 
unrealistic bond and angle stretching. The energy minimisation process consisted of 
50,000 iterations, first 100 steepest descent minimisation steps and the remainder 
employing the conjugate gradient algorithm. Minimisation was halted when the 
convergence criterion (0.5 cal/mol) was satisfied. 
 
Analysis of the resulting molecular coordinates was performed with ptraj, included in 
the AMBER programs. CCSs were estimated with MOBCAL using the trajectory 
method (TM) 50.  
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3.3. Results and Discussions 
 
3.3.1. Mass Spectrometry 
 
3.3.1.1. Aggregation Inhibiting Conditions 
 
Conditions in vitro which inhibit TTR (105-115) aggregation are low peptide 
concentrations and buffer conditions containing high percentages of organic solvents.  
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Figure 3.6 | n-ESI mass spectra of 40 µM TTR (105-115) in conditions which 
inhibit aggregation. a. buffer conditions of 74.5:24.5:1 ACN:H2O:HCOOH. b. 
buffer conditions of 49.5:49.5:1 ACN:H2O:HCOOH. 
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Under non-aggregating conditions the peptide is observed exclusively as a monomer, 
predominantly as a [M+2H]2+ ion with a smaller proportion of [M+H]+ ion (Figure 
3.6).  
 
When a sample of 10 mg/ml in 90:10 H2O:ACN adjusted to pH 2 with HCl is 
defrosted and left to aggregate, then diluted to a concentration of 40 µM in a solution 
of 49.5:49.5:1 H2O:MeOH:HCOOH prior to mass spectrometry, a wide variety of 
oligomers are observed, in opposition to Figure 3.6b. Therefore oligomer populations 
present in the more concentrated aggregating stock solution must persist under more 
dilute, non aggregating, conditions.  
 
3.3.1.2. Aggregation Promoting Conditions 
 
 
Samples of 10 mg/ml TTR (105-115) in solvent conditions of 90:10 H2O:ACN 
adjusted to pH 2 with HCl were observed to aggregate without agitation at room 
temperature, inferred from an increase in solution viscosity with time. Prior to MS 
analysis samples were diluted to a concentration of 80 µM in a solution of 
49.5:49.5:1 H2O:MeOH:HCOOH. The oligomer populations observed in the diluted 
solution are relevant to those present in the stock solution, as exemplified by the 
persisting oligomer populations which are described above when an aggregating 
stock solution is diluted into non aggregating conditions.  
 
Figure 3.7 shows a typical n-ESI mass spectrum obtained from a solution of the TTR 
(105–115) peptide immediately after dilution. 
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Figure 3.7 | n-ESI mass spectrum showing oligomers present and their 
associated charge states. Cartoons are for illustrative purposes only and do 
not correspond to validated structures. 
 
Oligomers of the general form [nM+zH]z+ are observed with 1  n  13 (Figure 3.7 
and Figure 3.8). With the notable exceptions of the work of Ashcroft et al. on 2m 
51 
and that of Nettleton et al. on bovine insulin 52, our observation of a wide range of 
oligomers is atypical of amyloidogenic systems. The spectrum is dominated by a 
peak at m/z 1202.0, corresponding to coincident species [M+H]+ and [2M+2H]2+, 
with other high-abundant ions at m/z 601.5, 1502.4, 1601.8, and 1441.8 assigned to 
[M+2H]2+, [5M+4H]4+, [4M+3H]3+ and [6M+5H]5+ respectively. Each oligomer is 
found in relatively few protonation states, which is similar to the findings of Bowers 
et al. for A 53. With the exception of [M+2H]2+, [M+H]+ and [2M+2H]2+, all of the 
observed species carry fewer charges than the number of peptides in the oligomer. 
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Large numbers of charges increase the CCS of an ion due to Coulombic 
repulsion 54,55 thus the absence of highly charged assemblies indicates that the 
observed ions either adopt compact geometries or are extended but possess a low 




Figure 3.8 | n-ESI mass spectrum showing an enlargement of the high m/z 
region of the mass spectrum showing oligomers present and their associated 
charge states. Cartoons are for illustrative purposes only and do not 
correspond to validated structures. 
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3.3.2. Ion Mobility Mass Spectrometry 
  
3.3.2.1. Zero Time Point Experiments 
 
The summed intensity of each ion’s ATD was recorded after the same number of 





Figure 3.9 | Distribution of oligomers at t = 0. Each bar represents the 
average maximum intensity of the ATD of each charge state of each 
oligomer. All ATDs were recorded at a drift voltage of 50 V. Labels 
correspond to the oligomeric charge state, +z. The data are averaged over 
three repeats; error bars represent the standard deviation.  
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Figure 3.10 | Distribution of oligomers at t = 0, showing an expansion of the 
region for n > 2. Each bar represents the average maximum intensity of the 
ATD of each charge state of each oligomer. All ATDs were recorded at a drift 
voltage of 50 V. Labels correspond to the oligomeric charge state, +z. The 
data are averaged over three repeats; error bars represent the standard 
deviation. 
 
When the data are viewed in this way, it is obvious that some species are dominant 
(Figure 3.9). The peak at 1202.0 corresponds mainly to [2M+2H]2+, thus the dimer is 
the most abundant species under aggregating conditions. The tetramer and pentamer 
are also seen in high abundance, the former solely as the ion [4M+3H]3+ and the 
latter principally as the ion [5M+4H]4+. When more than one charge state is 
observed, one value of z typically dominates. A very weak signal from the trimer is 
visible, which points to an instability for this species relative to the dimer and 
tetramer, in support of simulation results 39. Contributions from other oligomers 
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decay exponentially, with the exception of the [10M+zH]z+, which appears as a 
stable ‘magic-number’ oligomer 56. The presence of ‘magic number’ oligomers with 
increased stability strengthens the argument that the oligomers observed are present 
in solution, and not artefacts of the n-ESI process.  
 
Figure 3.10 shows that the higher-order aggregates are observed in unequal charge 
states: for example [10M+zH]z+ is seen with z = 6, 7, and 9 but not 8; [9M+zH]z+ is 
observed with z = 5 and 7 but not 6; and [11M+zH]z+ is present as z = 6, 7, and 10 
but not 8 and 9. Charge states that are not observed may be too weak to be detected 
and for some m/z values are coincident with very abundant species of lower 
oligomeric order; nonetheless they appear to have a lower stability that may be due 
to the adoption of favourable conformations by only some oligomers. We speculate 
that this is due to antiparallel or parallel arrangements of polypeptide chains that 
favour only certain charge and aggregation states.  
 
A simulation study by Paci et al. found the tetramers of TTR (105-115) were 
unstable 39, suggesting that the critical nucleus for amyloidogenesis is of greater 
oligomeric order than a tetramer. Given the stable nature and unusual prevalence of 
the decameric oligomers in these experiments, we postulate that this could be a 
candidate species for the critical nucleus. We can speculate that a decameric species 
could possibly also be one of the cytotoxic oligomers which characterise many 
aggregation processes. CCSs were determined for all of the species present. Results 
from this analysis are shown in Figure 3.11 and tabulated in Appendix Three.  
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Figure 3.11 | Graph showing the CCSs of all species observed at a zero time 
point. Labels are the associated positive charge of each oligomer. Error bars 
represent the standard deviation of five repeated measurements.    
 
As expected, an increase in CCS with multimeric order is observed. In addition, 
where an oligomer is present in a range of charge states, CCS increases with charge. 
However variation from a monotonic rate of increase in CCS with oligomeric order 
can allow assumptions concerning structural information to be made. The monomeric 
peptide is seen as both a singly and a doubly charged ion, with very similar CCSs of 
256.1 Å² and 272.7 Å² respectively. The dimer however is seen in a single charge 
state of z = 2 and has a CCS of 380.2 Å², significantly larger than the monomer 
species. The weak [3M+2H]2+ ion has a CCS of 508.5 Å², larger than the dimer and 
twice the size of the monomer. Oligomer CCSs increase in a linear fashion for the 
highest charge state for each oligomer, which is to be expected, but what is more 
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interesting is the lack of increase in CCS as a function of n when n > 3. For example, 
the CCSs for n = 4 and 5 are very similar when z = 3 (Figure 3.11), and the CCSs of 
the hexamer, heptamer, octamer and nonamer are within 10 % when z = 5 despite an 
increase in mass of >60 %.  
 
Thus packing to form a dense aggregate competes with Coulombic repulsion to 
determine the final CCS of an oligomer. Within any oligomer, the amino group at the 
N-terminus of each peptide is available for protonation. It is also possible that the 
proline residue can be protonated, although this is less probable as it has a lower 
basicity than the N-terminus. The protonation of both the amino group at the N-
terminus and the proline is likely to account for the observed [M+2H]2+ species. If 
this protonated group is packed in the interior of the aggregate and hence 
inaccessible, the oligomer will carry a low net charge relative to the number of 
peptides; if it is surface-exposed, ionization will drive charge–charge repulsion, 
Coulombic destabilisation, and expansion of the aggregate. Our observation that all 
of the species carry fewer charges than the number of peptides in the oligomer, as 
well as the comparatively small increase in CCS with a large increase in mass, 
suggests dense packing. Moreover, given the sequence of TTR (105–115), it is likely 
that this packing is governed by hydrophobic interactions; as these are weakened in 
the gas-phase, the species detected must have been preserved intact from solution. 
 
3.3.2.2. Time Course Experiments 
 
Oligomer populations were monitored during the lag phase of TTR (105-115) 
aggregation. Figure 3.12 and Figure 3.13 show mass spectra taken at intervals over 
an eight hour period, which is within the lag phase of TTR (105-115) self-
assembly 33. For the first four hours there is a rise in the observable oligomer 
population followed by a rapid decline in most of the aggregates, with the exception 
of the monomer, dimer (Figure 3.12) and tetramer species (Figure 3.13), which 
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The m/z ratios of some oligomeric species are coincident. However, these species 
may be separated in mobility space by their differing arrival times, revealing that the 
ratio of intensities of the two populations varies with time. The ATDs of coincident 
species at zero, two, four, six and eight hours at a drift voltage of 50 V are shown 
below, averaged over three repeats. 






 Arrival Time / µs



















Figure 3.14 | The arrival time distributions, at a drift voltage of 50 V, of [M+H]+ 
and [2M+2H]2+ at zero, two, four, six and eight  hours.  
 
When the dominant peak at 1202.0 is viewed in ATD space, the proportion 
attributable to dimer and monomer is seen to vary with time (Figure 3.14). Initially 
there is far more [2M+2H]2+ present than [M+H]+; however, at four hours relative 
enrichment of the monomer is observed. At both the six hour and eight hour time 
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points, the proportion of dimer is seen to rise again. The abundance of monomer at 4 
hours most probably originates from the break-up of larger oligomers owing to 
destabilisation either in solution or upon desolvation.  
 
These data, combined with those shown in Figure 3.12 and Figure 3.13, show a 
particular and significant persistence of dimer and tetramer whilst the other more 
transient oligomers contribute either to aggregation or off-pathway processes. The 
presence of the tetramer in an on-pathway process would be consistent with previous 
data, suggesting that the minimal unit of the mature fibril is assembled from four -
sheets in a “cross-” configuration 33.  






















Figure 3.15 | The arrival time distributions, at a drift voltage of 50 V, of 
[5M+3H]3+ and [10M+6H]6+ at zero, two, four, six and eight hours.  
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Figure 3.16 | The arrival time distributions, at a drift voltage of 50 V, of 
[3M+2H]2+ and [6M+4H]4+ species at zero, two, four, six and eight hours.  
 
At the four hour time point a peak is seen in the intensity of the lower multimeric 
order species in relation to the corresponding higher order m/z coincident species 
(Figure 3.15 and Figure 3.16). As a relative enrichment of monomeric species is 
observed at this time point (Figure 3.14) it seems likely that the increase in the 
population of smaller oligomeric species corresponds to a break-up of unstable 
higher order aggregates at this time point due to destabilisation either in solution or 
upon desolvation.   
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Figure 3.17 | CCS evolution of each oligomer as a function of time. 
 
Plotting the CCS as a function of time demonstrates a systematic increase in CCS for 
the majority of oligomers with n  4 (Figure 3.17), whilst the CCSs remain constant 
for the smaller oligomers. This observation is consistent with dynamic rearrangement 
of the larger n  4 oligomers and the adoption of increasingly extended, possibly 
-strand-like, conformations. 
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3.3.3. Simulations  
 
Experimental data from IM-MS measurements provide a coarse grained shape which 
can be compared with atomistically resolved structures derived either via 
computational routes or from NMR or crystal structures. Given atomic co-ordinates, 
it is possible to calculate a CCS that can be compared to an experimental 
measurement 50,55,57.  
 
Probable candidate geometries for TTR (105–115) oligomers were modelled using 
two approaches 46. In the first oligomers of monomeric to hexameric order, with 
antiparallel -sheet structural components were ‘cut out’ of solid state NMR 
data 32,33. These were subjected to molecular mechanics at 300 K for 5 ns. The 
second method utilised a simulated annealing (SA) approach to generate 300 gas-
phase structures for oligomers, with the lowest energy structures considered as likely 
candidates. With the exception of the monomer, which contained a cationic N-
terminus and a neutral C-terminus giving rise to [M+H]+, all simulated oligomers 
were of the form [nM+(n-1)H](n-1)+, achieved by addition of an anionic C-terminal 
carboxyl in one peptide. This neutrally charged zwitterionic peptide was placed in 
the centre of oligomers larger than dimeric order, allowing the anionic C-terminus to 
be bordered by positively charged N-termini of neighbouring peptides, thus 
increasing the stability of the array. Oligomers from monomeric to hexameric order 
were simulated. Point charges for neutral C-terminal residues were derived using the 
RESP procedure 58. 
 
Model isolated, ionised, antiparallel -sheets were energy-minimised (Section 3.2.4). 
After energy minimisation heating was conducted up to 350 K in 50 K steps over 
800,000 MD iterations (0.8 ns) and subsequently ‘relaxed’ in the gas-phase over 
5,000,000 MD iterations (5 ns). Coordinates before and after MD were used for 
further analysis. 
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The same sets of initial coordinates were also submitted to several cycles of SA in 
order to generate collapsed gas-phase structures. Peptides were first heated abruptly 
to a high temperature (800 K for the monomeric peptide and 600 K for multimeric 
assemblies) for 30,000 MD iterations (30 ps). Subsequently the system is cooled 
linearly to 0 K over 20,000 MD iterations (20 ps) after which it is energy-minimised. 
Peptide assemblies were prevented from drifting apart at high temperatures by 
application of a flat-bottomed harmonic restraint between the centres of mass of 
individual molecules with a cut off distance of 40 Å. This procedure was repeated 
numerous times (typically 500) and the coordinates resulting at the end of each SA 
cycle saved. 
 
Both approaches resulted in collapsed globular structures for the monomer and 
dimer, with no -sheet structure present. Following 5 ns of MD the trimer retained its 
-sheet structure, present in the NMR data; however this was not the case after SA, 
which engendered a collapse. This trend was repeated for tetrameric and pentameric 
oligomers. Candidate structures are depicted in supplementary information of Cole et 
al. 46. Theoretical CCSs were estimated with MOBCAL using the TM for structures 
produced by both methods.   
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Figure 3.18 | Graphical comparison between experimental CCSs and those 
generated by SA, in addition to -sheet structures pre and post molecular 
mechanics. Labels refer to the positive charge of each oligomer.  
 
Evidently from Figure 3.18 oligomer structures generated by SA are more 
representative of those observed by experiment. A direct comparison of SA CCSs 
and experimental CCSs is shown in Table 3.1. 
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 Collision Cross Section / Å²   
Species Theoretical  Experimental % Difference 
[M+H]+ 270.0 256.1 4.3 
[2M+H]+ 441.1 380.2* 6.4 
[3M+2H]2+ 567.0 508.5 14.1 
[4M+3H]3+ 737.0 662.7 8.7 
[5M+4H]4+ 878.0 846.5 5.0 
 
Table 3.1 | Comparision between the experimental and theoretically 
calculated CCSs. *experimental data not available for [2M+H]+, CCS is that 
of [2M+2H]2+.  
 
The overall agreement between the two sets of data is good. The disparity between 
the theoretical [2M+H]+ and the experimental [2M+2H]2+ CCSs can be accounted for 
by the [2M+2H]2+ species having a more collapsed structure due to increased 
attractive electrostatic interactions. Experimentally observed CCSs are consistently 
smaller than the calculated structures and increase in CCS with oligomeric order at a 
rate lower than that of the SA structures. Lower experimental CCSs could be due to 
injection energy effects or the presence of unresolved higher order oligomeric ions 
under the ATDs. Another contribution to this could be the presence of a protonated 
proline, a form not considered in these calculations, and more extensive simulations 
could produce structures in better agreement with experimental results. 
 
The comparison of experimentally derived CCSs with simulations demonstrates that 
the oligomers observed are compact globular structures with no extended -sheet. 
Experimental CCSs suggest that the solution phase structures are even more densely 
packed than those observed by simulation, a supposition supported by the narrow 
charge state distributions exhibited by each oligomer. Analysis of structures 45 
produced by SA suggests that TTR (105-115) monomers re-arrange, substituting 
intramolecular interactions with intermolecular non-covalent interactions.  
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3.4. Summary  
 
IM-MS provides a detailed insight into the molecular associations that ultimately 
lead to amyloid-like fibril formation. The amyloidogenic TTR (105–115) peptide 
forms a large variety of aggregates during the early stages of fibrillogenesis. Densely 
packed oligomers are observed, which are dominated by hydrophobic interactions, 
and dynamic remodelling of these oligomers occurs during the lag phase prior to 
fibril assembly. It is not possible to assess which of the many species are responsible 
for on pathway aggregation leading to amyloid fibril assembly, however of particular 
note is our observation of a stable tetrameric species, the oligomeric unit which is 
consistent with protofilament composition. Also of note is our detection of a stable, 
compact, and unusually prevalent decamer. It is commonly accepted that oligomers 
formed early in the aggregation process are toxic to a wide variety of cell types and 
that disease may result from the pathogenic effects of these “toxic oligomers”; we 
speculate that the transiently stable, compact, and prevalent decamer is a candidate 
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Insulin is the most frequently used model system in the study of fibril forming 
proteins. Aggregation of insulin at the site of injection and in pharmaceutical stocks 
is both detrimental to health and financially costly. In this chapter the oligomeric 
population of bovine insulin under aggregating conditions is studied by MS and IM-
MS. Multiple distinct conformations of oligomers up to hexameric order are 
discovered, and their identity confirmed using FT-ICR MS and CID. MD simulations 
trained by experimental data study the dominant monomeric and dimeric species in 
atomistic detail. 
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4.1. Introduction  
 
Insulin is a hormone produced in the  cells of the islets of Langerhans in the 
pancreas. It is vital for regulating the metabolism, stimulating the conversion of 
glucose into glycogen and thereby preventing a toxic build up of glucose in the blood 
stream. After its discovery in 1921 1 insulin became the subject of intense scientific 
interest; becoming the first protein to be sequenced in 1955 2 and its structure 
determined in one of the earliest successes of crystallography 3. The biologically 
active form of insulin is the monomer. An insulin monomer consists of two chains; 
acidic chain A (21 amino acids) and basic chain B (30 amino acids) which are 
cross-linked by two disulphide bridges, with an additional intra-chain disulphide 










Figure 4.1 | Amino acid sequences of bovine and human insulin. Disulphide 
bonds and shown in blue and differences in sequence are shown in red. 
  
Insulin is stored as a hexamer, stabilised by the presence of zinc2+ ions (Figure 4.2). 
The regulation of insulin hexamer to monomer conversion is an important 
homeostatic mechanism.  
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Figure 4.2 | Insulin hexameric structures at pH 6.8 a. Surface representation 
with monomeric subunits closer to the viewer depicted blue and further away 
units in purple b. Secondary structure representation:  helix – purple, 310 
helix – blue, extended  structure – yellow, turn – cyan, coil – white. 
Representation rendered using VMD from pdb file 2ZP6 4. 
 
Insulin hexamers are assembled from three dimers in which the nine N-terminal B 
chain residues can adopt either a helical conformation (R) or an extended state (T). 
This creates hexamers of the form T6, T3R3 and R6 which exist in an allosteric 
equilibrium 5. Three histidine residues at position 10 of the B chain coordinate the 
zinc ions in both conformations. In the R state the tetrahedral coordination of Zn2+ 
requires additionally a ligand, whilst T state Zn2+ adopts an octahedral geometry with 
an additional three water molecules. The conformational change between T and R 
states is caused by phenolic ligands binding in six hydrophobic pockets, of import as 
phenolic preservatives are often used in drug preparations. ESI MS can identify the 
stoichiometric changes which occur between T and R insulin hexamer conformations 
confirming that these different structures can be preserved into the gas-phase; 
additionally insulin tetramer, hexamer and decamer oligomers were observed to be 
present in the mass spectrum in the absence of zinc 6.  
 
Type 1 diabetes results from autoimmune damage to the  cells of the islets of 
Langerhans, causing a deficit in insulin production 7. This can be treated by insulin 
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replacement therapy, requiring careful monitoring of blood glucose levels and daily 
injections of insulin 7. Type 2 diabetes often occurs later in life when sufficient 
insulin cannot be produced to maintain blood glucose levels, or insulin is produced 
but not used effectively by the body 8. Injection of monomeric insulin provides the 
fastest relief for diabetes patients; however monomeric insulin is prone to 
aggregation, forming fibrils and precipitating out of solution, resulting in a less 
effective pharmaceutical preparation 9. Insulin 2Zn2+ hexamers are more stable 10,11, 
but after injection are hindered from absorption into the blood stream by their large 
size 9. Corresponding patient blood sugar level response is therefore slower as there 
is a delay whilst hexamers are broken down firstly into dimers, with subsequent 
dimer dissociation producing monomeric insulin which can reach tissues 9. Research 
into a faster acting form of insulin which would be less vulnerable to aggregation led 
to the development of monomeric insulin analogues 12, which are used extensively in 
modern diabetes treatment plans 13.   
 
Insulin has been the focus of a number of studies concerning protein self assembly 
and the resulting fibrillar aggregates 14.  Insulin is a predominantly -helical protein 
in its native state, forming a hexamer at neutral pH. Insulin aggregation in vivo 
occurs at the site of insulin injection 15. Waugh observed insulin fibrils in vitro in 
1946 and described the sigmoidal kinetics characteristic of amyloidogenesis 16.  The 
initial lag phase followed by a period of accelerated growth and culminating in 
saturation previously was ascribed to a nucleation and growth process similar to that 
observed in crystallisation 17. However, recent investigations by Knowles et al. 18 
suggest that primary nucleation is more rapid than previously thought, and that the 
characteristic sigmoidal growth curve is a result of secondary processes, including 
fragmentation. Burke and Rougvie in 1972 19 observed that insulin fibrils displayed 
the distinctive cross- X-ray diffraction pattern characteristic of amyloid fibrils 20. If 
the amino acid sequence is depleted at the C-terminus of the B chain, insulin 
becomes more amyloidogenic, whereas joining the N-terminus of the A chain to the 
C-terminus of the B chain reduces aggregation propensity. These experiments, 
supported by HDX data showing C-terminal flexibility 21, imply that the C-terminus 
of the B chain has a vital role in insulin aggregation 11.  
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Conditions which promote rapid fibrillogenesis in vitro are high protein 
concentrations, low pH (1.5 - 2.0) and temperatures of 60 to 70 °C 11,16,22, all of 
which favour monomerisation and partial unfolding of the protein. Under 
aggregating conditions Nettleton et al. observed bovine insulin oligomers up to 
dodecameric order using n-ESI MS, where the population of large oligomers 
decreased throughout the lag phase 14. Concurrent EM measurements showed a 
transition with time from amorphous aggregates to twisted un-branched fibrils 
containing protofilaments, whilst FTIR revealed a simultaneous increase in the 
proportion of  structure present 14. Further FTIR and CD experiments confirmed an 
initial -helical structure which converted to  structure as fibrils become visible by 
EM 23.  
 
During the early stages of self assembly (the apparent “lag” phase) it is predicted that 
a wide variety of different oligomeric species will be present, all potentially on-
pathway to self assembly 18. In this chapter significantly populated multiple oligomer 
populations of insulin present in the lag phase prior to fibril assembly are observed 
using IM-MS, giving new insight into the self assembly of insulin. These oligomers 
are unequivocally assigned using high resolution FT-ICR MS and CID experiments. 
Experimental CCS data is used to train MD simulations providing atomistic detail for 
the dominant dimeric species. The stability of several representative dimers is 
evaluated via binding energy calculations. The association of monomers must be the 
first step on any self assembly pathway and therefore studies into this interface are 
vital. This also might enable targeting of this interface by small molecule inhibitors 
to prevent amyloid formation. 
 
Chapter 4: Insulin 
 - 125 - 
4.2. Methodology 
 
4.2.1. Sample Preparation 
 
Bovine insulin (CAS number: 11070-73-8, Sigma Reference: I5500) was obtained as 
a lyophilised powder from Sigma Aldrich (UK), with a theoretical mass of 5733.49 
Da. The zinc content of the powder was approximately 0.5 %. The bulk of 
experiments were conducted by creating an aggregating solution of 3 mg/ml 
(523 µM) bovine insulin by dissolving the protein powder in H2O adjusted to pH 2 
with formic acid. Thioflavin T fluorescence measurements confirm that insulin 
amyloid fibrils are formed under these solution conditions. These samples were 
immediately flash frozen in liquid nitrogen and stored in a -28 °C freezer. Where 
experiments were performed at different concentrations or in different solution 
conditions, the sample preparation methodology was similar to that described above. 
Deconvolution of the mass spectra revealed an experimental bovine insulin 
monomeric mass of 5733.24 Da. The difference between theoretical and experiment 
masses of 0.25 Da is most probably due to calibration inaccuracies. 
 
4.2.2. Mass Spectrometry 
 
High resolution mass spectrometry was performed on a QTOF 2 mass spectrometer 
(Waters, Manchester, UK) and QTOF Ultima mass spectrometer (Waters, 
Manchester, UK). Mass spectra were recorded for samples in positive mode utilising 
an n-ESI ionisation source. The n-ESI source was modified to contain a heating 
block (described in Chapter Two, Section 2.2.1.2) which heated the glass capillary 
containing the sample prior to ionisation.  
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4.2.3. Ion Mobility Mass Spectrometry 
 
IM-MS measurements were performed on the ‘ MoQTOF’ 24.  Samples were ionised 
using an n-ESI source in positive mode with an applied capillary voltage of ~1.8 kV 
and a cone voltage of 50 V. Transmission of the oligomeric species required an 
elevated pressure in the source region as reported previously 25. Ions were 
accelerated through a potential difference of 39.7 V (unless otherwise stated) and 
injected into the drift cell. The drift cell was filled with helium gas at a pressure of 
between 3.0 and 3.5 Torr and a temperature between 298 and 303 K. The 
temperature and pressure of helium were recorded at the start and end of each 
mobility scan and the average taken. The voltage applied across the cell was varied 
from 60 V to 15 V and ATDs recorded at eight drift voltages.  
 
The resolution of the MoQTOF is not sufficient to give insulin 13C spacing. 
Therefore oligomeric species were assigned using zinc adduct spacing from the mass 
spectrum in addition to information gleaned from ATDs, CID and FT-ICR MS data.  
 
4.2.4. Collision Induced Dissociation 
Experiments 
 
Collision induced dissociation (CID) experiments in an argon filled collision cell 
were performed using a QTOF Ultima (Waters, Manchester, UK). Species were 
selected by their m/z value and accelerated into the collision cell at a variety of 
voltages. The kinetic energy of the ions entering the collision cell was increased by 
raising the collision voltage parameter until the signal from the parent ion had been 
completely lost and only product ions remained.  
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4.2.5. Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometry 
 
High resolution MS was performed on a 9.4 Tesla Apex Qe Fourier Transform Ion 
Cyclotron Resonance mass spectrometer (Bruker Daltonik GmbH). This provided 
13C isotopic distributions which confirmed the identification of peaks as isobaric 
aggromers or as conformers of the same species. The n-ESI source from a QTOF 
instrument was clamped in front of the capillary inlet and an external voltage applied 
to produce spray (for further details please refer to Chapter 2). The source 
accumulation time was 0.5 seconds; an excitation frequency sweep from 
24055.269 Hz to 161282.396 Hz was applied prior to detection from m/z 895 to 
6000. The voltages applied to the accumulation hexapole were 8.5 V on the entrance 
and 12 V on the exit. Data acquisition size was 1,048,576 bytes.  
 
Calibration of 6 to 10 ppm accuracy was achieved using Agilent Technologies ESI 
tune mix (catalogue number G2421A) and data processed using DataAnalysis 4.0 
(Bruker Daltonik GmbH). The simulated isotopic distributions were created from 
theoretical empirical formulas using the Simulate Isotopic Pattern function of 
DataAnalysis 4.0 (Bruker Daltonik GmbH). Isotopic patterns confirmed that all 
disulphide bridges in the insulin monomers, and in oligomer constituent monomers, 
were intact. 
 
4.2.6. Simulation Methodology 
 
All simulations were performed by Massimiliano Porrini. 
 
4.2.6.1. Monomeric Species [M+3H]3+ and [M+4H]4+ 
 
Insulin would be too computationally expensive to simulate with an explicit solvent 
model, therefore solvent was represented with a continuum solvation method, termed 
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“OBC” 26,27. The temperature control at 70 °C was implemented using the Langevin 
algorithm, with a collision frequency equal to 1.0 ps−1. All the bonds involving 
hydrogen atoms were constrained at their equilibrium value using the SHAKE 
algorithm 28, allowing the utilisation of a 2 fs time step. 
 
4.2.6.2. Correlation Between CCS and Rg 
 
The radius of gyration (Rg) and theoretical CCS were calculated for 500 structures of 
[M+3H]3+ to investigate whether there is a correlation between these two variables. 
To generate 500 structures of [M+3H]3+ an implemented loop scheme was used and 
is detailed below.  
 
DO i = 1, 500 
  heating from 0 K to 800 K in 6.4  ps 
  dynamics at 800 K for 60  ps 
  gradual exponential stepwise cooling from 800 K to 0 K, 2 ps per step 
  minimisation 
END DO 
4.2.6.3. MM-PBSA Calculations 
 
To perform Molecular Mechanic - Poisson-Boltzman Surface Area (MM-PBSA) 
calculations dimers were immersed in a TIP3P 29 water molecules box of 
approximately 80 x 70 x 70 Å3 (varying with the dimer under investigation) and 
containing between ~ 9500 and ~ 11500 water molecules. The system’s +6, +7 and 
+8 charge was neutralized with 6, 7 and 8 chloride ions respectively. After 
equilibrating temperature (70 C) and density at 1 atm of pressure, a production 
simulation of up to 25 ns in NPT ensemble was run, with temperature collision 
frequency of 2.0 ps−1 and a pressure relaxation time of 2.0 ps. All of the bonds 
involving hydrogen atoms were constrained at their equilibrium values, so that a time 
step of 2.0 fs could be used. To derive the electrostatic interactions a particle mesh 
Ewald (PME) method 30 was implemented, using a radial cut off of 8.0 Å.  
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4.3. Results and Discussions 
 
4.3.1. Mass Spectrometry  
 
Mass spectrometry oligomer populations reflect those present in solution 31. 
Conditions which promote insulin fibrillogenesis are high protein concentrations, 
low pH (1.5 - 2.0) and temperatures of 60 to 70 °C 11,16,22. However, the precise 
conditions employed affect the rate of fibrillogenesis and the morphology of fibrils 
produced. For example, different acids produce different rates of insulin 
fibrillisation 32 and different mature fibril morphologies 33. MS and IM-MS 
experiments were undertaken in a variety of solution conditions, to assess the impact 
of protein concentration, solution pH and acid type on oligomer populations.  
 
4.3.1.1. Different Acids 
 
Experiments were undertaken with both formic (HCOOH) and hydrochloric (HCl) 
acid solution conditions, at a variety of insulin concentrations. Figure 4.3 is a 
comparison of the mass spectra produced when similar concentrations of insulin 
were prepared in aqueous formic and hydrochloric acids at pHs of 2.0 and 1.6 
respectively.  
 
Under both conditions the dominant spectral peak in Figure 4.3 can be assigned as 
[M+4H]4+. Despite the greater acidity of the hydrochloric acid solution, for formic 
acid the monomeric charge envelop includes both [M+5H]5+ and [M+6H]6+ species 
at significant abundance. This may be because although more extended monomeric 
states are of greater prevalence under the more acidic HCl solution conditions, heavy 
adduction of insulin monomers by Cl- ions reduces the net positive charge monomers 
carry and are detected with. Another possibility is that acid-induced refolding of 
insulin is occurring in the HCl solution 34.  
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Figure 4.3 | Bovine insulin in aqueous formic (pH 2) and hydrochloric acid 
(pH 1.6) at similar concentrations.  
 
Although the intensity of the higher order oligomers appears greater in hydrochloric 
acid, this is misleading as the quality of mass spectra are inferior, as visible in the 
raised baseline visible at the lower m/z values. Additionally, due to the repeated 
adduction of oligomers by chloride ions, the spectrum resolution is substantially 
degraded. Chloride adducts could be removed by increasing the cone voltage applied 
to the source region of the mass spectrometer, leading to a more disruptive 
desolvation process. However, this caused fragmentation of the higher order 
oligomers, thereby negating it as a strategy. Conversely, aqueous formic acid 
solution conditions generated a wider array of oligomeric species, both in terms of 
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charge states and multimeric order, with substantially better resolution and fewer 
adducts. 
 
4.3.1.2. Different Protein Concentrations 
 
Insulin was prepared in a range of different concentrations in both hydrochloric and 
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Figure 4.4 | Bovine insulin at three concentrations, in aqueous hydrochloric 
acid at pH 1.6.  
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Figure 4.5 | Spectra of insulin in aqueous formic acid at various 
concentrations.  
 
The dominant species in the majority of spectra is [M+4H]4+. An exception to this is 
for the lower concentrations of insulin in aqueous formic acid where [M+5H]5+ is of 
the highest intensity. At higher concentrations, independent of acid type, there is an 
increase the number and population of larger oligomers observed. This could provide 
an explanation for the dominance of low charge state monomers at higher 
concentrations, as these could result from the dissociation of larger oligomers. An 
enlargement of the higher m/z region for formic acid solution conditions allows 
greater discernment (Figure 4.6).  
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Figure 4.6 | Enlargement of the high m/z region of the spectra of insulin in 
aqueous formic acid at various concentrations.  
 
At 500 µM and above a wide range of larger oligomers are present at significant 
intensities. Higher order oligomer populations remain quantitatively similar with 
increasing concentrations after a threshold of 500 µM has been reached. If the 
formation of oligomers was a n-ESI effect no such threshold would exist. Therefore a 
solution of aqueous formic acid containing insulin at a concentration of 523 µM was 
chosen for the majority of further experiments. This decision was made based on the 
higher quality spectra formic acid afforded, coupled with the abundant range of 
oligomers displayed at this concentration. It should be noted that IM-MS 
measurements of oligomers formed in a solution of aqueous hydrochloric acid 
showed very similar CCSs to those formed in formic acid (data not shown). For 
Chapter 4: Insulin 
 - 134 - 
clarity only CCSs of insulin oligomers formed in formic acid solutions are discussed 
later in this chapter.  
 
4.3.1.3. Different pHs 
 
To obtain solutions of different pHs a stock solution of bovine insulin in aqueous 
formic acid was diluted with water, ammonium acetate and acetic acid in varying 






























































































































































Figure 4.7 | Mass spectra of 40 µM insulin at varying pHs.  
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Surprisingly, results obtained were at odds with previous publications; whilst 
Nettleton et al. report dominant [6M+11H]11+ and [6M+10H]10+ species at pH 4 14, in 
our experiments monomeric species dominate the mass spectra at all pHs employed, 
although hexameric species are present. We speculate that this might be due to the 
lower insulin concentrations employed in this experiment as Nettleton et al. utilise 
2 mM concentrations. In line with expectations, a pH 2 solution produces a greater 
average charge per monomer than more basic solutions. However, more unusually, 
pH 5.5 has a dominant [M+4H]4+ species whilst at pH 4.7 the [M+3H]3+ species is in 




















































































































































































































































Figure 4.8 | Enlargement of the high m/z region of the mass spectra of 40 µM 
insulin at varying pHs. The poor quality of the spectrum at pH 4.7 is due to 
increased salt adduct presence.  
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The above figure displays an enlargement of the higher m/z region. At pH 5.5 all 
hexameric and heptameric species are more abundant than in more acidic solutions. 
pH 5.5 possibly favours the formation of hexamers in solution as it mimics the 
physiological conditions found in the secretory vesicles where insulin is formed 35. 
The preponderance of heptamers is more perplexing, as they are of no known 
relevance in vivo. It may be a consequence of the increased hexamer quantity, as 
monomer addition to these would create greater numbers of heptamers than might 
otherwise be expected. This would suggest a very dynamic system, with unstructured 
hexamers available for monomer addition. At pH 2, where aggregation of insulin is 
known to occur, a greater range of species and more high mass oligomers are 
observed.  
 
4.3.1.4. Selected Conditions 
 
Bovine insulin was dissolved in water, adjusted to pH 2 with formic acid, to a 
concentration of 523 µM. At room temperature these solution conditions promote 
aggregation; however fibrillogenesis takes place over a period of months rather than 
the hours taken at elevated temperatures 36. In support of this, the mass spectra and 
conformer distributions reported below did not vary significantly throughout any 6.5 
hour experiment. We have confirmed that fibrils are indeed formed under these 
conditions by Thioflavin T fluorescence measurements and EM observations (data 
not shown). The resulting mass spectrum (Figure 4.9) shows a wide variety of 
species. Oligomers of the general form [nM+zH]z+ are observed with 1  n  15. All 
of the species observed by n-ESI MS carry more charges than the multimeric order 
of the oligomer. The largest intensity species are attributed to two monomers of 
adjacent charge states: [M+5H]5+ and [M+4H]4+ at m/z values 1147 and 1434. 
However, there is also a significant contribution from peaks at m/z values 1639 and 
2294, where the principal contribution is from dimeric species (see below). Zinc 
adducts are present on all peaks, due to the presence of zinc in the insulin 
preparation. However, the dominant peak of both monomers and oligomers is 
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4.3.1.5. Aggregate Destabilisation 
 
Experiments which destabilise aggregate populations by subjecting them to greater 
forces, either during desolvation or inside the mass spectrometer, can give valuable 
insight into oligomer stability and dynamics within the population.  
 
4.3.1.6. Cone Voltage Experiments 
 
As mentioned previously, when the cone voltage is increased, aggregate species are 
observed to break up.  
 
The dimeric species [2M+5H]5+ and [2M+4H]4+ increase in abundance as the cone 
voltage is raised (Figure 4.10). This suggests that the populations of these lowly 
charged dimers are created, in part, by the fragmentation of larger oligomers which 
are vulnerable to harsh desolvating conditions. Conversely, the peak corresponding 
to [2M+7H]7+ decreases with the increasing cone voltage, although it is more 
persistent at high cone voltages than the populations of [4M+11H]11+ and [3M+8H]8+ 
which also decline. The most significant variations in the monomer population with 
increasing cone voltage occur for [M+3H]3+, which increases in intensity. 
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Figure 4.10 | Spectra taken at increasing cone voltages showing oligomer 
population changes.   
 
CID experiments, described in detail later in the chapter, show that the [2M+7H]7+ 
dissociates into [M+3H]3+ and [M+4H]4+. Therefore the increase in [M+3H]3+ 
intensity observed in Figure 4.9 could be due to the fragmentation of the [2M+7H]7+ 
ion and resulting repopulation of the [M+3H]3+ and [M+4H]4+ species. 
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Figure 4.11 | Spectra taken at increasing cone voltages, enlarged to show in 
detail the region between 40 V and 60 V.  
 
As can be observed from Figure 4.11, no appreciable dissociation of multimers takes 
place at cone voltages below 60 V. As a cone voltage of 50 V is employed in the 
experiments which follow, we are operating below the limit at which voltages 
dissociate oligomers. High voltages cause more energetic collisions between 
oligomers and the solvent or desolvation gases, however, the voltage must be 
sufficient to allow oligomer desolvation.  
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4.3.1.7. Collision Voltage Experiments 
 
In an analogous experiment, raising the energy with which ions enter the collision 
cell can cause the break up of large oligomeric species into smaller species and the 
fragmentation of monomers into small peptides. In the figures beneath, there is a 
clear decrease in the populations of trimers, tetramers and pentamers with increasing 
collision voltages. Higher collision energies cause more highly charged species to 
experience a greater acceleration and impact with gas atoms. However, as these ions 
are travelling faster they will undergo fewer collisions as they travel through the 
collision cell. These conflicting effects suggest that the persistence of [M+4H]4+ and 
[M+3H]3+ visible in Figure 4.12 is most probably due to their repopulation by the 
break up of [2M+7H]7+, rather than that they possess a greater stability than 
[M+6H]6+ or [M+5H]5+, which visibly decline with increasing collision voltage.  
 
 
Figure 4.12 | Spectra at increasing collision voltages showing oligomer 
population changes.  
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Focusing again on the dimeric species present; [2M+7H]7+ is only very sparsely 
populated when the collision voltage is greater than 10 V (Figure 4.13). Conversely 
[2M+5H]5+ persists with a greater relative abundance at higher collision energies, 
even at a voltage of 45 V. This is not analogous to the explanation for changing 
monomer intensities above, as although [2M+7H]7+ will experience greater 
acceleration and more forceful collisions than [2M+5H]5+, the charge density of the 
dimers is considerably less than that of the monomers. There is also an appreciable 
quantitative increase in the population of [2M+5H]5+, a phenomenon unexplained by 




Figure 4.13 | Spectra at increasing collision voltages enlarged to show in 
detail the m/z region between 1500 and 2500.   
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Further experiments were performed (data not shown) in which the pressure in the 
source of the mass spectrometer was lowered. These conditions are observed to break 
up the higher order oligomers, and identical trends with the decrease of [2M+7H]7+ 
and increase in the relative population of [2M+5H]5+ are perceived. 
 
As demonstrated above, under electrospray conditions which best preserve 
oligomers, a predominant species is [2M+7H]7+. When however, experimental 
conditions favour the break-up of aggregates, we observe an increase in the 
intensities of species assigned to [2M+5H]5+ and [2M+4H]4+. It can be inferred that 
[2M+7H]7+ is significantly populated in solution, whereas the lower charge state 
dimers arise from fragmentation of larger species. Given that the dimer is a stable 
product ion and also a dominant species in the mass spectrum (Figure 4.9 (a)) we 
speculate that a dimer may be the core stacking unit in larger aggregates and 
therefore a key component of the fibrillogenesis process. A proposed schematic of 
this process is displayed in Figure 4.14.  
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Figure 4.14 | Schematic of a proposed insulin dimer assembly mechanism. 
[2M+5H]5+ and [2M+7H]7+ structures are generated by molecular modelling 
(described later in the chapter) and rendered with VMD software.  
 
4.3.1.8. Time Course Experiments 
 
In order to observe changes in oligomeric populations during insulin aggregation a 
time course was conducted. An eppendorf of bovine insulin, at a concentration of 
523 M in an aqueous solution acidified to pH 2 with formic acid, was heated to 
67 °C in a Jencons digital dry bath. The source heating block, described in detail in 
Chapter Two, was used to ensure samples were kept at 67 °C, prior to ionisation, 
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whilst the experiment was conducted. A six hour time course was performed; sample 



































































































































Figure 4.15 | Time course spectra of 523 M insulin in an aqueous solution 
acidified to pH 2 with formic acid, heated to 67 °C.  
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Figure 4.16 | Enlarged higher m/z region of time course spectra of 523 M 
insulin in an aqueous solution acidified to pH 2 with formic acid, heated to 
67 °C. 
 
No significant changes in the relative oligomer populations occurred over the 
experimental time course (Figure 4.15 and Figure 4.16). The experimental conditions 
utilised are conducive to aggregation, which was indirectly observed in the clogging 
of capillary tips as shown in Figure 4.17. IM-MS was also performed for a two hour 
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Figure 4.17 | Photographs of capillary tips blocked by aggregating insulin 
solutions during time course experiments. 
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4.3.2. Ion Mobility Mass Spectrometry 
 
4.3.2.1. Multiple Conformation Observations 
 
IM-MS has the valuable ability to differentiate between different conformational 
forms of ions, and also ions which have coincident m/z values, by their differing 
mobilities when travelling through a drift cell. Deconvolution of the ATDs of insulin 
oligomers [2M+7H]7+, [2M+9H]9+, [3M+8H]8+, [3M+10H]10+, [4M+11H]11+, 
[5M+11H]11+, [5M+12H]12+ and [6M+13H]13+ revealed multiple peaks present in the 
ATDs for all drift voltages. These could correspond to multiple conformations of a 
single species or oligomers of a coincident m/z (aggromers). Bernstein et al. recently 
observed multiple peaks in the ATD of a [2M-5H]5- A amyloidogenic peptide 
species; they postulated that these corresponded to higher order hexamer aggromers, 
which stacked to form a dodecameric paranucleus 37. A stacking mechanism would 
validate the assignation of the additional ATD peaks we observe experimentally to 
much larger oligomers, without the need for the presence of intermediate order 
oligomers which might otherwise be expected. 
 
To validate assignment of ATD peaks as either conformers of a species, or m/z 
coincident species, high resolution FT-ICR MS and CID are utilised.  Figure 4.18, 
Figure 4.19, Figure 4.20 and Figure 4.21 illustrate the use of IM-MS, CID and 
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4.3.2.2. Collision Induced Dissociation 
Experiments 
 
CID experiments provide information on parent ion stability; however they can also 
aid parent ion identification. An exemplar of this is Figure 4.21, where the 
oligomeric order n = 1 or 2 with associated charge z = 3 or 6. In the mass spectrum 
the dominant species is [M+3H]3+ so when two peaks are observed in the 
corresponding ATD the question arises whether compact and extended 
conformations of monomers are present or whether the more mobile species is the 
m/z coincident dimer [2M+6H]6+. Mass isolation of this m/z peak and fragmentation 
of the corresponding species reveals [2M+5H]5+ and [M+4H]4+ product ions. Neither 
of these could have been produced by the dissociation of [M+3H]3+, confirming the 
presence of a coincident m/z dimer - [2M+6H]6+ .  
 
Conversely the ATD of [2M+7H]7+ (Figure 4.18) exhibits three distinguishable 
species, one of which could be assigned to coincident oligomer [4M+14H]14+, 
however following CID only monomeric product ions were formed, indicative that 
the multiple ATD peaks result from distinct conformations of [2M+7H]7+. Six other 
oligomers: [2M+9H]9+, [3M+8H]8+, [3M+10H]10+, [4M+11H]11+, [5M+11H]11+ and 
[5M+12H]12+ exhibit multiple peaks in their ATDs which CID results (lack of 
product ions of higher oligomeric order than the postulated parent ion) suggest are 
different conformations of one species.  
 
4.3.2.3. Fourier Transform Ion Cyclotron 
Resonance Mass Spectrometry 
 
FT-ICR MS can be utilised to obtain a high resolution 13C isotopic mass spectrum 
which can identify very small populations of oligomeric species at a coincident m/z 
to a dominant spectral peak. Figure 4.21 illustrates this as the isotopic pattern of 
[3M+6H]6+ and [2M+4H]4+ species can be observed underlying the principal 
[M+2H]2+ species even though the ATD shows no evidence of the presence of 
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multiple coincident aggromers. Where sufficient signal was obtained to analyse 
isotopic distributions, oligomeric species [2M+7H]7+, [3M+8H]8+, [4M+11H]11+, 
[5M+11H]11+ and [5M+12H]12+ produced isotopic distributions consistent with the 
elemental composition and charge of that species and that species alone (Figure 4.18, 
Figure 4.19 and Figure 4.20). By contrast, in Figure 4.21 the species assigned 
nominally as [M+3H]3+ shows an isotopic distribution of a 3+ ion (red circles) and 
also a contribution from a species with double the charge (blue circles) and hence 
double the mass - [2M+6H]6+. The ATD of this species can therefore be conclusively 
defined as containing dimer and monomer; the higher charge state of the dimer 
means that it travels faster through the drift cell.  
 
ATD, FT-ICR MS and CID data are displayed for oligomeric species [3M+7H]7+  
(Figure 4.18), [4M+9H]9+ ( Figure 4.19) and [6M+11H]11+ (Figure 4.20) which are as 
the experimentally observed adjacent charge states to species ([3M+8H]8+, 
[4M+11H]11+ and [6M+13H]13+) which display multiple ATD peaks. These adjacent 
charge state oligomers possess close to the same number of protonable sites and are 
thus assumed to be the most structurally similar species to the oligomers which 
display multiple conformations. At low drift voltages only single conformations are 
observed, and this is confirmed by FT-ICR MS and CID data.  
 
Spectra from FT-ICR MS are of sufficient resolution to identify whether all the 
disulphide bridges in each oligomer are intact. For all species present the simulated 
isotopic trace for the elemental composition of oligomers with all disulphide bridges 
intact matches the experimental isotopic pattern. Intact disulphide bridges have 
previously been detected in insulin extracted from insulin fibrils in vitro 38 and in in 
vivo amyloid deposits 15. The presence of these disulphide bonds places important 
restrictions on the conformational space each oligomer can explore, and indeed these 
constraints have been observed to limit the configurations of protofilament sheet 
packing 39. Therefore these are important restraints and are utilised in the following 
molecular modelling.  
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FT-ICR MS and CID experiments, combined with data from ATDs has allowed us to 
conclude that additional ATD peaks in insulin oligomeric species [2M+7H]7+, 
[2M+9H]9+, [3M+8H]8+, [3M+10H]10+, [4M+11H]11+, [5M+11H]11+ and 
[5M+12H]12+ should be assigned as extended conformations, as the data show no 
evidence for aggromer presence. Multiple conformations of an oligomeric species 
have been reported in small (~6 amino acids), potentially amyloidogenic, peptides 40. 
Our experimental timescale for IM-MS measurements is milliseconds and therefore 
these conformational families are stable over at least that time window.  
 
The difference in the ratio of the intensities of the assigned m/z coincident species 
(for example, in Figure 4.21, the intensity of [4M+10H]10+ differs between the ATD 
and FT-ICR MS data) can be attributed to differences in the transfer optics of the two 
instruments (the IM-MS instrument possessing a source that has been optimised for 
the preservation of non-covalent interactions) and the differing timescales for 
analysis; milliseconds for IM-MS compared to seconds for FT-ICR MS. 
 
A number of previous studies 41,42 have indicated multiple peaks in ATDs of protein 
oligomers, however the use of CID and FT-ICR MS allow assignments to be based 
on solid experimental evidence. This is conclusive evidence for multiple, distinct, 
conformations of oligomeric species whose assignment has been achieved by further 
experiments. In every case the most compact conformation of the oligomer is present 
in the highest abundance, with two, three or four other larger conformers present. It 
is worth noting that the monomeric species only show single distinguishable 
conformers in each charge state.  
 
4.3.2.4. Coulombic Forces on Oligomers 
 
A large number of charges will increase the CCS of an aggregate due to Coulombic 
repulsion 43,44, therefore the presence of extended species in the ATDs could be 
attributed to charge driven structural unfolding in the gas-phase. De la Mora derived 
an empirical relation for the maximum number of charges on the surface of a protein 
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which retains its native fold 45. In Equation 4.1 z is the number of charges and MR is 
the mass of the protein (or in this case, the oligomer). 
RMz 0778.0=  Equation 4.1  
 
Figure 4.22 shows this relation plotted against the experimentally observed charge 
states for different oligomeric orders.  

































Figure 4.22 | The observed charge carried by each oligomer compared to the 
de la Mora relation for the maximum number of charges able to be carried on 
the surface of a protein which retains its native fold. 
 
With the exceptions of [M+6H]6+ and [2M+9H]9+ the observed charge on all insulin 
oligomer species is below the limit which can be accommodated on the surface of a 
protein of this size without Coulombic unfolding. Therefore the range of observed 
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conformers for each oligomer, and the differences in the charge oligomers carry, are 
likely to represent inherent structural variations present in solution rather than 
structures generated by Coulombically driven gas-phase unfolding. This is supported 
by several studies that show insulin can adopt multiple conformations at low pH and 
high concentrations 46,33 and allows us to link the conformations we observe via IM-
MS with atomistically resolved candidate geometries from MD simulations in 
implicit solvent.  
 
4.3.2.5. Oligomer Distributions 
 
Cumulative ATDs of each ion present in the mass spectrum were recorded after the 
same number of scans. These ATDs were fitted with a Gaussian distribution (or 
distributions if conformers or coincident m/z oligomers were present) and the area of 
the distributions noted. Plotting the areas of ATD distributions versus the multimeric 
order enables the consideration of the relative abundances of each oligomer.  
 
From Figure 4.23 it is observed that the monomer is the most abundant species; 
presenting in dominant charge states of 3+ and 4+. The dimer is the next most 
prevalent species. The hexamer appears as an extremely stable species, an 
observation which is consistent with the storage of insulin as a hexamer in vivo.  
There appears to be a slight preference for trimeric, hexameric, nonameric and 
dodecameric species compared to the neighbouring oligomeric states, possibly 
suggesting an increased stability of this trimeric, or multiple of trimeric, 
arrangement. The tetramer and octamer contribute only weakly to the spectrum, 
pointing to instability in these species relative to the other oligomeric orders.  
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Figure 4.23 | Distribution of Oligomers at t = 0: Each bar represents the 
integrated area of the ATD for each oligomer at a drift voltage of 50 V. Where 
more than one charge state is observed the bar is divided proportionately. 
Positive charge states are indicated by the number above the bar. The data 
are averaged over three repeats; error bars represent the standard deviation.  
 
Figure 4.23 also shows that some species have an unequal charge state distribution. 
For the dimeric species [2M+zH]z+ is observed with z = 4, 5, 6, 7 and 9. Due to the 
abundance of the [2M+7H]7+ species, the [2M+8H]8+ ion is presumed to be present, 
but is irresolvable in ATD space from [M+4H]4+, which is one of the most dominant 
spectral peaks.  
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Figure 4.24 | Distribution of Oligomers at t = 0, showing an expansion of the 
region for n > 2. Each bar represents the integrated area of the ATD for each 
oligomer at a drift voltage of 50 V. Where more than one charge state is 
observed the bar is divided proportionately. Positive charge states are 
indicated by the number above the bar. The data are averaged over three 
repeats; error bars represent the standard deviation. 
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4.3.2.6. Collision Cross Sectional Values 
 
We have obtained CCS values for the oligomeric species observed, from the four 
charge states seen for the monomeric form of insulin to the single charge state of the 





Figure 4.25 | CCSs of oligomers observed at t = 0 for 523 µM insulin in 
aqueous pH 2 formic acid. Labels are the associated positive charge state of 
each oligomer. Error bars represent the standard deviation of three repeated 
measurements. Multiple conformations of the same oligomeric species are 
coloured: green for [2M+7H]7+, magenta [2M+9H]9+, red [3M+8H]8+, blue 
[3M+10H]10+, violet [4M+11H]11+, pink [5M+11H]11+, purple [5M+12H]12+ and 
orange [6M+13H]13+. 
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As observed in the previous chapter for TTR(105-115), an increase in CCS with 
multimeric order is observed. All species carry more charges than the number of 
proteins in the oligomer but, as discussed previously, the charges carried by each 
oligomer are below the limit which would force structural unfolding. Therefore more 
extended oligomers present in solution, which have a greater number of ionisable 
sites, acquire more charges in the n-ESI process and thus a correlation between 
oligomer size and charge state is observed.  
 
However, there are exceptions to this, as the number of solvent accessible sites on a 
solution structure influences the charge on the gas-phase oligomer. Thus it is possible 
for the [2M+5H]5+ species to have the same CCS as the smallest conformation of 
[2M+7H]7+ due to a lower availability of protonation sites on the former structure. 
Likewise the CCS of [5M+9H]9+ is very similar to that of the smallest conformers of 
[5M+11H]11+ and [5M+12H]12+. As [2M+8H]8+ is substantially larger than all but the 
least populated conformation of [2M+7H]7+, the presence of an additional 
protonation site hints that a major structural reorganisation has occurred. 
[3M+10H]10+ is more compact than [3M+7H]7+ and some conformers of [3M+8H]8+, 
suggesting a condensed structure which possesses many accessible protonation sites. 
A similar story occurs for [4M+10H]10+ and the smallest [4M+11H]11+ conformer 
which display more compact CCSs than [4M+9H]9+. Compact structures which 
possesses greater availability of ionisable residues, relative to [6M+9H]9+ 
[6M+10H]10+ and [6M+11H]11+, are observed for the two smallest [6M+13H]13+ 
conformers.  
 
A plateau in CCS for oligomers of the same charge ([7M+13H]13+, [8M+13H]13+ and 
[9M+13H]13+) is observed, which suggests dense aggregate packing as there is no net 
increase in the number of protonable sites exposed with oligomer addition. 
Unexpected decreases in CCSs are observed between [4M+7H]7+ and [5M+7H]7+, 
[5M+8H]8+ and [6M+8H]8+,  [6M+10H]10+ and [7M+10H]10+, [7M+11H]11+ and 
[8M+11H]11+ and finally [8M+13H]13+ and [9M+13H]13+. In some cases the decrease 
is covered by the standard deviation in both measurements; however the reduction in 
CCS between [4M+7H]7+ and [5M+7H]7+, and [7M+11H]11+ and [8M+11H]11+ is 
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not, suggesting a more efficient packing and possible structural reorganisation of 
[5M+7H]7+ and [8M+11H]11+ compared to their neighbouring lower order oligomers 
of the same charge. 
 
Oligomers exhibiting multiple conformations can span a large CCS range. The 
[2M+7H]7+ conformational families extend from 1217 to 1701 Å2 and [2M+9H]9+  
conformations have CCSs between 1679 and 2565 Å2. However, as the charge on 
[2M+9H]9+ is above the de la Mora limit, it is not possible to extrapolate from these 
gas-phase conformers to solution behaviour. The CCS distribution occupied by 




Figure 4.26 | Conformational populations of insulin monomer and each of the 
oligomers as measured using IM-MS. Data have been obtained from the 
areas of the deconvoluted peaks in the m/z selected ion ATDs. To aid 
interpretation, information from each charge state has been merged via a 
Gaussian fit to provide this composite plot, which highlights the separation 
capabilities of IM-MS.  
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Figure 4.26 further demonstrates the separation power of IM-MS, enabling 
determination of the size distribution of all aggregates (i.e. monomer ions span CCSs 
of 704 to 978 Å2) but also unequivocally (coupled with high resolution FT-ICR MS) 
assigns sizes to oligomeric orders (for example the ion at m/z 1639 can be identified 
uniquely as a dimer of CCS 1217 Å2).  These data can be compared advantageously 
to size exclusion chromatography (SEC). Fink et al. 47 used SEC to study insulin 
aggregation, assigning distinguishable ‘sizes’ to the hexamer, to compact and 
expanded dimers, and to compact, expanded, and unfolded monomer. With no mass 
information such data could be misinterpreted: Figure 4.26 demonstrates that 
conformational space occupied by the monomer and dimer populations significantly 
overlap, as does the conformational space occupied by species including the trimer, 
tetramer, pentamer and hexamer.  
 
4.3.2.7. Injection Energy Experiments 
 
Injection energy studies were carried out to ensure that the extended oligomer 
conformers observed were not caused by structural unfolding in the gas-phase, due to 
activation of the ions by high-energy collisions as they are transported in the mass 
spectrometer. IM-MS data were acquired whilst varying the voltage that injects the 
ions into the drift tube, known as the injection energy. The ATDs of [2M+7H]7+, at a 
drift voltage of 20V, are shown at a range of injection energies in Figure 4.27. 
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Figure 4.27 | [2M+7H]7+ ATDs acquired at a range of injection energies. 
 
The [2M+7H]7+ ATDs are shifted to higher arrival times only when the injection 
voltage is higher than 45 V. This behaviour is replicated in all ATDs which contain 
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features that FT-ICR MS and CID have identified as extended conformations. As 
IM-MS experiments were performed with an injection energy of 39.7 V, this 
indicates that these extended conformers are present in solution, and not a result of 
structural unfolding in the mass spectrometer.   
 
4.3.2.8. ATD Observations 
 
All ATDs for species of n > 6 contain a lower populated peak which arrives before 
the main species peak (Figure 4.28 and Figure 4.29). This peak is also present in two 
pentameric and three hexameric species. Due to the high m/z values of these species 
and their relatively high molecular weights, dissection of peak identity by either CID 
or FT-ICR MS has not been successful. There are two possibilities for the identity of 
these earlier arriving species; either they are significantly more compact and less 
populated conformations of the nominal species, or coincident m/z higher order 
aggromers. Both possibilities are shown graphically and discussed below.  
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Figure 4.28 | ATDs at a DV of 60 V showing the earlier arriving species 
present. Labels correspond to the assignment of the later arriving more 
populated species.  
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Figure 4.29 | ATDs at a DV of 60 V showing the earlier arriving species 
present. Labels correspond to the assignment of the later arriving more 
populated species. 
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Figure 4.30 | CCSs of oligomers observed at t = 0 for 523 µM insulin in 
aqueous pH 2 formic acid, with earlier arriving ATD peaks assigned as 
compact species. Labels are the associated positive charge state of species. 
Error bars represent the standard deviation of three repeated measurements.  
 
The degree of compaction experienced by the oligomers, for the above assignment to 
be correct, would be extreme (Figure 4.30). The smallest conformation of 
[2M+7H]7+ and the compact [5M+7H]7+ species have CCSs that are the same within 
experimental error. Hence, using this interpretation of the data, a two and a half times 
increase in mass would not result in any increase in size. Perhaps more striking is 
that the compact [6M+8H]8+ species possess a CCS substantially smaller than that of 
the [2M+8H]8+. If the oligomers are assumed to be spherical, their density can be 
calculated. [2M+8H]8+ has a density of 0.24 Da/Å3 whilst a compact [6M+8H]8+ 
species would have a density of 0.82 Da/Å3, almost three and a half times greater. As 
average density of globular protein standards has been reported as 0.44 Da/Å3 42, a 
density of 0.82 Da/Å3 seems unlikely. Thus the assignment of the earlier arriving 
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ATD peaks as coincident m/z higher order oligomers appears more probable, and the 




Figure 4.31 | CCSs of oligomers observed at t = 0 for 523 µM insulin in 
aqueous pH 2 formic acid with earlier arriving ATD peaks assigned as higher 
m/z species. Labels are the associated positive charge state of species. Error 
bars represent the standard deviation of three repeated measurements.  
 
The largest oligomer observed would therefore be a 24mer with a molecular weight 
of 137.6 kDa, to date the largest oligomeric species observed for an amyloidogenic 
system by IM-MS. The average of the densities of the coincident m/z higher order 
oligomers is 0.43 Da/Å3, in good agreement with the literature 42, which lends 
support to this assignment.  
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Figure 4.32 | The observed charge carried by each oligomer compared to the 
de la Mora relation for the maximum number of charges able to be carried on 
the surface of a protein which retains its native fold. The grey squares are the 
earlier arriving ATD peaks assigned as higher order oligomers.  
 
The de la Mora relation plotted in Figure 4.32 shows that if the assignment of the 
earlier arriving ATD peaks as larger oligomers is correct only the [10M+14H]14+, 
[10M+16H]16+, [12M+16H]16+, [12M+18H]18+, [14M+20H]20+, [14M+22H]22+ and 
[16M+22H]22+ species have a sufficiently low charge to prevent significant 
Coulombically driven unfolding. Thus differences in the charge these oligomers 
carry are likely to be due to inherent structural variations present in solution. Of these 
species; [10M+16H]16+ and [12M+16H]16+ and [14M+22H]22+ and [16M+22H]22+ 
have CCSs which agree with their standard deviations. All other higher order 
oligomers carry more charges, and thus their CCS is likely to be governed, in part, by 
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charge driven unfolding. Regardless of this, the CCSs of these higher order 
oligomers suggest substantial compaction. The [12M+16H]16+, [12M+18H]18+ and 
[12M+22H]22+ dodecameric species have CCSs which are less than or equal to that 
of [12M+17H]17+, indicating the former possess a greater availability of solvent 
accessible ionisable residues but have undergone a structural compaction. Other 
oligomers of higher than dodecameric order display the expected correlation between 
increasing charge and increasing CCS.  
 
4.3.3. Molecular Modelling  
 
4.3.3.1. MD of Oligomers from Monomeric to 
Hexameric Order 
 
The initial coordinates files used to carry out MD simulations were those of the 
crystal structure of dimeric bovine insulin, pdb code 2ZP6 4. Starting with this 
structure several multimeric species were constructed, from monomer up to hexamer, 
by applying crystallographic symmetry transformations given in the pdb file. After 
removing the zinc di-cations and submitting the structures to the web site H++ 48 
(imposing a pH of 2), all the structures were minimised in vacuo. Related CCS 
values were calculated using MOBCAL software 49, implementing the trajectory 
method (TM). The results are given in Table 4.1. 
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Table 4.1 | CCSs for the oligomeric species from monomeric to hexameric 
order. A structure surface representation for all the species is displayed: the 
monomeric units closer to the reader are depicted in orange, further away 
units are depicted in green.  
 
Following minimisation, the dimer has a calculated CCS of 1319 Å2, very similar to 
that of one of the experimentally measured [2M+7H]7+ conformations (1324 Å2). 
Thus the second most populated gas-phase conformation of [2M+7H]7+ occupies a 
volume similar to that of the crystal structure. 
 
4.3.3.2. Monomeric Species [M+3H]3+ and [M+4H]4+ 
 
The total charge of dimeric bovine insulin in solution at pH 2 is +8 if all of the acidic 
side chains are protonated. However the insulin dimer extracted from the hexameric 
crystal structure pdb 2ZP6 4 yielded a net charge of +7 on submission to the 
webserver H++ 48, as Glu4 from the A chain of one of the monomers is surrounded 
by many positively charged side chains, and thus remains unprotonated. This is in 
support of the high population of [2M+7H]7+ observed by MS and IM-MS. The 
dimer was split into two monomeric species [M+3H]3+ and [M+4H]4+, facilitating  
further investigation of the very compact (1217 Å2) and highly extended (1709 Å2) 
conformations adopted by [2M+7H]7+. [M+3H]3+ and [M+4H]4+ were subjected to 
MD for 152 ns using the Amber10 software package 50, implementing the Amber 
ff99SB-ILDN force field 51. During dynamics, snapshots were collected every 2 ps to 
give an ensemble of 76,000 structures for each monomeric species.  
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Figure 4.33 | Rg and RMSD time series recorded for 150 ns of dynamics for 
[M+4H]4+ and [M+3H]3+. 
 
Both monomeric species sampled complex conformational landscapes (Figure 4.33): 
Rg spanned values between 10 and 22 Å, whereas the backbone root mean square 
deviations (RMSDs) span values up to 15 Å. As expected the [M+4H]4+ species 
explores, on average, a larger conformational space due to its higher charge.  
 
4.3.3.3. Correlation Between CCS and Rg 
 
Through a simulated annealing dynamics loop, 500 structures of [M+3H]3+ were 
stored. The implemented loop scheme is detailed in Section 4.2.6.2 and the implicit 
solvent model adopted is described in Section 4.2.6.1 with a 0.002 ps time step. The 
runs were conducted with NAMD 52 software. For the 500 obtained structures of the 
[M+3H]3+ monomer, Rg and CCS were calculated. The related scatter plot is given in 
Figure 4.34 together with the line of the linear regression (which has a correlation 
coefficient equal to 0.83).  
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Figure 4.34 | Correlation between Rg and CCS for simulated [M+3H]
3+ 
structures. The values were derived from a simulated annealing procedure in 
implicit solvent. 
 
A linear correlation between Rg and CCS can be observed in Figure 4.34, 
demonstrating the two variables are comparable. 
 
4.3.3.4. Cluster Analysis 
 
The first 2 ns of the dynamics run were discarded, leaving 75,000 structures of each 
monomeric species from the original ensemble. A cluster analysis 53 was performed 
on these structures, which derived 10 clusters of conformations. To construct the 
similarity matrix of distances the backbone RMSD between the pairs of structures 
was measured. This procedure resulted in 10 conformational families, whose 
populations are given in Table 4.2.  
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Clusters I II III IV V VI VII VIII IX X 
[M+3H]
3+
 27.7 25.1 18.7 7.8 6.8 5.8 3.7 1.8 1.8 0.8 
[M+4H]
4+
 23.9 22.0 14.5 8.9 6.5 6.0 6.0 5.9 5.8 0.4 
 
Table 4.2 | Cluster populations (given in %) of conformations sampled along 
the MD runs of the two monomeric species. 
 
4.3.3.5. Protein-Protein Docking 
 
To elucidate the structure of the most abundant and most compact dimer, [M+3H]3+ 
and [M+4H]4+ species with the lowest calculated Rg were used in a protein-protein 
docking procedure, implementing the webserver Hex 54, based on both shape and 
electrostatic correlation. After docking, the dimer with the lowest Rg was selected 
and subjected to dynamics in vacuo for 15 ns. The dynamical evolution of its CCS is 
reported in Figure 4.35. Despite the fact that our simulation time is short compared 
with the experimental timescale, and too short to sample the conformational change 
that occurs to a desolvating protein effectively 55, we find conformations which are 
consistent with the experimental results.  
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Figure 4.35 | Gas-phase dynamical evolution of the CCS for the most 
compact dimer. The structure with the lowest CCS is displayed. The 
experimental CCS for the most dominant, most compact, [2M+7H]7+ species 
is 1217 ± 33 Å2. 
 
Across the dynamics trajectory a correlation between secondary structure and 
compactness exists. This also holds true for the constituent monomers and in Figure 
4.36 and Figure 4.37 we show the scatter plot of Rg values versus helicity, beta and 
turn content, assessed through the DSSP algorithm 56. For both [M+3H]3+ and 
[M+4H]4+ the proportion of -strand secondary structure is notably higher for the 
smallest explored conformations, especially for the [M+3H]3+ species. 
Quantitatively, if Rg values are divided into quartiles, from the most compact to the 
most extended structures, the average percentages of -strand content are 1.74, 0.88, 
0.55 and 0.21 for [M+4H]4+ and 14.09, 8.81, 5.63 and 3.04 for [M+3H]3+. Other 
types of secondary structure are more equally distributed along the Rg values (Figure 
4.36, Figure 4.37). It should be reiterated that the native state of insulin is 
predominantly -helical, and that, both experimentally and computationally, all of 
the disulphide bonds remain intact within the oligomers.  
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Figure 4.37 | Rg versus secondary structure percentage content for [M+3H]
3+.  
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As shown above, by selecting and docking the most compact monomers, MD 
simulations provide conformations of the insulin dimer that correspond to the 
compact species we observe experimentally. For all oligomeric species observed 
experimentally, the most significantly populated conformation is the most compact 
form, and the above simulations indicate that these may possess enhanced -sheet 
structure.  
 
Of the 10 conformational families (I-X) for both [M+3H]3+ and [M+4H]4+ the largest 
(I and II) each contain on the order of 25 % of the conformations sampled for each 
species (Table 4.2). Figure 4.38 displays the representative structures for the most 
populated cluster of each monomer species.  
 
Figure 4.38 | Representative structures (tubes) and conformations (lines) of 
the most populated cluster for [M+4H]4+ (blue) and [M+3H]3+ (red).   
 
Representative structures of these most populated clusters were assembled using the 
same protein-protein docking approach. The resulting 1000 ‘best docking’ dimers 
were minimised in vacuo and the CCSs calculated for the 100 species lowest in 
energy (Figure 4.39).  
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Figure 4.39 | CCS values of the dimers derived from the protein-protein 
docking between the representative structures of the most populated 
families. The lowest energy “best docking” dimer is displayed with a surface 
representation with [M+4H]4+ shown in blue and [M+3H]3+ in red.  
 
The corresponding values (Figure 4.39) distribute around a mean value of 1612 ± 
38 Å2, in agreement with the experimentally measured CCS of 1564 ± 10 Å2 for the 
[2M+7H]7+ second largest conformational family. 
 
4.3.3.6. Contact Interface and Stability of Dimers 
Derived from Docking 
 
To analyse the interacting residues at the interface between assembled monomeric 
units, the distribution of the  carbon pairwise (CA-CA) distances over the 1000 
structures derived from the docking procedure have been calculated. The notation 
mi
(j) was assigned to the monomeric units, where i = I, II, . . . , X characterises a 
representative structure of one of the ten clusters reported in Table 4.2 (only the first 
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two most populated clusters have been considered in this case ie. i = I and II). The 
notation j represents the considered net charge (i.e. j = 3 or 4). The cut off for the 
CA-CA distance to be included was set equal to 10 Å.  
 
The representative structure of the most populated cluster was assembled with itself 
and with the representative one of the second most populated, obtaining six families 

























(4). A dimer is selected from each mi
(j)
mk
(l) family which is representative of the 
most frequent monomer monomer interface and is the lowest in energy. The resulting 
distributions are projected onto a xy plane, where x and y are the numbered sequences 
of the first and second monomer respectively. This procedure enables the selection of 




Figure 4.40 | xy projection of the distributions of  carbon pairwise distances. 
The two upper, middle and lower figures are related to the [2M+6H]6+, 
[2M+7H]7+ and [2M+8H]8+ species respectively. In particular the figures A, B, 
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The stability of each lowest energy dimer was evaluated by testing the interaction 
energy between the monomers that form dimers with the Molecular Mechanics 
Poisson Boltzmann Surface Area (MM-PBSA) calculation implemented in the 
Amber software package 57. Dimers were immersed in a box of TIP3P 29 water 
molecules and a neutral charge achieved by the addition of chloride ions, further 
details are given in Section 4.2.6.3. Using this approach, the binding energy of two 
monomeric structures that form a dimer can be calculated, overcoming the “static” 
picture resulting from docking by including dynamical features of the derived 
dimers.  
 
Even though the energy evaluation is overestimated in absolute value, as the entropic 
contribution is neglected, this approach gives a sufficiently good representation of 
the relative trend between similar systems 58, like the selected dimers in this work.  
 
The results of the calculations are shown in Figure 4.41; all of the binding free 
energies are negative, testifying that the dimers derived from the protein-protein 
docking are stable. Furthermore, the more compact dimers are the most stable ones 
with the most negative binding energies. This correlates with our experimental 
observation of the most compact dimers being the most abundant.  
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Figure 4.41 | Values of binding energy between monomers forming the 
selected dimers. The binding energy calculated via MM-PBSA for each 
selected dimer (mi
(j)mi
(j)) is depicted along with the final structure for each 
from the MD trajectory. A and B chains are displayed in yellow and silver 
respectively  
 
Analysis of the contributions to the binding energy indicates that in all six cases 
hydrophobic interactions add favourably to the driving force for self assembly (Table 
4.3). This does not hold true for the hydrophilic interactions, which are negative in 
only two out of six cases. This confirms that hydrophobic interactions are 
fundamental in stabilising the assembly of the monomeric units.  Even though the 
docking procedure was performed using monomers unfolded in implicit solvent, and 
hence likely to favour surface-exposed hydrophilic residues and burial of 
hydrophobic groups, the MM-PBSA procedure has revealed the importance of the 
hydrophobic interactions in the monomer-monomer contact interface. 
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 A B C D E F 
Hydrophobic 
(kcal/mol) 
-6.8 -8.7 -7.4 -6.2 -10.4 -4.9 
Hydrophilic 
(kcal/mol) 
103.6 13.0 21.6 -27.7 49.9 -66.9 
 
Table 4.3 | Hydrophobic and hydrophilic contributions to the solvation energy 
of the representative dimer structures. The values are derived from the 
Poisson-Boltzmann (PB) and surface area (SA) approaches respectively, 
with the MM-PBSA procedure. Letters A, B, C, D, E and F refer to the 















The interaction interface is retained during each 25 ns simulation, as shown by the 
residue specific average <RMSD> value (Figure 4.42). The highest values of the 
<RMSD> are from residues that do not participate in the interface; these are located 
at the termini of the both chains, although there is greater variability in the B chain 
(Figure 4.41). The interface between monomers in the different dimers is not 
identical, with both A-B/A-B and A-B/B-A stacking mechanisms observed. 
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Figure 4.42 | Residue number versus the <RMSD>. Lines marked with letters 
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Figure 4.43 | Structures with residues coloured to show the <RMSD> where 
blue is lowest, green intermediate and red largest. Letters A, B, C, D, E and F 













(4) respectively.   
 
During the dimer dynamics 25 structures were saved (one every nanosecond), from 
which the water molecules were stripped out. These structures were then minimised 
in vacuo and their CCS calculated. The results are displayed in Figure 4.44, CCS 
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(4) (E) and mI
(4)mII
(4) (F).  
 
4.3.3.7. Comparison with CryoElectron Microscopy 
 
Using low resolution 3D structures of fibrils, Jiménez et al. 39 postulate that a single 
protofilament of insulin consists of stacked monomers, and further that each insulin 
molecule occupies two layers, where the A and B chains of insulin stack on top of 
the other, connected by disulphide bridges. From the given electron densities of the 
single protofilament they estimate a dimension of 30 x 40 Å2 39. From this, if we 
assume that the inter layer spacing is less than the smallest dimension, which it must 
be if the layers are connected by disulphide bridges, we can obtain a value for Rg of 
~19.5 Å for the smallest unit that forms these protofilaments. From the relationship 
we have derived between Rg and CCS (Figure 4.34), we can compare this to our 
measured values. The most extended monomer from our implicit solvent calculations 
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has an Rg of 21.4 Å and a corresponding CCS of ~1391 Å
2.  The average values of Rg 
for monomers are 13.2 Å (CCS 1120 Å2), and 13.9 Å (CCS 1160 Å2), for [M+3H]3+ 
and [M+4H]4+ respectively (Figure 4.33). Results from IM-MS show that monomeric 
species never have a CCS that exceeds 1000 Å2, and the most populated have a lower 
CCS than this (Appendix 4). The dimeric species we observe experimentally have 
CCS that are more comparable to the Rg derived from the data of Jiménez et al. 
39, 
and interestingly our most populated gas-phase dimers correspond to Rg between 
12.8 and 36.3*. It is tempting to speculate that the structures in the gas-phase where 
the dielectric constant is 1 may be more similar to those present in the hydrophobic 
environment of the protofilaments 59, and indeed our data show that a dimeric 
building block cannot be ruled out. If, as postulated by Jiménez et al. 39, the 
protofilament is comprised of stacked monomers, these must elongate substantially 
as the fibrils grow. IM-MS shows that monomers only exist as a single 
conformational family (Figure 4.26), whereas higher order oligomers have several 
stable conformers over the millisecond IM-MS experimental timescale, which may 
reveal the extended forms required for fibril growth.   
 
4.3.3.8. Simulating Extended Dimers 
 
By selecting and docking [M+3H]3+ and [M+4H]4+ structures with the highest Rg 
(Figure 4.33, structure at ~33 ns for [M+3H]3+ and ~106 ns for [M+4H]4+) in an 
identical fashion to that described previously, dimers with CCSs which reproduce the 
experimental values of the larger [2M+7H]7+ conformations can be simulated. The 
results are presented in Figure 4.45 and the mean value is equal to 1874.3 Å2. This 
average differs by ~170 Å2 from the target experimental value of 1701.0 Å2 for the 
largest [2M+7H]7+ conformation. However, one should consider that its standard 
deviation is equal to 158 Å2, whilst the experimental value is for a conformational 
family which was only observed once (Appendix 4). 
                                                 
* corresponds to the range of dimer CCSs, displayed in Figure 4.24, at half 
peak height. 
Chapter 4: Insulin 
 - 188 - 
 
Figure 4.45 | CCS values of the dimers derived from the protein-protein 
docking between the structures with the highest Rg values. The dimer of the 
best docking is displayed with a surface representation with [M+4H]4+ shown 
in blue and [M+3H]3+ in red. 
 
In order to reproduce the values of the most extended dimers, these very stretched 
monomeric structures have been manually joined in the four possible ways: N-N, C-
C, N-C and C-N, where the C and N refer to the C-terminus and N-terminus 
respectively and the first letter of the pairs always refers to [M+3H]3+. The structures 
are shown in Figure 4.46.  
 
 
Figure 4.46 | The N-N, C-C, C-N and N-C docking structures in surface 
representation with [M+4H]4+ shown in blue and [M+3H]3+ in red. 
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Notably a geometry as extended as that observed experimentally for two 
conformational families of the [2M+9H]9+ species might be explained by this end-
on-end association on elongated monomers. CCS values calculated for the above 
structures were 2469.2 Å2, 2406.7 Å2, 2318.0 Å2 and 2304.7 Å2 respectively which 
compare favourably with the experimental [2M+9H]9+ CCSs of 2305 ± 251 Å2 and 
2565 ± 72 Å2.  
 
4.4. Summary  
 
MS allows observations of insulin oligomers up to dodecameric order before the 
onset of accelerated fibril growth, with dominant monomeric and dimeric species 
discerned. The additional separation power of IM-MS enables the identification of 
multiple conformations of insulin oligomers from dimeric to hexameric order and the 
observation of higher order aggromers composed of up to 24 monomers. Identities of 
multiple conformations have been confirmed by FT-ICR MS and are stable for 
milliseconds (IM-MS timescale) to seconds (FT-ICR MS timescale). This indicates 
that these species have a sufficiently high energy barrier to prevent inter-conversion 
during measurement. For all oligomeric species observed, the most significantly 
populated conformation is the most compact form. Modelling, for the first time 
trained by experimental measurements, has been used to characterise at atomistic 
detail aggregates bigger than a monomer. Modelling suggests that the most 
experimentally prevalent, conformationally compact, species are enriched in -sheet 
secondary structure. Dimers of this form would fit the electron density previously 
found in single protofilaments of insulin. 
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A Peptides and Inhibitors 
 
 
A peptides A(1-40) and A(1-42) are implicated in the pathogenic mechanisms of 
Alzheimer’s Disease. In this chapter,  MS (in both positive and negative ionisation 
modes) and IM-MS are utilised to analyse A peptide oligomer populations and the 
complexes they form with the retero-inverso OR2 peptide, which has been reported 
to be an inhibitor of A oligomerisation and fibril formation. IM-MS results 
elucidate a compaction of A peptides in complex with retero-inverso OR2, which 
could be the mode of action of this inhibitor. 
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5.1. Introduction  
 
Amyloid  (A) peptides are formed by the proteolytic cleavage of the 
transmembrane amyloid  precursor protein (APP) 
1
, a cell traffic regulating 
glycoprotein 
2
 which is expressed at high levels in the mammalian brain. The action 
of a  secretase outside the membrane, followed by a  secretase transmembrane 
cleavage, produces an A peptide of between 36 and 43 amino acids in length 
(Figure 5.1). The peptides A(1-40) and A(1-42) are the most frequent products of 
this cleavage 
3
 and are amyloidogenic in nature 
4
. An alternative, non-amyloidogenic, 
pathway occurs when APP is cleaved by an  secretase 
5
, followed by the same  
secretase transmembrane cleavage. The peptides produced by this succession of 









Figure 5.1 | Schematic of the production of A peptides from APP by the 
action of secretase enzymes. a. Cleavage of APP by  secretase followed by 
b.  secretase transmembrane cleavage producing c. A peptides  
 
The localisation of A(1-40) and A(1-42) production is different; in neurons, 
A(1-40) creation occurs in the endoplasmic reticulum, whilst A(1-42) is formed in 
the trans-Golgi network 
7
. Although 10 times less numerous than A(1-40) in vivo, 
A(1-42) is strongly linked to the aetiology of, and is more abundant in, the amyloid 
plaques which are diagnostic of Alzheimer’s disease 
8
. Elevated A(1-42) levels in 
plasma are also correlated with the development of Alzheimer’s disease 
9
. A(1-42) 
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is comparatively more cytotoxic to neurons than A(1-40) 
10-13
 and in vitro has a 
higher aggregation propensity 
14
. A(1-40) and A(1-42) fibrils both possess the 
cross- structure shared by all amyloid fibrils 
15
 and have -turn- motifs which are 
of similar conformation with parallel stacking and an in-register configuration 
16
. 
Figure 5.2 summarises the current models for the -turn- motifs present in A(1-40) 




Figure 5.2 | Schematic of the central residues of A peptides (a) amino acid 
sequence of A(1-42) (b) Structural constraints in A(1-40) and A(1-42) 
fibrils. SSNMR measurements of A(1-40) fibrils suggest side chain packing 
between Phe19 and Ile32, Leu34 and Val36, Gln15 and Val36 and His13 and 
Val40 (blue dashed lines). Molecular contacts have been reported within the 
monomer unit of A(1-42) fibrils between Phe19 and Gly38 (red dashed 
line) 17 and between Met35 and Ala42 (orange dashed line) 18. In both 
A(1-40) and A(1-42), the turn conformation is stabilised by hydrophobic 
interactions (green residues) and by a salt bridge between Asp23 and Lys28 
(black dashed line). Figure and caption adapted from Ahmed et al. 16.  
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SSNMR studies combined with computational approaches have allowed a structural 
model of lyophilised mature A(1-40) fibrils, formed at pH 7.4, to be proposed. The 
core region of the fibrils is formed by two -strands from each A(1-40) monomer, a 
-turn- fold, comprising residues 12 to 24 and 30 to 40
 19,20
. The A(1-40) 
monomers are stacked predominantly in an in-register and parallel alignment 
21-23
. 
A(1-40) N-termini are flexible and solvent exposed 
24-26
; specifically residues 1 to 
10 are unstructured 
19,20
. TEM of A(1-40) fibrils reveals morphological differences 
dependant on agitation or quiescence, with SSNMR reporting that different 
molecular structures and intermolecular contacts within the fibril cause 
polymorphism 
27
. Fibrillar A(1-42) is reported to possess an unstructured 
N-terminus up to residue 10 
16,17,28
 and a lack of structure in the last two or three 
amino acids of the C-terminus 
29
. The central A(1-42) residues compose two 
parallel and in-register  strands 
23,29,30
, with residues 18 to 42 composing the 
-turn- configuration 
17
. The remainder of the C-terminal residues are protected 
from solvent exchange 
17,28
. As mentioned in Chapter One, there is confusion in the 
literature as to the nomenclature and identity of prefibrillar intermediates. 
Observations of A protofibrils by AFM and TEM are varied, including 2 to 5 nm 
spheres, connection of these spheres into beaded chains and closed chain rings 
31-34
. 
A protofibrils exhibit binding with Congo Red and Thioflavin T dyes, diagnostic of 
the presence of -sheet structure 
34
. Proline scanning mutagenesis has been used to 
elucidate A protofibril structure discovering similar flexible N and C-termini to 




A(1-40) and A(1-42) exist in vitro as monomers prior to their aggregation into 
soluble oligomers and amyloid fibrils 
36
. The monomeric conformations of A(1-40) 
and A(1-42) are slightly different, with A(1-42) possessing greater -sheet and 
-turn structure 
37
. Soluble oligomer protofibril precursors, which are in rapid 
equilibria with the monomers, have been observed for both A(1-40) and A(1-42), 
via photo-induced cross linking 
38
. A(1-40) and A(1-42) are postulated to 
participate in differing assembly pathways; Bitan et al. report that A(1-40) forms an 
equilibrium of monomers, dimers, trimers and tetramers 
37
, whereas A(1-42) has 
been proposed to rapidly form structurally disorganised pentamers and hexamers 
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which act as ‘paranuclei’, associating into larger oligomer and protofibrils 
37
. This is 
supported by a recent paper by Ahmed et al. 
16
 which reports A(1-42) oligomers of 
mostly pentameric and hexameric order but a small population of decamers and 
dodecamers, which they postulate to have pentameric and hexameric building blocks. 
These A(1-42) oligomers, which contained no -sheet structure, were more toxic to 
murine neurons than A(1-42) protofibrils or mature fibrils 
16
. This is of particular 
interest as small oligomers are found in the brains of Alzheimer’s patients 
39
 and in in 
vitro studies 
40,41
. Thus there is accumulating evidence that A oligomers, 
particularly the A(1-42) decamer and dodecamer 
42-44
, are the principle pathological 
species in the progression of Alzheimer’s disease 
45,46
, for example; A oligomers are 
reported to cause neuron dysfunction 
47-49
 and murine memory loss 
42
. The additional 
two C-terminal residues present in A(1-42) result in a marked increase in 
aggregation propensity and cytotoxicity. Ahmed et al. 
16
 suggest that this is due to 
the additional hydrophobic residues in A(1-42) increasing the stability of neurotoxic 
oligomers.  
 
5.1.1. A MS, IM-MS and Modelling  
 
Grasso has recently written a comprehensive review of the use of MS to study A 
peptides 
36
, therefore this brief review focuses on studies which have utilised IM-MS 
and molecular modelling.  
 
IM-MS, in conjunction with molecular modelling, has been used to investigate 
A(1-42) monomer structure 
50
. Simulated A(1-42) monomers in solution were 
found to be conformationally dynamic and could be classified into three 
conformational families. Secondary structure calculated for these monomers in silico 
consisted of mostly turns and loops with some helical elements in the C-terminus. A 
combination of calculated CCSs of solvent free structures and theoretical CCSs of 
the monomer families after dehydration, agreed well with the experimental ATD of 
the most dominant mass spectral peak [A(1-42)-3H]
3-
. The advantage conferred by 
using IM-MS to elucidate the early stages of the aggregation process is clear as 
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demonstrated by Bernstein et al. 
51
 in the comparison of oligomeric species of 
A(1-42) and the non-amyloidogenic variant A(1-42) F19P. The mass spectral peak 
corresponding to the [2M-5H]
5-
 species yielded an ATD which suggested differences 
between the WT and mutant peptides (Figure 5.3a and b). After injection energy 
studies the ATD peaks were assigned as dimeric and tetrameric species for A(1-42) 
F19P, and dimer, tetramer, hexamer and dodecamer species for A(1-42).   
 
 
Figure 5.3 | ATDs of [2M-5H]5- for A(1-42) (a,b) and A(1-40) (d,e), showing 
the wild type (a,d) and mutation F19P (b,e). D denotes a peak assigned as a 
dimer, T a tetramer, H a hexamer and Do dodecamer. Figure and caption 
from Bernstein et al. 52. 
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The ATD of WT A(1-40) more closely resembled that of A(1-42) F19P than that 
of WT A(1-42). This led the authors to propose that A(1-42) possessed the ability 
to form a more open tetramer than other A peptides and A(1-42) alloforms 
52
. It is 
hypothesised that these open tetramers could associate with dimers to form 
hexamers, which stack together to form dodecamers; a species capable of beginning 
the fibril assembly process, a finding supported by cross-linking studies 
37,38,53
. 
Bernstein et al. 
52
 also postulated that this dodecameric species was the soluble 
species implicated by Lesné et al. 
42
 in murine memory impairment. When A(1-40) 
is present with A(1-42) in solution, A(1-42) oligomerisation is inhibited, as the 
largest oligomeric species formed are mixed A(1-42):A(1-40) tetramers which 
appear not to be growth competent, possibly due to their compact nature, thus 
preventing the formation of the putative toxic dodecamer 
54
.   
 
MS and IM-MS Experiments performed on A(1-40) have yielded conflicting 
results. Negative ionisation mode MS and IM-MS revealed oligomers up to 
tetrameric order 
52
, however a positive ionisation mode MS and IM-MS study 
undertaken by Kloniecki et al. 
55
, using a different instrument, yielded oligomers 
composed of up to 16 monomers 
55
. Differing A(1-40) preparations and increased 
instrument sensitivity in the later study are suggested as the origin for this 
difference 
55
. However the presence of higher order oligomers, including a 
dodecameric A(1-40) species, has serious implications for the self assembly 
pathways postulated by Bernstein et al. 
52
 (described above). MS and IM-MS 
experiments conducted in this chapter attempt to resolve this conflict.  
 
5.1.2. A Aggregation Inhibitors 
 
A peptide residues 16 to 22, KLVFFAE, are believed to play a vital role in the 
aggregation process 
56,57
. Extensive research has been carried out to design inhibitors 
with recognition sequences that can target this region. One class of inhibitors are 
known as  breakers. These are short peptides which bind to the target region and 
discourage the formation of -sheet secondary structure 
58
. In the A context,  
Chapter 5: A Peptides and Inhibitors 
 - 201 - 
breakers contain a proline residue, which, when it binds to the target sequence, 
creates a kink and breaks the -sheet hydrogen bonding pattern (Figure 5.4) 
59,60
.  
breakers have been reported to inhibit the creation of mature fibrils, although their 













Figure 5.4 | Schematic of  breaker peptides in action.  
 
There are three classes of A aggregation inhibitors, as defined by Necula et al. 
61
, 
these are shown in Table 5.1.  
 
A Aggregation Inhibitor Action 
Class I Inhibit oligomerisation 
Class II Inhibit the formation of both oligomers and fibrils 
Class III Inhibit fibril formation but not oligomerisation 
Table 5.1 | Table of A aggregation inhibitors. 
 
5.1.2.1. Retro Inverso OR2 
 
Retro-inverso OR2 is a peptide based on OR2, a known A oligomer and fibril 
formation inhibitor 
62
. OR2 has the amino acid sequence H2N-Arg-Gly-Lys-Leu-Val-
Phe-Phe-Gly-Arg-NH2, which mimics the A residue sequence 16-20 to encourage 
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binding. OR2 is a modified version of OR1, possessing an amidated C-terminus. 
OR1 has been reported to prevent the formation of mature A fibrils without 
influencing oligomer formation 
62
. OR2 contains additional amino acids to those 
which comprise the binding sequence Lys-Leu-Val-Phe-Phe to increase 
functionality. The presence of cationic arginine residues at both termini increases 
solubility and discourages self-aggregation, whilst glycine spacers 
62
 aid interactions 
between A and the binding sequence region of OR2. However, OR2 is vulnerable to 
proteolytic cleavage which limits its potential as a therapeutic. To design a peptide 
with similar activity (and therefore the need to preserve the three dimensional shape 
of OR2) which was resistant to proteolytic attack, the L-amino acids of OR2 were 
substituted with D-enantiomers and all peptide bonds reversed 
63,64
. This resulted in 
the retro-inverso version of OR2 (RI-OR2) with sequence: 
H2N-rGklvffGr-Ac 
65
. RI-OR2 was found to be resistant to 
proteolytic degradation by a variety of enzymes, all of which caused degradation of 
OR2. RI-OR2 also possessed a much higher stability in blood plasma and human 




Analysis of thioflavin T studies indicate that an equimolar quantity of RI-OR2 blocks 
the process of fibril formation by A(1-40) and A(1-42) more effectively than an 
equimolar quantity of OR2. However, at substoichiometric concentrations of 
inhibitor OR2 appeared to perform better. Both OR2 and RI-OR2 inhibit A(1-42) 
aggregation more effectively than that of A(1-40) 
65
, not a disadvantage given the 
higher amyloidogenicity of A(1-42) than A(1-40). Oligomer formation by both 
forms of A was monitored using a sandwich immunoassay 
62
 and reported to be 
prevented by both OR2 and RI-OR2 at inhibitor:A ratios of 2:1, 1:1 and 1:2 with 
increased efficacy against A(1-42) oligomer formation 
65
. Additional experiments 
utilised SDS page and immunodetection to determine that A(1-42) oligomers of 
nonameric to dodecameric order and dimeric to tetrameric order, which were present 
in an aggregating control sample, were not present in a 1:1 stoichiometric mix of 
RI-OR2:A(1-42). OR2 and RI-OR2 were also found to protect against the 
cytotoxicity of aggregated A(1-42) 
65
. Surface plasmon resonance experiments 
showed that RI-OR2 binds to A(1-42) monomers and fibrils quickly, with a binding 
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affinity of 9 µM and 12 µM respectively 
65
. Whereas OR1 is a class III inhibitor, 
inhibiting fibrillisation but not oligomerisation, both OR2 and RI-OR2 can be 
classified as class II inhibitors 
61
 as they prevent oligomerisation, fibril formation and 
extension. This class of inhibitors are postulated to stabilise a non-aggregating 
conformation of A, which RI-OR2 achieves by binding to the KLVFF motif. Taylor 
et al. 
65
 suggest that A(1-42) monomer binding is the means by which oligomer 
formation and aggregation is prevented. A(1-40) and A(1-42) have slightly 
different monomeric conformations (as described previously) 
37
 and thus the 
interaction of RI-OR2 to monomeric A(1-42) is either stronger or it acts more 




5.2.1. Sample Preparation 
 
Inhibitor RI-OR2 was obtained as a lyophilised powder from Mark Taylor at 
Lancaster University 
*
. Recombinant A peptides were purchased from rPeptide 
(Bogart, USA) and arrived pre-treated with hexafluoro-2-propanol. A peptides were 
deseeded by dissolving in trichloroacetic acid and thioanisole, incubating for an hour, 
and the liquid removed in a nitrogen stream. The residue is then dissolved in 




To create an aggregating solution the peptide was dissolved at a concentration of 
100 µM in H2O adjusted to pH 2 with hydrochloric acid. These samples were 
immediately flash frozen in liquid nitrogen and stored in a -28 °C freezer. 
 
                                                 
*
 Division of Biomedical and Life Sciences, School of Health and Medicine, 
Lancaster University, Lancaster LA1 4YQ, UK. 
†
 Deseeding procedure carried out by Mark Taylor at Lancaster University. 
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In initial negative ionisation mode experiments, samples were ziptipped to remove 
Cl
-
 adducts. Ziptipping utilised Millipore ZipTip® C18 pipette tips, the procedure is 




1. Wetting solution of 100 % ACN: repeat x 2. 
2. Equilibrium solution of 0.1 % TFA in milli-Q water: repeat x 2.  
3. Peptide solution: repeat x 10. 
4. Wash solution of 5 % MeOH in 0.1 TFA in milli-Q water: repeat x 2. 
5. Elution solution of 1 % HCOOH in 50 % aqueous MeOH: repeat x 4. 
 
Solution conditions following ziptipping were therefore 49.5:49.5:1 
MeOH:H2O:HCOOH.  
 
5.2.2. Mass Spectrometry 
 
High resolution mass spectrometry was performed on a QTOF 2 mass spectrometer 
(Waters, Manchester, UK) in both positive and negative ionisation modes. High 
resolution mass spectra provided 
13
C isotopic distributions which confirmed the 
identification of peaks where several assignations might have been made due to the 
presence of oligomers with a coincident m/z.  
 
5.2.3. Ion Mobility Mass Spectrometry 
 
IM-MS measurements were performed on an in-house modified QTOF 1 (Waters, 
Manchester, UK) the ‘MoQTOF’ 
66
 (Chapter 2, Section 2.3.1).  Samples were 
ionised using an n-ESI source in positive mode with an applied capillary voltage of 
~1.8 kV and a cone voltage of 40 V. Ions were accelerated through a potential 
difference of 36 V and injected into the drift cell. The drift cell was filled with He 
gas at a pressure of between 3.0 and 3.5 Torr and a temperature between 300 and 
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305 K. The temperature and pressure of helium was recorded at the start and end of 
each mobility scan and the average taken. The voltage applied across the cell was 
varied from 60 V to 15 V and ATDs were recorded at eight voltages.  
 
5.2.4. Collision Induced Dissociation 
Experiments 
 
Collision induced dissociation (CID) experiments in an argon filled collision cell 
were performed using a QTOF 2 (Waters, Manchester, UK). Peaks were selected by 
their m/z value and accelerated into the collision cell at a variety of voltages. The 
kinetic energy of the ions entering the collision cell was increased by raising the 
collision voltage parameter until the signal from the parent ion had been completely 
lost and only product ions remained.  
 
5.3. Results and Discussions 
 
5.3.1.    Mass Spectrometry of A(1-40), A(1-42) 
and RI-OR2 
 
For the purpose of clarity in mass spectrometry notation, A(1-40) and A(1-42) are 
referred to as A40 and A42 respectively. Negative ionisation MS experiments 
were attempted with unziptipped samples but were unsuccessful due to suppression 
of sample signal by chloride adduct peaks. Therefore all data acquired in negative 
ionisation mode utilised ziptipped samples (procedure detailed in Section 5.2.1).  
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5.3.1.1. Negative Ionisation Mode 
1000 2000 3000 4000 5000 6000
1118 1119 1120 1121 1122 1123 1124
2237 2238 2239 2240 2241 2242 2243 2244 2245









Figure 5.5 | Mass spectra of ~50 µM ziptipped RI-OR2 in pH 2 49.5:49.5:1 
MeOH:H2O:HCOOH. 
 
As the amino acid sequence of the RI-OR2 peptide contains no aspartic or glutamic 
acid residues, and thus possesses a low gas phase acidity, it is unsurprising that the 
species observed are not more than singularly charged. The inclusion of arginine 
residues at both termini of RI-OR2 to discourage self-aggregation 
62
 has been 
successful, as from Figure 5.5 a dominant [(RI-OR2)-H]
-
 species can be discerned, 





 has an intensity of 0.04 % and 
[3(RI-OR2)-H]
- 
an intensity of 0.002 %.  
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Figure 5.6 | Mass spectrum of ~50 µM ziptipped A(1-40) in pH 2 49.5:49.5:1 
MeOH:H2O:HCOOH. 
 
The peak corresponding to [A40-3H]
3-
 dominates the mass spectrum displayed in 
Figure 5.6, in addition there is a significant contribution from the [A40-2H]
2-
 
species. The most populated oligomeric species observed is [2A40-3H]
3-
; other less 











. Negative ionisation 
mode MS in the literature 
52
 also reports a dominant [A40-3H]
3-
 species, followed 







, however no oligomers of greater than dimeric order were discerned via 
MS with an unique m/z. The difference in A(1-40) charge state distribution can be 
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accounted for by the different pH (7.4) and solution conditions (25 mM ammonium 
acetate) employed by Bernstein et al. 
52
, which favour higher negative charge states 
of A(1-40).  








Figure 5.7 | Mass spectrum of ~50 µM ziptipped A(1-42) in pH 2 49.5:49.5:1 
MeOH:H2O:HCOOH. 
 
Despite the similarity of the dominant mass spectral peaks displayed in Figure 5.6 
and Figure 5.7, enlargements of the mass spectrum of A(1-42) reveal a paucity of 
oligomers compared to A(1-40), under identical solution and experimental 
conditions. Figure 5.7 displays a dominant peak corresponding to [A42-3H]
3-
, a less 
intense [A42-2H]
2-
 signal and small peak corresponding to the presence of 
[2A42-3H]
3-
. This is a similar charge state distribution to that of A(1-40) (Figure 
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5.6) however there is only one dimeric species, and no trimers or tetramers detected. 
Bernstein et al. 
51
 report a dominant [A42-3H]
3-










disparity in A(1-42) charge state distribution can be accounted for by the differing 
pHs of the two experiments, with those conducted by Bernstein et al. at a more basic 
pH (near 8) which, in negative ionisation mode, favours a shift towards higher 
A(1-42) charge states.   
 
5.3.1.2. Interactions between A Peptides and 
RI-OR2 
 
A peptides were mixed with RI-OR2 to observe the interactions between the 
peptides and the inhibitor.  
 
As can be observed in Figure 5.8, the [(RI-OR2)-H]
-
 species dominates the mass 
spectrum and, as a result, A(1-40) charge states are only visible on enlargement of 
their m/z regions. The distribution of A(1-40) charge states (not visible in Figure 
5.8) matches that observed when A(1-40) is analysed in isolation (Figure 5.6). 
However, additional peaks corresponding to the presence of A(1-40) and RI-OR2 









 are observed and are 
displayed in the insets of Figure 5.8.  
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Figure 5.8 | Mass spectra of ~50 µM ziptipped A(1-40) and RI-OR2 in an 





 is again the dominant species in the mass spectrum displayed in 
Figure 5.9. The A(1-42) charge states are only visible on enlargement of their m/z 
regions, but their distribution matches that observed when A(1-42) is analysed in 










. These are displayed in the inset of Figure 5.9. The relative 
abundances of the A and RI-OR2 complexes is similar for both A(1-40) and 
A(1-42); [A+(RI-OR2)-3H]
3-
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Figure 5.9 | Mass spectra of ~50 µM ziptipped A(1-42) and RI-OR2 in an 
~1:1 mixture. Solvent conditions are 49.5:49.5:1 MeOH:H2O:HCOOH  at 
pH 2. 
 
Due to the low intensities of some of the complex peaks identified in the 1:1 
A:RI-OR2 solutions, the mass spectra of which are displayed in Figure 5.8 and 
Figure 5.9, CID experiments were performed to verify their presence. The results of 
these experiments and the corresponding dissociation pathways are shown in Figure 
5.10.  
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Figure 5.10 | Schematic of the dissociation pathways of RI-OR2 and A 
complexes. Dashed lines represent product species which were not 
experimentally observed.  
  
CID verified that all complexes had been correctly identified. Figure 5.10 shows that 
the dissociation of complexes of A(1-42) with RI-OR2 follow similar pathways to 
that of complexes composed of A(1-40) and RI-OR2. The dissociation pathways of 
all complexes between A and RI-OR2 produce a product [(RI-OR2)-H]
-
 ion. The 
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prevalence of [(RI-OR2)-H]
-
, both in CID experiments and in mass spectra suggest it 
is a very stable species.  
 
To increase the signal intensity of the A peptides in the A:RI-OR2 mixture, and as  
RI-OR2 is reported to inhibit aggregation of A(1-42) at substoichiometric 
concentrations 
65
, the concentration of RI-OR2 was decreased by a factor of 10 and 
100. As both RI-OR2 and A solutions were ziptipped before use, all concentrations 
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      10:1
 
Figure 5.11 | Mass spectra of ziptipped A(1-40) and ziptipped RI-OR2 in 
~100:1 (50 µM A(1-40): 0.5 µM RI-OR2) and ~10:1 mixture (50 µM 
A(1-40): 5 µM RI-OR2). Solvent conditions are 49.5:49.5:1 
MeOH:H2O:HCOOH  at pH 2. 
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Figure 5.12 | The relative intensities of the lowest abundance complexes in 
~10:1 mixture (50 µM A(1-40): 5 µM RI-OR2). 
 
In both mass spectra shown in Figure 5.11, the charge state distribution of A(1-40) 
and RI-OR2 matches that of the peptides in isolation (Figure 5.5 and Figure 5.6). 
[A40+(RI-OR2)-3H]
3-
 is the dominant complex present both in 100:1 and 10:1 
A40:RI-OR2 solutions, and indeed is the only complex present in the 100:1 
A40:RI-OR2 solution. This suggests that the most efficient binding between 
A(1-40) and RI-OR2 occurs when a single RI-OR2 peptide binds to an A(1-40) 
monomer. Figure 5.12 displays the complex abundances in the 10:1 A40:RI-OR2 
solution, but, in brief, of the additional complexes present the next most abundant is 
[A40+2(RI-OR2)-3H]
3-
, followed by the [A40+(RI-OR2)-2H]
2-
 complex. The 
lowest abundance complexes present are [2A40+(RI-OR2)-4H]
4- 
(which is not 
observed in a 1:1 ratio A40:RI-OR2 solution) and [A40+2(RI-OR2)-2H]
2-
 which 
are of a similar abundance to [2A40-3H]
3-
.  
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Figure 5.13 | Mass spectra of A(1-42) and RI-OR2 in a ~100:1 (50 µM 
A(1-42): 0.5 µM RI-OR2) and ~10:1 mixture (50 µM A(1-42): 5 µM 
RI-OR2). Solvent conditions are 49.5:49.5:1 MeOH:H2O:HCOOH  at pH 2. 
 
In both mass spectra shown in Figure 5.13, the charge state distribution of A(1-42) 
and RI-OR2 matches that of the peptides in isolation (Figure 5.5 and Figure 5.7). 
[A42+(RI-OR2)-3H]
3-
 is the dominant complex present both in 100:1 and 10:1 
A42:RI-OR2 solutions. In the 10:1 A42:RI-OR2 ratio solution an additional 
complex, [A42+(RI-OR2)-2H]
2-
, is observed. This suggests that, as for A(1-40), 
the most efficient binding between of A(1-42) and RI-OR2 occurs when a single 
RI-OR2 peptide binds to an A(1-42) monomer. Only 1:1 complexes of 
A42:RI-OR2 are observed in these solutions, this increased specificity may be why 
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RI-OR2 has a greater efficacy in preventing A(1-42) aggregation at 




5.3.1.3. Positive Ionisation Mode 
 
Positive ionisation mode MS was utilised to analyse RI-OR2 and the A peptides 
further. Preliminary studies showed that there were far less adduction and signal 
suppression in positive mode than in negative. Therefore samples were not ziptipped 
before use.  
2+




Figure 5.14 | Mass spectrum of 100 µM unziptipped RI-OR2 in aqueous HCl 
at pH 2. 
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The dominant species in the mass spectrum shown in Figure 5.14 is the 
[(RI-OR2)+2H]
2+
 ion, with [(RI-OR2)+3H]
3+
 as the only other species present. This 
suggests that RI-OR2 is predominantly monomeric in solution, again supporting the 
non-aggregating nature of RI-OR2 facilitated by the insertion of cationic arginine 
residues 
62
. These arginine residues are the most likely sites of protonation for the 
dominant [(RI-OR2)+2H]
2+
 species. The location of the third protonation site is 
likely to be the lysine residue, or, less probably, the N-terminal amine.  










Figure 5.15 | Mass spectrum of 100 µM unziptipped A(1-40) in aqueous HCl 











, suggesting A(1-40) is 
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predominantly monomeric in solution. The most populated higher order aggregate is 
[2A40+5H]
5+
. Other oligomeric species detected in lower abundances (not visible in 

















. The mass 
spectrum acquired by Kloniecki et al. (supplementary information) 
55
 of 100 M 
A(1–40) in 10 mM ammonium acetate (pH 7.4) is superficially similar to Figure 
5.15, as the charge state distributions of the dominant monomeric and dimeric 
species are alike. Table 5.2 details the A(1–40) species observed in these 
experiments, and those reported in the literature, in both positive and negative 























 + - - - 
[A40+6H]
6+
 + + - - 
[A40+5H]
5+
 + + - - 
[A40±4H]
4±
 + + + + 
[A40±3H]
3±
 + + + + 
[A40±2H]
2±
 + + + + 
[2A40±7H]
7±
 + + - + 
[2A40+6H]
6+
 - + - - 
[2A40±5H]
5±
 + + + - 
[2A40±4H]
4±
 - + + - 
[2A40±3H]
3±
 + - - + 
[3A40+10H]
10+
 + - - - 
[3A40±8H]
8±
 + - - + 
[3A40±7H]
7±
 + + - + 
[3A40+5H]
5+
 + + - - 
[3A40+4H]
4+
 + - - - 
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[4A40-10H]
10-
   - - + - 
[4A40+9H]
9+
   + + - - 
[4A40+7H]
7+
 + + - - 
[4A40-6H]
6-
 - - - + 
[4A40+5H]
5+
 + - - - 
[5A40+13H]
13+
 - + - - 
[5A40+11H]
11+
 + - - - 
[5A40+9H]
9+
 + - - - 
[5A40+8H]
8+
 + - - - 
[5A40+7H]
7+
 + - - - 
[5A40+6H]
6+
 + - - - 
[6A40+13H]
13+
 + - - - 
[6A40+11H]
11+
 + - - - 
[6A40+10H]
10+
 - + - - 
[6A40+7H]
7+
 + - - - 
 
Table 5.2 | A(1–40) species observed in these experiments and reported in 
the literature in both positive and negative ionisation modes. Kloniecki et 
al. 55 observe many additional higher order oligomers, the largest 
[16A40+19H]19+, however those over hexameric order are not included in 
Table 5.2.  
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Figure 5.16 | Mass spectrum of 100 µM unziptipped A(1-42) in aqueous HCl 













. The most populated higher order 
aggregate is [2A42+5H]
5+
. Additional oligomeric species discerned, but too low in 













. The monomeric 
and dimeric charge state distribution and oligomeric species present are similar to 
that of A(1-40). Bernstein et al. (in supplementary information) 
52
 observe a 
dominant [A42+4H]
4+
, a less intense [A42+3H]
3+
 species and a very broad m/z 
peak in the spectrum, which CID experiments suggest consists of unresolved higher 
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order oligomers. No experimental conditions are specified, but if they are identical to 
those utilised in the main body of the experimental work they are 30 M A(1-42) at 
pH 7.4.  Table 5.3 details the A(1–42) species observed in these experiments, and 



























 - + - - 
[A42+6H]
6+
 + + - - 
[A42±5H]
5±
 + + - - 
[A42±4H]
4±
 + + + - 
[A42±3H]
3±
 + + + + 
[A42±2H]
2±
 - + + + 
[2A42+7H]
7+
 - + - - 
[2A42+6H]
6+
 - + - - 
[2A42±5H]
5±
  - + + - 
[2A42+4H]
4+
 - + - - 
[2A42-3H]
3-
 - - - + 
[3A42+6H]
6+
 - + - - 
[4A42-10H]
10-
 - - + - 
[4A42+9H]
9+
 - + - - 
[6A42-15H]
15-
 - - + - 
[10A42-25H]
25-
 - - + - 
[12A42-30H]
30-
 - - + - 
 
Table 5.3 | A(1–42) species observed in these experiments and reported in 
the literature in both positive and negative ionisation modes.  
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5.3.2. Ion Mobility Mass Spectrometry 
 
All rotationally averaged CCSs obtained are tabulated in Appendix 5.  
 
5.3.2.1. CCSs of A(1-40), A(1-42) and RI-OR2 
 
IM-MS data were acquired for A(1-40), A(1-42) and RI-OR2 individually and in 
mixtures of peptide and inhibitor. Figure 5.17 displays the monomeric CCSs 




Figure 5.17 | A(1-40), A(1-42) and RI-OR2 monomer CCS distributions.  
 
Figure 5.17 displays a correlation between charge state and CCS for both A 
peptides and RI-OR2, with increasing charge giving rise to larger CCSs; a result of 
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 for both A(1-40) and A(1-42), perhaps indicating that 
the addition of one charge causes unfolding of the conformational family which 
corresponds to [A+2H]
2+
. However, this trend is not present in the CCSs acquired 
by Bernstein et al. 
52 
where there is only a small increase in line with that observed 
between other charge states. The data acquired by Kloniecki et al. 
55
 displays no 




. In our experiments there 







 agree within experimental error. This 
suggests that the extended [A42+5H]
5+
 conformation of A(1-42) can either 
accommodate an additional two charges without further unfolding or that it is fully 







, monomeric CCSs of A(1-40) and A(1-42) agree within 
experimental error for the same charge states. CCS data acquired by Bernstein et al. 
51,52 
show larger A(1-42) monomeric conformations than A(1-40) conformations of 
the same charge state, however, as no standard deviation is recorded it is not possible 
to tell whether this difference is statistically significant. All experimental CCSs for 
both A(1-40) and A(1-42)  were substantially more compact than those reported in 
the literature and a wider array of charge states was observed.  
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Figure 5.18 | A(1-40) oligomer CCS distribution in positive ionisation mode. 
Data shown are an average of three repeats and error bars reflect the 
associated standard deviation.  
 





 revealed earlier arriving peaks 





. Figure 5.18 displays the CCSs of all A(1-40) oligomers observed 
as a function of charge. The expected increase in CCS with charge and multimeric 







within experimental standard deviation, suggesting a packing phenomenon akin to 
that seen for TTR(105-115) (Chapter Three, Figure 3.11). The highest charge states 
of the tetramer, pentamer and hexamer species have CCSs which agree within 
experimental error. 
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Figure 5.19 | A(1-42) CCS distribution in positive ionisation mode. Data 
shown are an average of three repeats and error bars reflect the associated 
standard deviation. 
 
Figure 5.19 shows the CCSs of A(1-42) oligomers as a function of charge. 
A(1-42) oligomers of up to tetrameric order are observed, and for most there is a 
correlation between increasing oligomeric order, charge and CCS. The CCSs of all 
A(1-42) dimers agree, within experimental standard deviation, to that of a dimer of 





 agree within experimental error, echoing the 
packing tendency described in more detail previously.   
 
5.3.2.2. Mass Spectra and CCSs of Complexes 
between A Peptides and RI-OR2 
5.3.2.2.1. A(1-40) and RI-OR2 
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Mass spectra of unziptipped A(1-40) and RI-OR2 at a 1:1 ratio, Figure 5.20, 
revealed charge state distributions similar to those present when the peptides were 
analysed separately (Figure 5.14 and Figure 5.15). Seven complexes of A(1-40) and 






















visible in Figure 5.20.  












Figure 5.20 | Mass spectrum of unziptipped A(1-40) and RI-OR2 at a 1:1 
ratio and concentrations of 50 µM in pH 2 aqueous HCl.  
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Rotationally averaged CCSs were calculated for all species and complexes observed 
in the mass spectra and are displayed in Figure 5.21. For clarity Figure 5.21 does not 
display the CCSs of A(1-40) oligomers larger than the trimeric species; CCSs of all 
A(1-40) oligomers can be found in Figure 5.18 and tabulated in Appendix 5. 
 
Figure 5.21 | The CCSs of A(1-40) up to trimeric oligomeric order, RI-OR2 
and complexes of A(1-40) and RI-OR2. A(1-40) and RI-OR2 were 
unziptipped at concentrations of 50 µM in pH 2 aqueous HCl and a 1:1 ratio. 
Data shown are an average of three repeats and error bars reflect the 
associated standard deviation. 
 















. This is unexpected as each complex 
is ~1.1 kDa more massive than its counterpart A(1-40) species and such a 
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significant increase in mass would be expected to result in an appreciable increase in 
CCS. [A40+2(RI-OR2)+3H]
3+ 
has a CCS which agrees within experimental 
standard deviation with [A40+(RI-OR2)+3H]
3+
, which is itself significantly more 
compact than [A40+3H]
3+
. The CCSs of [A40+2(RI-OR2)+4H]
4+
 agrees within 
experimental standard deviation with [A40+4H]
4+
, despite the ~2.2 kDa disparity in 
mass between the two species. A possible mechanism for the mode of action of 
RI-OR2 could be a compaction of A(1-40) monomers in solution, thus preventing 
the presence of an elongated, aggregation competent monomeric species.  
 
However, there are complexes which are less compact than their corresponding 
A(1-40) monomers. [A40+(RI-OR2)+5H]
5+
 possesses a larger CCS, and thus is in 
a more extended conformation, than [A40+5H]
5+





agree within experimental standard 




are the least 
intense monomeric species present, it can be inferred that they are less populated in 
solution than other A(1-40) monomeric species. These extended monomeric 
conformations, and the lack of compaction RI-OR2 binding entails, could be the 




5.3.2.2.2. A(1-42) and RI-OR2 
 
From Figure 5.22 it can be observed that the charge state distributions of A(1-42) 
and RI-OR2 are very similar to those when the two peptides are individually 
analysed (Figure 5.14 and Figure 5.16). Three complexes of A(1-42) and RI-OR2 
are detected; the most populated is [A42+(RI-OR2)+4H]
4+
 (this is the only complex 
shown in Figure 5.22), followed by [A42+(RI-OR2)+3H]
3+
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Figure 5.22 | Mass spectrum of unziptipped A(1-42) and RI-OR2 at an 
approximately 1:1 ratio and concentrations of 50 µM in pH 2 aqueous HCl. 
 
Rotationally averaged CCSs were calculated for all species observed in the mass 
spectra. For clarity, Figure 5.23 does not display the CCSs of A(1-42) oligomers 
larger than the trimeric species; CCSs of all A(1-42) oligomers observed are 
displayed in Figure 5.19 and tabulated in Appendix 5.  
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Figure 5.23 | The CCSs of A (1-42), RI-OR2 and complexes up to trimeric 
oligomeric order. A(1-42) and RI-OR2 were unziptipped at concentrations of 
50 µM in pH 2 aqueous HCl and a 1:1 ratio. Data shown are an average of 
three repeats (except [A42+(RI-OR2)+3H]3+ which is an average of two 
repeats) , and error bars reflect the associated standard deviation. 
 
The CCS of [A42+(RI-OR2)+4H]
4+
 is significantly more compact than 
[A42+4H]
4+
, but agrees to within experimental error with [A42+3H]
3+
. The 
complex with an additional RI-OR2 monomer, [A42+2(RI-OR2)+4H]
4+
, has a CCS 
which agrees within experimental standard deviation with the ~2.2 kDa less massive 
[A40+4H]
4+
. Although the mean CCS of [A42+(RI-OR2)+3H]
3+
 is less than that 
of [A42+3H]
3+
, within experimental error their CCSs agree.  
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The mechanism by which RI-OR2 inhibits A oligomer formation could be by 
sequestering the monomers into a more compact structure which, in the case of 
A(1-42), could prevent their association into an ‘open tetramer’ and from there to a 
paranucleus 
51
. The presence of more extended A(1-40) conformers complexed with 
RI-OR2 could be the reason why RI-OR2 is a less effective inhibitor of A(1-40) 

















A(1-42) monomer RI-OR2 monomer Compacted complex





Figure 5.24 | Postulated mechanisation of RI-OR2 action to inhibit the 
oligomerisation and fibril formation a) A(1-42) b) A(1-40).  
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5.4. Conclusions  
 
Mass spectra of RI-OR2 in negative and positive ionisation modes reveal 
predominantly monomeric states. The dominant species of A(1-40) and A(1-42) 
are monomers, in both ionisation modes. A(1-40) oligomers were observed of up to 
tetrameric order in negative ionisation mode and hexameric order in positive 
ionisation mode. Fewer higher order oligomers were observed for A(1-42): dimers 
in negative ionisation mode and a tetrameric species in positive ionisation mode. 
Complexes of A and RI-OR2 were observed when the A peptides were mixed with 
the inhibitor. Complex stoichiometries of A:RI-OR2, A:2RI-OR2 and 
2A:RI-OR2 are observed but 1:1 complexes are generally more populated than 
other stoichiometries. In the majority of cases complexes of A and RI-OR2 possess 
substantially more compact CCSs than the corresponding A species of the same 
charge state. This compaction of an elongated A species could be the mechanism by 
which RI-OR2 inhibits A oligomer formation. Further investigations could be 
fruitful in characterising interactions between RI-OR2 and A peptides, providing 
insight into the mode of action of this potential therapeutic. 
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Mass spectrometry, ion mobility mass spectrometry and molecular modelling have 
provided valuable insights in to the early aggregation of three systems: TTR 
(105-115), insulin and A peptides. In this chapter the conclusions of this thesis are 
presented and further work is suggested. 
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In Chapter Three, MS and IM-MS were utilised to reveal the changes of oligomer 
populations in an aggregating solution of the amyloidogenic endecapeptide TTR 
(105-115). Initially oligomeric species from dimeric to tridecameric order are 
observed and the relative populations of these fluctuate over an eight hour time 
period. Throughout the time course the dimer is the most prevalent species, others of 
note are a stable tetrameric species which persisted throughout the experimental time 
period and an unusually prevalent and transiently stable decamer. Although neither 
MS nor IM-MS allows the differentiation between on and off pathway species, 
identifying these transient oligomers by their m/z ratio and mobility is important as, 
for disease related proteins or peptides, they may play a role in pathogenesis.  
 
IM-MS elucidated the conformational space TTR (105-115) oligomers inhabit; for 
oligomers which populate multiple charge states there is a correlation between 
increasing charge and increasing CCS, due to repulsive Coulombic forces. Although 
oligomer CCSs increase in a linear fashion for the highest charge state for each 
oligomer, there is a lack of increase in CCS when n > 3 for oligomers of the same 
charge state. A large increase in oligomer mass can result in only a small increase in 
CCS, suggesting dense packing. This suggests there is a competition between 
Coulombic repulsion and packing to form a dense aggregate. All oligomers for which 
n > 2 carry fewer charges than the number of constituent peptides and each peptide’s 
most probable protonation site is the N-terminus. This implies some N-termini are 
inaccessible and packed in the interior of the aggregate and, given the amino acid 
sequence of TTR (105–115), it is likely that this packing is governed by hydrophobic 
interactions. Comparison of experimental oligomer CCSs with simulations revealed 
that the oligomers observed are compact globular structures and contain no extended 
-sheet elements. Investigations into TTR (105-115) using double IR-UV double 
resonance spectroscopy, in collaboration with Professor Tom Rizzo 
*
, are currently 
being undertaken by Jakub Ujma, a member of Dr Perdita Barran’s research group. 
Ions are electrosprayed, mass selected and cooled to ~6 K in a linear 22 pole ion trap. 
IR and UV laser pulses irradiate the ions and the resulting spectra from detected 
                                                 
* Laboratory of Molecular Physical Chemistry, Ecole Polytechnique Fédérale de Lausanne. 
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fragments produced after photon absorption are collected 
†
. This will be used 
unequivocally confirm or refute the presence of -sheet in TTR (105-115) oligomers.  
 
In Chapter Four the early aggregation of bovine insulin was studied; the most 
populated species are monomers and dimers, but oligomers up to dodecameric order 
are detected before the onset of accelerated fibril growth. An experimental time 
course was undertaken but no significant changes in the relative oligomer 
populations were observed. At a zero time point in the aggregating solution, the 
orthogonal dimension provided by IM-MS facilitates the observation of multiple 
conformations of insulin oligomers from dimeric to hexameric order and the 
identification of higher order aggromers composed of up to 24 monomers. The 
presence of multiple oligomer conformations are confirmed by FT-ICR MS and CID 
measurements, and for all oligomeric species observed, the most significantly 
populated conformation is the most compact form. Injection energy experiments and 
the empirical de la Mora relation suggest that extended conformations are not the 
result of gas phase unfolding events but represent structures present in solution.  
 
Molecular modelling was employed to characterise the multiple conformations of the 
prevalent 7+ dimer. Both the compact and extended experimental CCSs could be 
replicated and modelling suggests that the conformationally compact, most 
experimentally prevalent, dimeric species is enriched in -sheet secondary structure. 
Dimers of this form would fit to the electron density previously found in single 
protofilaments of insulin. Further work which could be undertaken into this system 
could be an IM-MS analysis of whether the conformations of insulin oligomers 
change over time, particularly if there are changes in the multiple conformational 
families which are present in the dimeric to hexameric species.  
 
The aggregation of A peptides A(1-40) and A(1-42) and their interactions with 
aggregation inhibitor RI-OR2 were characterised by MS and IM-MS in Chapter Five. 
Monomeric species dominated the mass spectra in both negative and positive 
ionisation modes for all three peptides. RI-OR2 is designed to discourage self 
                                                 
† Professor Tom Rizzo’s website http://lcpm.epfl.ch/page-53589-en.html 
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aggregation and MS indicated that this strategy has been successful as only a very 
small population of dimers and trimers were observed. Differences are observed in 
the oligomeric species populations present for A(1-40) and A(1-42), with higher 
order oligomers present for both A peptides in positive ionisation mode. The largest 
A(1-42) oligomers observed were dimers in negative ionisation mode and tetramers 
in positive ionisation mode. Higher order oligomers were discovered for A(1-40); 
oligomers of tetrameric order in negative ionisation mode and hexameric order in 
positive ionisation mode.  
 
When A peptides were mixed with aggregation inhibitor RI-OR2 complexes 
between the two peptides were observed in small quantities. Various stoichiometries 
of complexes between the A peptide and RI-OR2 were present, with 1:1 complexes 
generally the most populated. Additional stoichiometries detected were A:2RI-OR2 
and 2A:RI-OR2. The use of IM-MS to probe the conformational landscape found 
that complexes of A and RI-OR2 predominantly possessed substantially more 
compact CCSs than the corresponding A species of the same charge state. This 
compaction of an elongated A species could be the mechanism by which RI-OR2 
inhibits A oligomer formation. However two complexes of A(1-40) and RI-OR2 
with the highest charge states were more extended than the corresponding A(1-40) 
monomeric charge state CCSs, possibly explaining why RI-OR2 is a less effective 
inhibitor of A(1-40) aggregation. Further investigations, both experimentally and 
utilising molecular modelling, could be fruitful in characterising interactions between 
RI-OR2 and A peptides and determining the interaction loci, providing insight into 
the mode of action of this potential therapeutic. A detailed time course of A peptide 
aggregation could also give valuable clues to how the aggregation processes of 
A(1-40) and A(1-42) progress and differ.  
 
The use of other experimental techniques to complement those employed in this 
thesis would be advantageous. In particular, concurrent fluorescence and EM time 
course studies, conducted in parallel to MS and IM-MS experiments, would allow 
direct comparison of temporal oligomer evolution and fibrillogenesis. Additionally 
CD experiments could be employed to monitor changes in the secondary structural 
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elements present in the aggregating solutions, although these measurements give 
population averages and not detail of individual oligomeric species. SEC and AUC, 
although of lower resolution than MS, would allow a quantitative comparison of the 
oligomeric species present in solution to be made with the relative abundances of the 
oligomeric ions observed in the gas phase by MS and IM-MS.  
 
To conclude, the analytical techniques of MS and IM-MS, combined with molecular 
modelling, have proved to be powerful tools in elucidating details of the oligomeric 
species present in protein and peptide aggregation. The investigation of more 
aggregating systems would be rewarding. In addition to in vitro studies, the speed 
and sensitivity of these analytical techniques recommends their potential use in 



























Glycine Gly G 54.02146 57.05 202.7 
Alanine Ala A 71.03711 71.08 206.4 
Serine Ser S 87.03203 87.08 207.6 
Proline Pro P 97.05276 97.12 214.3 
Valine Val V 99.06841 99.07 208.7 
Threonine Thr T 101.0477 101.1 211.7 
Cysteine Cys C 103.0092 103.1 206.2 
Leucine Leu L 113.0841 113.2 209.6 
Isoleucine Ile I 113.0841 113.2 210.8 
Asparagine Asn N 114.0429 114.1 212.8 
Aspartic acid Asp D 115.0269 115.1 208.6 
Glutamic acid Glu E 128.0586 128.1 215.6 
Lysine Lys K 128.095 128.2 221.8 
Glutamine Gln Q 129.0496 129.1 214.2 
Methionine Met M 131.0405 131.2 213.3 
Histidine His H 137.0589 137.1 223.7 
Phenylalanine Phe F 147.0684 147.2 212.1 
Arginine Arg R 156.1011 156.2 237.0 
Tyrosine Tyr Y 163.0633 163.2 213.1 




                                                 
* Harrison, A. G. The gas-phase basicities and proton affinities of amino acids 
and peptides. Mass Spectrom. Rev. 16, 201-217 (1997). 
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Appendix 2: Amino Acid R Groups 
 
 


















Figures from the website of the Department of Biology, Penn State 
University https://wikispaces.psu.edu/display/bio110/Carbon+and+Life 
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Appendix 3: TTR (105-115) CCSs 
 
 
 CCS / Å² 
Species Average Standard Deviation 
[M+H]+ 256.1 11.1 
[M+2H]2+ 272.7 20.0 
[2M+2H]2+ 380.2 24.5 
[3M+2H]2+ 508.5 71.6 
[4M+2H]2+ 443.1 17.8 
[4M+3H]3+ 662.7 57.6 
[5M+3H]3+ 665.7 51.5 
[5M+4H]4+ 846.5 42.7 
[6M+4H]4+ 848.3 85.1 
[6M+5H]5+ 1013.5 75.9 
[7M+4H]4+ 853.8 33.0 
[7M+5H]5+ 1038.6 63.2 
[7M+6H]6+ 1210.8 54.2 
[8M+5H]5+ 1096.5 78.4 
[9M+5H]5+ 1120.6 77.3 
[9M+7H]7+ 1458.8 82.9 
[10M+6H]6+ 1132.1 131.7 
[10M+7H]7+ 1436.7 72.9 
[10M+9H]9+ 1775.3 82.3 
[11M+6H]6+ 1328.0 63.8 
[11M+7H]7+ 1478.4 61.5 
[11M+10H]10+ 1976.3 166.3 
[12M+7H]7+ 1477.1 11.4 
[13M+12H]12+ 2335.5 115.3 
 
Table A1 | Rotationally averaged CCSs for all oligomeric species observable 
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 CCS / Å² 
Species Average Standard Deviation 
[M+6H]6+ 978.9 22.2 
[M+5H]5+ 912.3 5.6 
[M+4H]4+ 805.7 4.3 
[M+3H]3+ 704.5 24.1 
[2M+8H]8+ 1611.1 8.5 
[2M+6H]6+ 1095.6 20.1 
[2M+5H]5+ 1200.9 9.0 
[2M+4H]4+ 961.3 17.0 
[3M+7H]7+ 1682.1 14.6 
[4M+10H]10+ 1907.1 84.5 
[4M+ 9H]9+ 2160.4 102.6 
[4M+7H]7+ 1754.2 40.7 
[5M+9H]9+ 2265.7 35.0 
[5M+8H]8+ 1982.8 57.4 
[5M+7H]7+ 1680.3 8.3 
[6M+11H]11+ 2695.9 86.1 
[6M+10H]10+ 2465.2 41.2 
[6M+9H]9+ 2205.2 26.2 
[6M+8H]8+ 1888.6 62.3 
[7M+13H]13+ 3113.1 64.7 
[7M+12H]12+ 2938.0 66.6 
[7M+11H]11+ 2791.2 68.2 
[7M+10H]10+ 2399.6 82.6 
[8M+15H]15+ 3608.7 102.6 
[8M+13H]13+ 3198.7 60.7 
[8M+11H]11+ 2575.3 63.6 
[9M+14H]14+ 3476.1 29.5 
[9M+13H]13+ 3146.3 62.0 
[11M+17H]17+ 4134.9 46.7 
[12M+17H]17+ 4040.2 36.3 
 
Table A3 | Rotationally averaged CCSs for multimeric species observable at 
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 CCS / Å² 
Species Average Standard Deviation 
[2M+7H]7+ 1217.0 32.5 
[2M+7H]7+ 1323.7 49.3 
[2M+7H]7+ 1563.9 9.6 
[2M+7H]7+ 1701.0 * 
[2M+9H]9+ 1678.9 179.1 
[2M+9H]9+ 2305.3 250.5 
[2M+9H]9+ 2565.2 71.6 
[3M+8H]8+ 1487.6 22.0 
[3M+8H]8+ 1621.9 97.7 
[3M+8H]8+ 1764.3 48.1 
[3M+8H]8+ 1948.3 * 
[3M+10H]10+ 1722.9 35.4 
[3M+10H]10+ 2560.9 136.6 
[3M+10H]10+ 1609.2 333.0 
[4M+11H]11+ 1954.2 47.9 
[4M+11H]11+ 2363.6 107.3 
[4M+11H]11+ 2731.0 7.2 
[4M+11H]11+ 3034.8 * 
[5M+11H]11+ 2259.4 64.3 
[5M+11H]11+ 2516.9 30.5 
[5M+11H]11+ 2877.9 * 
[5M+12H]12+ 2249.5 49.6 
[5M+12H]12+ 2622.0 4.7 
[5M+12H]12+ 2911.3 107.5 
[5M+12H]12+ 3418.7 * 
[6M+13H]13+ 2207.9 148.5 
[6M+13H]13+ 2663.4 108.7 
[6M+13H]13+ 2997.8 80.2 
[6M+13H]13+ 3246.5 * 
[6M+13H]13+ 3673.1 * 
 
Table A4 | Rotationally averaged CCSs for multimeric species present with 
several conformations observable at t = 0. The CCSs show the mean and 
standard deviation of three repeated measurements. * represents species 
which were only identified in one repeat and therefore no standard deviation 
could be calculated.  
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  CCS / Å² 
Species Average Standard Deviation 
[5M+7H]7+ 1263.3 21.0 
[5M+8H]8+ 1490.5 109.6 
[6M+8H]8+ 1463.4 17.0 
[6M+9H]9+ 1641.2 17.3 
[6M+11H]11+ 1971.2 148.8 
[7M+10H]10+ 1803.3 74.7 
[7M+11H]11+ 1996.3 48.3 
[7M+12H]12+ 2183.0 46.8 
[7M+13H]13+ 2291.8 122.6 
[8M+11H]11+ 1964.7 79.8 
[8M+13H]13+ 2399.0 9.3 
[8M+15H]15+ 2763.5 156.3 
[9M+13H]13+ 2306.6 41.5 
[9M+14H]14+ 2537.0 23.2 
[11M+17H]17+ 3100.3 59.9 
[12M+17H]17+ 2992.3 105.4 
 
Table A5 | If the earlier arriving ATD peaks are assigned as compact species 
the above rotationally averaged CCSs result. The CCSs show the mean and 
standard deviation of three repeated measurements. 
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 CCS / Å² 
Species Average Standard Deviation 
[10M+14H]14+ 2526.6 41.9 
[10M+16H]16+ 2981.0 219.3 
[12M+16H]16+ 2926.7 33.9 
[12M+18H]18+ 3282.4 34.6 
[12M+22H]22+ 3942.4 297.5 
[14M+20H]20+ 3606.6 149.3 
[14M+22H]22+ 3992.5 96.5 
[14M+24H]24+ 4366.0 93.6 
[14M+26H]26+ 4583.6 245.1 
[16M+22H]22+ 3929.4 159.5 
[16M+26H]26+ 4798.1 18.5 
[16M+30H]30+ 5527.1 312.6 
[18M+26H]26+ 4613.2 83.1 
[18M+28H]28+ 5073.9 46.4 
[22M+34H]34+ 6200.6 119.8 
[24M+34H]34+ 5984.7 210.9 
 
Table A6 | If the earlier arriving ATD peaks are assigned as coincident 
m/z oligomers the above rotationally averaged CCSs result. The CCSs 
show the mean and standard deviation of three repeated 
measurements. 
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 CCS / Å² 
Species Average Standard Deviation 
[(RI-OR2)+3H]3+ 302.9 0.8 
[(RI-OR2)+2H]2+ 246.0 2.3 
 
Table A7 | Rotationally averaged CCSs of RI-OR2. The CCSs show the 




 CCS / Å² 
Species Average Standard Deviation 
[A40+2H]2+ 333.0 3.9 
[A40+3H]3+ 567.8 8.8 
[A40+4H]4+ 650.8 6.9 
[A40+5H]5+ 725.3 13.8 
[A40+6H]6+ 767.2 12.3 
[2A40+4H]4+ 665.9 7.9 
[2A40+5H]5+ 912.2 31.5 
[2A40+6H]6+ 999.5 86.1 
[2A40+7H]7+ 1115.3 134.9 
[2A40+9H]9+ 1274.2 34.9 
[3A40+5H]5+ 1007.6 51.4 
[3A40+7H]7+ 1217.5 41.7 
[4A40+7H]7+ 1249.2 11.4 
[4A40+9H]9+ 1528.8 40.7 
[4A40+14H]14+ 2033.4 126.5 
[5A40+13H]13+ 2027.7 58.5 





Table A8 | Rotationally averaged CCSs of A(1-40). The CCSs show the 
mean and standard deviation of three repeated measurements. 
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[A42+2H]2+ 375.4 23.3 
[A42+3H]3+ 552.9 48.1 
[A42+4H]4+ 646.5 14.3 
[A42+5H]5+ 742.1 10.7 
[A42+6H]6+ 757.4 9.7 
[A42+7H]7+ 771.9 72.2 
[2A42+4H]4+ 750.6 46.6 
[2A42+5H]5+ 860.2 88.6 
[2A42+6H]6+ 985.6 114.0 
[2A42+7H]7+ 1022.3 25.4 
[3A42+6H]6+ 1125.9 69.9 
[4A42+9H]9+ 1623.7 43.2 
 
Table A9 | Rotationally averaged CCSs of A(1-42). The CCSs show the 
mean and standard deviation of three repeated measurements. 
 
 CCS / Å² 
Species Average Standard Deviation 
[A40+(RI-OR2)+3H]3+ 497.7 21.0 
[A40+(RI-OR2)+4H]4+ 582.8 21.8 
[A40+(RI-OR2)+5H]5+ 780.0 17.5 
[A40+(RI-OR2)+6H]6+ 819.6 52.5 
[A40+(2RI-OR2)+3H]3+ 507.2 24.3 
[A40+(2RI-OR2)+4H]4+ 635.8 30.2 
[2A40+(RI-OR2)+5H]5+ 837.7 32.1 
[A42+(RI-OR2)+3H]3+ 528.0 10.3 
[A42+(RI-OR2)+4H]4+ 597.2 30.0 
[A42+(2RI-OR2)+4H]4+ 645.3 23.0 
  
Table A10 | Rotationally averaged CCSs of complexes between A and 
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